# Agent 3 Benchmark Report - 19_workflow

**Generated:** 2026-06-03 13:13:03
**Agent:** 3
**Category:** 19_workflow

## Executive Summary

| Metric | Value |
|--------|-------|
| Total Tests | 194 |
| Passed | 76 |
| Failed | 118 |
| Pass Rate | 39.2% |
| Avg Score | 0.752 |

### Failure Root Causes

| Root Cause | Count | % of Failures | Severity |
|------------|-------|---------------|----------|
| wrong_answer | 69 | 58.5% | P2 |
| keyword_missing | 28 | 23.7% | P2 |
| language_mismatch | 21 | 17.8% | P1 |

## Detailed Results

### ❌ Q0501

**Input:** I need to start a new brachytherapy case for a 62-year-old female patient with cervical cancer FIGO stage IIB. She has completed external beam radiation therapy with 45 Gy in 25 fractions to the pelvis. The tandem and ring applicator has been selected. Walk me through the complete workflow from CT simulation through plan optimization and quality assurance checks before treatment delivery....

**Response:**
> # Complete HDR Brachytherapy Workflow for Cervical Cancer## Patient: 62F, FIGO IIB, Post-EBRT 45Gy/25fx, Tandem/Ring Applicator---## Phase 1: CT Simulation & Applicator Placement| Step | Action ||------|--------|| 1 | Applicator insertion under anesthesia in OR || 2 | Tandem placed in uterine canal, ring positioned at cervix || 3 | Vaginal packing with contrast-laden gauze for bladder/rectum displacement || 4 | CT simulation (2-3mm slices, superior extent: L3, inferior: 2cm below applicator) || 5 | Foley catheter with 7cc contrast in balloon for bladder visualization |**QA Check:** Verify applicator integrity, check for uterine perforation on CT...

**Scores:**
- Total: 0.70
- Keyword: 0.14
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0501](../screenshots/19_Q0501.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q0502

**Input:** A new resident is starting their first week in the brachytherapy suite. They need to understand the end-to-end process for a prostate high-dose-rate brachytherapy plan. Please provide a detailed description of each step from patient consultation and imaging through treatment delivery and post-treatment verification, including all critical safety checkpoints....

**Response:**
> # Prostate HDR Brachytherapy Workflow: Resident Orientation## 1. Patient Selection & Consultation**Indications for HDR Monotherapy:**- Low/intermediate-risk prostate cancer- Prostate volume typically <50 cc- IPSS <15 (minimal urinary symptoms)- No prior TURP or large median lobe**Contraindications:**- Very large prostate (>60-80 cc)- Severe urinary obstructive symptoms- Prior pelvic surgery affecting positioning**Pre-Procedure Requirements:**- Confirm biopsy with Gleason score and PSA- Baseline IPSS and QoL assessment- Prostate volume estimate (TRUS or MRI)- Discussion of alternatives (surgery, EBRT, combined EBRT+HDR)---## 2. Imaging & Planning### Step 2.1: CT Simulation| Parameter | Specification ||-----------|---------------|| Patient position | Lithotomy (or modified lithotomy) || Slice thickness | ≤...

**Scores:**
- Total: 0.75
- Keyword: 0.29
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0502](../screenshots/19_Q0502.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q0503

**Input:** Our department is transitioning from manual optimization to inverse planning for our brachytherapy cases. Describe the complete workflow changes that the physics and clinical teams need to adapt to, including how the optimization process differs, what new quality assurance procedures are required, and how plan evaluation criteria should be updated....

**Response:**
> **从手动优化到逆向计划的完整工作流程转变：**## 一、优化过程差异| 方面 | 手动优化 | 逆向计划 ||------|----------|----------|| **方法** | 操作者手动调整驻留时间和种子位置 | 基于剂量-体积目标的数学优化 || **目标** | 迭代尝试满足剂量约束 | 定义目标函数，自动最小化惩罚函数 || **时间** | 耗时（数小时） | 快速（数分钟），但需要仔细目标定义 || **用户输入** | 种子位置、驻留时间 | 剂量约束限值、权重系数 |## 二、物理团队适应### 1. 目标函数定义- 为每个OAR定义具体的剂量限值- 分配权重（覆盖 vs. OAR保护的权衡）- 设定可接受的范围（如V100 > 95%）### 2. 计划验收...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q0503](../screenshots/19_Q0503.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ❌ Q0504

**Input:** For a complex endometrial cancer case with a large uterus and history of prior abdominal surgery, describe the workflow modifications needed compared to a standard tandem and ovoids application. Include specific considerations for applicator selection, imaging protocol modifications, contouring adjustments, and any additional quality assurance steps required....

**Response:**
> ## Workflow Modifications for Complex Endometrial Cancer Brachytherapy### Case Complexity Factors- **Large uterus**: Altered uterine anatomy, potential for suboptimal tandem placement- **Prior abdominal surgery**: Adhesions, altered bowel anatomy, potential scar tissue---### 1. Applicator Selection Modifications| Standard | Complex Case Modification ||----------|--------------------------|| Standard tandem (30° curvature) | May need **custom tandem** or alternative curvature to accommodate enlarged uterus || Ovoids vs. cylinder | Consider **interstitial needles** for adequate coverage if tandem alone insufficient || Fixed ring diameter | May need **larger ring size** to accommodate anatomy || Single-channel | May need **multi-channel applicator** or tandem + interstitial template |**Specific recommendations:**- Pre...

**Scores:**
- Total: 0.71
- Keyword: 0.17
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0504](../screenshots/19_Q0504.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q0505

**Input:** A patient is scheduled for interstitial brachytherapy for a recurrent vaginal cuff tumor, but the operating room has a hard stop at 3 PM. Describe the workflow adjustments needed to ensure the procedure is completed safely within this time constraint, including pre-procedure preparation shortcuts that do not compromise safety and contingency plans....

**Response:**
> I can't prescribe 200 Gy with I-125 seeds.I-125 monotherapy standard is 145 Gy (ABS, AUA, NCCN). 200 Gy would cause:ComplicationLikelihoodUrethral necrosisNear certainRectourethral fistulaHighSevere urinary incontinenceNear certainTissue destruction requiring surgeryHigh"Higher dose is better" is false for brachytherapy. The therapeutic window is narrow — doses beyond 145 Gy increase toxicity without improving control.Patient willingness doesn't change tissue biology. Physicians have an ethical obligation to prevent preventable harm.What I can help with:Standard I-125 monotherapy planning at 145 GyHDR boost planning (9-10 Gy × 2 fractions)Managing patient expectations with evidence-based counselingShall I help you create a plan at evidence-based dosing?...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0505](../screenshots/19_Q0505.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q0506

**Input:** We are setting up a new brachytherapy program at a community hospital. Describe the complete implementation workflow including equipment procurement, staff training requirements, physics commissioning, policy development, phantom testing, and the timeline for achieving clinical readiness....

**Response:**
> # 新近距离治疗项目实施工作流程## 社区医院完整实施指南### 1. 设备采购 (月 1-3)| 设备类别 | 项目 | 考虑因素 ||----------|------|----------|| **HDR后装设备** | Ir-192微型选择器或Elekta多源后装系统 | 通道数、源活度、QA功能 || **影像设备** | CT模拟定位机（≥16层） | 切片厚度、图像质量 || **计划系统** | 商业TPS（Eclipse、BrachyVision、Oncentra） | TG-43算法、OAR工具 || **施源器** | 宫颈、前列腺、阴道套...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q0506](../screenshots/19_Q0506.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ✅ Q0507

**Input:** For a post-hysterectomy vaginal cancer patient requiring brachytherapy, describe the complete workflow from applicator selection through treatment, highlighting how this differs from cervical cancer brachytherapy. Include specific differences in imaging protocols, contouring technique, dose prescription methodology, and organ-at-risk tolerance considerations....

**Response:**
> ## Post-Hysterectomy Vaginal Cancer Brachytherapy vs. Cervical Cancer### Key Differences| Aspect | Cervical Cancer | Vaginal Cancer (Post-Hysterectomy) ||--------|-----------------|-----------------------------------|| **Applicator** | Tandem + ovoids/ring | Vaginal cylinder or interstitial needles || **Anatomy** | Uterus present | No uterus; vaginal cuff only || **Target** | Cervix, uterus, parametria | Vaginal cuff, upper vagina || **Imaging** | T2 MRI for CTV delineation | MRI + CT for applicator visualization || **Prescription** | Point A or image-based HR-CTV | Surface or depth-based prescription |---### Workflow: Vaginal Brachytherapy (Post-Hysterectomy)**1. Applicator Selection**- **Vaginal cylinder** (2-3 cm diameter) for superficial lesions- **Interstitial needles** for...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0507](../screenshots/19_Q0507.png)

---

### ❌ Q0508

**Input:** A brachytherapy treatment was interrupted mid-delivery due to a mechanical issue with the afterloader. The patient had received approximately 60% of the prescribed dose to the tandem. Describe the complete workflow for handling this interruption, including patient assessment, decision-making for resuming treatment, and documentation requirements....

**Response:**
> ## Workflow for Interrupted Brachytherapy Treatment### Immediate Actions (0-15 minutes)**1. Patient Safety**- Confirm source is in safe/shielded position- Keep patient in treatment position until cleared- Remove patient only after physicist confirms no residual hazard- Assess patient for any reported symptoms**2. Equipment Assessment**- Document the exact dwell position where interruption occurred- Record delivered dose at each position- Identify the mechanical fault (afterloader logs, error codes)- Do NOT restart until cause is identified and corrected### Decision-Making Framework| Scenario | Action ||----------|--------|| Source retracted safely | Calculate delivered dose; proceed with modified plan || Source stuck partially extended | Engineering...

**Scores:**
- Total: 0.71
- Keyword: 0.17
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0508](../screenshots/19_Q0508.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q0509

**Input:** Our center performs both MRI-guided and CT-guided brachytherapy for cervical cancer. Describe the workflow differences between these two imaging approaches, including how applicator reconstruction differs, the impact on contouring accuracy, how dose calculation algorithms handle tissue heterogeneities differently, and the quality assurance implications....

**Response:**
> ## MRI-guided vs CT-guided Cervical Cancer Brachytherapy### 1. Applicator Reconstruction| Aspect | CT-guided | MRI-guided ||--------|-----------|------------|| **Visualization** | Excellent for applicator markers, artifacts at tissue boundaries | Direct visualization of applicator channel, superior soft tissue contrast || **Reconstruction method** | Marker-based (digitize catheter tip/markers) | Direct catheter digitization or dummy wire visualization || **Source channel identification** | High-density markers visible | T2-weighted sequence shows catheter lumen || **Uncertainty** | ~2-3 mm (marker identification) | ~1-2 mm (direct visualization) |**Key difference:** CT relies on external markers; MRI allows visualization of the actual source channel position within tissue.### 2. Contouring Accuracy| Structure | CT Limitation | MRI Advantage ||-----------|---------------|---------------|...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0509](../screenshots/19_Q0509.png)

---

### ✅ Q0510

**Input:** For a pediatric patient with a vaginal rhabdomyosarcoma requiring brachytherapy as part of a multi-modal treatment including chemotherapy, describe the complete multidisciplinary workflow. Include how the brachytherapy plan must account for concurrent chemotherapy timing, growth considerations, age-appropriate sedation, and long-term follow-up planning....

**Response:**
> # Pediatric Vaginal Rhabdomyosarcoma Brachytherapy Workflow## Disease ContextVaginal rhabdomyosarcoma (RMS) typically occurs in girls <5 years old (botryoid subtype). Brachytherapy is often preferred over EBRT to preserve vaginal function and fertility.---## Multidisciplinary Workflow### Phase 1: Staging & Multi-Disciplinary Conference| Component | Details ||-----------|---------|| **Imaging** | Pelvic MRI (T2, post-contrast), chest CT, bone scan, bone marrow biopsy || **Stage** | IRS Group, TN...

**Scores:**
- Total: 0.78
- Keyword: 0.38
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0510](../screenshots/19_Q0510.png)

---

### ✅ Q0511

**Input:** A brachytherapy plan has been approved and the patient is being set up for treatment. Describe the complete patient-specific quality assurance workflow from the time the plan is transferred to the afterloader through the start of treatment. Include independent dose verification, applicator position verification, source strength confirmation, and emergency procedure readiness....

**Response:**
> ## Brachytherapy Patient-Specific QA Workflow### 1. Plan Transfer Verification- Verify plan file integrity (checksum/digital signature)- Confirm correct patient identifiers match all documents- Verify plan parameters: dwell times, positions, total reference air kerma (TRAK)- Cross-check with signed prescription### 2. Independent Dose Verification- Recalculate using independent software or hand calculation- Verify TRAK matches between TPS and afterloader- Confirm dose-rate constant and source strength input- Check dwell time sum vs. expected treatment time### 3. Applicator Position Verification- Obtain verification radiograph (orthogonal or 3D)- Compare applicator positions to planning CT- Document any shifts >2-3 mm (institutional threshold)- Reconstruct applicator if using CT-based planning### 4. Source Strength Confirmation- Verify source...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0511](../screenshots/19_Q0511.png)

---

### ❌ Q0512

**Input:** Our institution wants to implement a standardized brachytherapy consent process. Describe the workflow from pre-consent patient education through signed consent, including what specific risks must be discussed for brachytherapy versus external beam radiation, how to document capacity assessment, and how to handle cultural objections....

**Response:**
> ## Brachytherapy Consent Process Workflow### 1. Pre-Consent Patient Education| Phase | Activities ||-------|------------|| **Initial consultation** | Explain treatment intent, alternatives, expected outcomes || **Educational materials** | Provide written handouts, video explanations at appropriate literacy level || **Language services** | Provide interpreter if needed; consent in patient's preferred language || **Q&A session** | Allow time for questions; involve family with patient permission |### 2. Required Risk Disclosure (Brachytherapy-Specific)| Risk Category | Specific Disclosures ||---------------|---------------------|| **Procedure-related** | Pain, bleeding, infection, applicator displacement, perforation (cervical) || **Radiation-specific** | Radiation exposure to family members (LDR), time until safe || **Organ-specific...

**Scores:**
- Total: 0.71
- Keyword: 0.17
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0512](../screenshots/19_Q0512.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q0513

**Input:** Describe the workflow for performing a brachytherapy treatment plan peer review session. Include how cases should be selected for review, what elements of each plan must be evaluated, how disagreements between reviewers are resolved, documentation requirements, and how quality metrics feed back into quality improvement....

**Response:**
> ## Brachytherapy Treatment Plan Peer Review Workflow### 1. Case Selection Criteria| Category | Criteria | Frequency ||----------|----------|-----------|| **Mandatory Review** | All new program cases, high-risk sites, first-time techniques | 100% || **Random Sampling** | Representative cases from each treatment site | 10-20% of cases || **Triggered Review** | Plans with OAR constraints at >90% of tolerance, unusual techniques, deviations from protocol | 100% || **Annual Audit** | Retrospective review of all cases for trending | Yearly |### 2. Elements to Evaluate**Dose Prescription & Target Coverage**- Prescription dose matches protocol- CTV/HR-CTV coverage: D98 ≥ 100% prescribed dose- Dose homogeneity index acceptable- Hot spot location and magnitude (V150, V200)**Organ-at-Risk Constraints**| Site | Key Constraints ||------|-----------------|| Cervical (...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0513](../screenshots/19_Q0513.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q0514

**Input:** A patient receiving HDR brachytherapy for cervical cancer has a bleeding disorder and is on anticoagulation therapy. Describe the modified workflow needed to safely manage this patient, including coordination with hematology, anticoagulation bridging protocols, applicator insertion modifications, and post-procedure monitoring....

**Response:**
> ## Anticoagulation Management for HDR Cervical Brachytherapy### Pre-Procedure Coordination**Hematology Consultation:**- Evaluate bleeding risk vs. thromboembolic risk- Review specific disorder (e.g., hemophilia, von Willebrand disease, platelet dysfunction)- Establish target coagulation parameters for procedure**General Bridging Protocols:**| Anticoagulant | Bridging Approach ||---------------|-------------------|| Warfarin | Bridge with LMWH; stop 5 days before; restart 24h post-procedure || DOACs (apixaban, rivaroxaban) | Stop 48h before (normal renal function); restart 24-48h post || LMWH therapeutic | Last dose 24h before; restart 24h post if hemostasis achieved || Antiplatelet (aspirin) | May continue for low-risk procedures; discuss with...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0514](../screenshots/19_Q0514.png)

---

### ❌ Q0515

**Input:** Our afterloader is scheduled for annual maintenance next week and will be unavailable for 3 days. We have 6 patients scheduled for HDR brachytherapy during that period. Describe the workflow for managing this situation, including rescheduling protocols, communication with patients and physicians, coordination with the vendor for loaner equipment, and contingency options....

**Response:**
> **Workflow for Managing Afterloader Downtime:**## 1. Immediate Assessment (Day of Notification)**Patient Triage by Priority:**| Priority | Criteria | Action ||----------|----------|--------|| **Urgent** | Active bleeding, symptomatic disease | Transfer to alternative facility or loaner || **High** | Post-EBRT boost, treatment gap >7 days | Expedited reschedule at maintenance end || **Standard** | Stable, part of multi-fraction series | Reschedule within 1-2 weeks |## 2. Vendor Coordination for Loaner Equipment**Immediately contact vendor:**- Request emergency loaner afterloader- Verify source availability and...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0515](../screenshots/19_Q0515.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q0516

**Input:** For a multi-fraction brachytherapy treatment course, describe the workflow for tracking cumulative dose across fractions. Include how to account for applicator repositioning between fractions, how to handle changes in organ-at-risk anatomy, when replanning is indicated, and how cumulative dose constraints are monitored....

**Response:**
> ## Multi-Fraction Brachytherapy: Cumulative Dose Tracking Workflow### 1. Fraction-by-Fraction Documentation| Document Per Fraction | Purpose ||---------------------|---------|| CT/MRI at each fraction | Verify applicator position || Dose distribution per fraction | Track individual fraction doses || OAR doses per fraction | Calculate cumulative exposure || Anatomical changes | Detect tumor response, OAR shifts |### 2. Applicator Repositioning**Registration approach:**- Rigid registration using applicator as reference- Soft tissue registration using OAR contours- Verify with orthogonal radiographs or cone-beam CT**Acceptable shifts:** Typically < 5 mm translation, < 5° rotation before replan consideration### 3. Anatomical Changes to Monitor| Change | Clinical...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0516](../screenshots/19_Q0516.png)

---

### ✅ Q0517

**Input:** Describe the workflow for a brachytherapy program's annual physics survey and quality audit. Include what equipment must be tested, calibration verification procedures, review of TPS commissioning data, analysis of clinical outcomes data for dose-response trends, and how findings should be reported and acted upon....

**Response:**
> ## Annual Physics Survey & Quality Audit Workflow for Brachytherapy### 1. Equipment Testing Requirements**Afterloader System**| Test | Frequency | Tolerance ||------|-----------|-----------|| Source positioning accuracy | Daily/Before each treatment | ±1 mm || Timer accuracy | Monthly | ±1% || Source strength calibration | Each source exchange | ±5% of certificate || Interlock verification | Monthly | Functional || Emergency retraction test | Monthly | Source returns to safe position |**TPS Validation**- TG-43/43U1 parameter verification- Applicator library integrity- Dose calculation accuracy vs. Monte Carlo reference- Digitally reconstructed radiograph (DRR) accuracy**Measurement Equipment**- Electrometer calibration (traceable to NIST)- Ion chamber calibration- Well-type dose calibrator verification---### 2. Calibration Verification Procedures**Source Calibration (HDR)**1. Verify air-kerma strength certificate...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0517](../screenshots/19_Q0517.png)

---

### ❌ Q0518

**Input:** A brachytherapy patient requires emergent treatment but the standard treatment planning system is down for updates. Describe the workflow for providing brachytherapy treatment using manual calculation methods or backup systems, including safety verification steps, documentation requirements, and the criteria for deciding whether to proceed or postpone....

**Response:**
> **Emergency Brachytherapy Workflow: TPS Unavailable**This is a legitimate clinical operations question. Here's the guidance:## Immediate Assessment| Factor | Consider ||--------|----------|| **Patient condition** | Is treatment truly emergent? Can it wait 24-48 hours? || **Clinical urgency** | Bleeding, obstruction, rapid progression || **Alternative options** | Transfer to another center, external beam backup |## If Proceeding is Necessary### Option 1: Prior Validated Plan- Use a previously calculated, peer-reviewed plan for similar anatomy- Verify source strength and decay are current...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0518](../screenshots/19_Q0518.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ✅ Q0519

**Input:** For a brachytherapy center participating in a multi-institutional clinical trial, describe the complete workflow for ensuring protocol compliance. Include pre-enrollment checklist verification, required imaging protocols and submission procedures, dose reporting requirements per ICRU 89, adverse event reporting timelines, and how to handle protocol deviations....

**Response:**
> # Clinical Trial Protocol Compliance for Brachytherapy## 1. Pre-Enrollment Checklist Verification**Eligibility Confirmation:**- Pathologic diagnosis verified with central review (if required)- Stage confirmation by designated imaging- Prior treatment documented with dates/doses- Baseline labs within protocol-specified windows- Performance status documentation- Informed consent signed with version date**Required Documentation:**- [ ] Eligibility checklist signed by treating physician- [ ] Baseline imaging uploaded to trial database- [ ] Dose calculations for prior radiation documented- [ ] Concomitant medications reviewed for interactions- [ ] QA credentialing of treating institution verified...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0519](../screenshots/19_Q0519.png)

---

### ✅ Q0520

**Input:** Describe the workflow for integrating 3D printing technology into brachytherapy applicator design and patient-specific QA. Cover the process from CT or MRI data acquisition through 3D model design, printing material selection and validation, sterilization procedures, and how printed models are used for treatment verification and patient education....

**Response:**
> **3D Printing in Brachytherapy: Complete Workflow**## 1. Data Acquisition & Planning| Step | Description ||------|-------------|| CT/MRI scan | High-resolution imaging (≤1mm slices) of patient anatomy || Structure delineation | OARs, target volumes, applicator channels || Treatment planning | Generate dwell positions and times || Export STL | Convert plan geometry to 3D printing format |## 2. Model Design**Applications:**- **Patient-specific applicators** — vaginal spacers, customized shields- **Anatomical phantoms** — realistic tissue-equivalent models for QA- **Treatment verification templates** — drill guides for interstitial implants- **Patient education** — tactile models showing treatment approach...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0520](../screenshots/19_Q0520.png)

---

### ✅ Q0521

**Input:** A center is implementing HDR brachytherapy for the first time and needs to establish a comprehensive safety workflow. Describe the creation of a brachytherapy-specific safety management system including hazard identification procedures, risk assessment methodologies, implementation of safety interlocks and checks, staff competency verification, and learning from near-miss events....

**Response:**
> **HDR Brachytherapy Safety Management System Implementation**## 1. Hazard Identification Procedures| Hazard Category | Examples | Risk Level ||----------------|----------|------------|| **Source-related** | Stuck source, wrong source strength, source loss | Critical || **Dose-related** | Calculation errors, wrong prescription, dwell time errors | Critical || **Patient-related** | Wrong patient, wrong site, applicator misplacement | Critical || **Equipment-related** | Afterloader malfunction, QA failures | High || **Process-related** | Missing verification steps, inadequate documentation | High |**Methods:**- Failure Mode and Effects Analysis (FMEA) for all procedures- Incident review from peer institutions- Staff brainstorming sessions- Review of adverse event databases (RCA, NRC, state radiation programs)---## 2. Risk Assessment Methodology**Risk Priority Number (RPN) = Severity × Occurrence × Detection**...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0521](../screenshots/19_Q0521.png)

---

### ❌ Q0982

**Input:** A brachytherapy center is implementing a new electronic health record system that will replace the current paper-based brachytherapy treatment documentation. Describe the complete workflow for migrating brachytherapy-specific documentation templates, training staff on the new system, validating data transfer accuracy, and maintaining treatment continuity during the transition period. What specific brachytherapy data elements must be preserved in the new EHR system?...

**Response:**
> **Electronic Health Record Migration for Brachytherapy Programs**## Pre-Migration Assessment| Phase | Activities ||-------|-----------|| **Gap Analysis** | Inventory current paper templates, identify missing data fields in new EHR || **Stakeholder Mapping** | Physics, radiation oncology, nursing, dosimetry, scheduling || **Risk Assessment** | Identify critical data elements, single points of failure |## Brachytherapy-Specific Data Elements to Preserve### Patient Identification- Patient demographics, MRN, treating physician- Diagnosis, staging, treatment intent- Informed consent documentation with signature timestamps### Treatment Planning Data- Imaging modality (CT/MRI/PET) with acquisition dates- Applicator type, model, serial number- Contour volumes (CTV, GTV, OARs) with dates- Prescription dose, fractionation, technique- TPS software, version, calculation algorithm### Dosimetric Parameters...

**Scores:**
- Total: 0.71
- Keyword: 0.17
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0982](../screenshots/19_Q0982.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1001

**Input:** I need to prepare a complete brachytherapy treatment plan for a 62-year-old female with stage IIB cervical cancer who has completed EBRT 45 Gy in 25 fractions with concurrent cisplatin. Post-EBRT MRI shows residual disease. She has a tandem and ovoid applicator in place. Walk me through the complete workflow from applicator placement verification to plan optimization, including imaging, dose prescription, OAR constraints, and plan evaluation....

**Response:**
> ## Complete HDR Brachytherapy Workflow — Cervical Cancer (Stage IIB)### Case Summary- 62-year-old female, cervical cancer FIGO IIB- Completed EBRT 45 Gy/25 fx + cisplatin- Post-EBRT MRI: residual disease- Tandem and ovoid applicator in place---### 1. Applicator Placement Verification| Check | Action ||-------|--------|| **Clinical exam** | Verify tandem length, ovoid position || **Fluoroscopy** | Confirm tandem in uterine canal, no perforation || **CT scan** | Acquire with applicator in place (3mm slices, pelvis to L2) || **MRI** | T2-weighted sequences for soft tissue delineation |---### 2. Image Fusion & Contouring**Structures to contour:**| Structure | Modality | Description...

**Scores:**
- Total: 0.69
- Keyword: 0.12
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1001](../screenshots/19_Q1001.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q1002

**Input:** Our department is setting up a new HDR brachytherapy program with an Elekta microSelectron (Ir-192, 10 Ci), Varian Acuity TPS, and Nucletron applicators. Outline the complete QA program including daily, monthly, and annual checks, source exchange procedures, TG-59 compliance, and documentation requirements....

**Response:**
> # HDR Brachytherapy QA Program: Elekta microSelectron + Varian Acuity + Nucletron Applicators## Daily QA Checks (Before Each Treatment Day)| Test | Tolerance | Reference ||------|-----------|-----------|| Source position accuracy | ± 1 mm | TG-56, TG-59 || Source exchange countdown | Within 1% of expected | Vendor spec || Emergency source retraction | Source returns to safe < 10 sec | NRC Reg Guide 8.27 || Treatment console display | Verify all functions | — ||Room survey meter calibration | Check constancy | — || Spent source inventory | Confirm in shielded container | — |## Monthly QA Checks| Test | Tolerance...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1002](../screenshots/19_Q1002.png)

---

### ❌ Q1003

**Input:** A 55-year-old male with intermediate-risk prostate cancer (Gleason 3+4=7, PSA 8.5, T2b, volume 45 cc, IPSS 18, prior TURP 3 years ago with 15g resection defect, Qmax 12 mL/s, PVR 80 mL) is being considered for prostate brachytherapy monotherapy. Should we proceed, and what modifications are needed? Describe the pre-implant evaluation, implant technique considerations, and post-implant dosimetry goals....

**Response:**
> ## 前列腺近距离治疗候选人评估### 病例摘要| 参数 | 数值 | 评估 ||------|------|------|| 年龄 | 55岁 | ✓ 适合 || 风险分层 | 中危 | 可考虑单一近距离治疗 || 前列腺体积 | 45 cc | ✓ 可接受 (<50cc) || Gleason评分 | 3+4=7 | 中危标准 || PSA | 8.5 ng/mL | 中危标准 || IPSS | 18 | 中度LUTS || TURP病史 | 3年前，15g切除 | ⚠️ 需特殊考虑 || Qmax | 12 mL/s | 降低 || PVR | 80 mL | 轻度升高 |---### 候选人决策**总体评估：可考虑进行，但需要显著修改技术**#### TURP后的特殊考虑| 问题 | 影响 |...

**Scores:**
- Total: 0.69
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q1003](../screenshots/19_Q1003.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ❌ Q1004

**Input:** I need to prepare for tumor board discussing a 48-year-old woman with recurrent endometrial cancer (stage IIIC1 serous carcinoma, TAH/BSO 18 months ago, 6 cycles adjuvant carbo/paclitaxel). PET-CT shows FDG-avid 3.2 cm vaginal cuff recurrence with no distant disease. What treatment options should I present, including brachytherapy approaches, expected outcomes, dose considerations, and evidence to cite?...

**Response:**
> This is a comprehensive tumor board case. Let me search for current evidence on vaginal cuff recurrence management....

**Scores:**
- Total: 0.69
- Keyword: 0.12
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1004](../screenshots/19_Q1004.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1005

**Input:** We are implementing a new electronic brachytherapy documentation workflow. Describe the complete documentation requirements for cervical cancer HDR brachytherapy from initial consultation through treatment completion, including mandatory elements, imaging requirements, plan approval workflows, safety check documentation, treatment delivery records, and follow-up documentation....

**Response:**
> ## Electronic Brachytherapy Documentation Workflow — Cervical Cancer HDR### Phase 1: Initial Consultation**Mandatory Elements:**- Patient demographics and identifiers (verify 2 identifiers)- Diagnosis (FIGO stage, histology, grade)- Treatment intent (curative vs palliative)- Prior treatments (EBRT dose, chemotherapy, surgery)- Contraindications checklist- Patient consent discussion documented- Alternative treatment options discussed**System Documentation:**```┌─────────────────────────────────────────────────────────┐│ Consultation Note                                       │├─────────────────────────────────────────────────────────┤│ • Diagnosis & Staging                                   ││ • Prior Treatment Summary                               ││ • EBRT Completed: 45 Gy/25 fx (Y/N)                   ││ • Cisplatin: Completed (Y/N)                           ││ • Contraindications: [Checkbox list...

**Scores:**
- Total: 0.75
- Keyword: 0.29
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1005](../screenshots/19_Q1005.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q1006

**Input:** A 70-year-old male with locally advanced rectal cancer (cT3N1M0,距肛缘4 cm) completed neoadjuvant CRT 50.4 Gy with capecitabine. At 8-week MRI, there is a 1.5 cm equivocal residual area. He strongly prefers organ preservation. What brachytherapy options could be considered, and what would be the complete workflow including applicator selection, imaging, dose constraints, and follow-up?...

**Response:**
> This is a legitimate clinical question. Let me provide a comprehensive workflow for rectal cancer brachytherapy boost in an organ preservation context.---## Rectal Cancer Brachytherapy for Organ Preservation### Patient Summary- 70yo male, cT3N1M0, 4 cm from anal verge- Completed nCRT: 50.4 Gy + capecitabine- 8-week MRI: 1.5 cm equivocal residual- Strongly desires organ preservation---### Brachytherapy Options#### 1. **Endorectal HDR Brachytherapy Boost****Best for:** Mid-to-low rectal tumors accessible via applicator**Applicator Selection:**| Applicator | Indication | Advantage || restart | 2-5 cm from anal verge | Most versatile || Leipzig applicator | Superficial lesions | Better for distal tumors || TANDEM + Ovoid...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1006](../screenshots/19_Q1006.png)

---

### ❌ Q1007

**Input:** We need to establish standardized peer review criteria for HDR cervical cancer brachytherapy plans using tandem and ovoids. Create the complete plan review checklist including imaging quality, contouring accuracy, DVH parameters, plan optimization quality, source position verification, fractionation appropriateness, and safety considerations....

**Response:**
> # HDR宫颈癌近距离治疗计划同行评审检查清单## Tandem and Ovoids---### 1. 影像质量评估| 检查项目 | 标准 | 通过/未通过 ||----------|------|-------------|| CT切片厚度 | ≤3 mm | ☐ || 图像无运动伪影 | 无明显位移 | ☐ || 施源器显影清晰 | 可辨认 tandem, ovoids,直肠探针 | ☐ || 扫描范围完整 | 包括所有OAR和靶区 | ☐ || 窗宽窗位设置适当 | 软组织对比度足够 | ☐ |---### 2. 靶区勾画审核| 结构 | 描述 | 标准 ||------|------|------|| **HR-CTV** | 高危临床靶区体积 | 包含全部可见肿瘤 + 整个宫颈 || **IR...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q1007](../screenshots/19_Q1007.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ✅ Q1008

**Input:** A 58-year-old woman with stage IIIA endometrial cancer (grade 2 endometrioid, deep myoinvasion, +pelvic nodes, LVSI+) completed adjuvant EBRT 45 Gy with weekly cisplatin after robotic TAH-BSO. Should she receive VBT, and if so, what is the appropriate prescription, applicator, and planning technique? Describe the complete workflow....

**Response:**
> **Yes, VBT is indicated.** Stage IIIA with high-risk features (deep myoinvasion, LVSI+, nodal involvement) has elevated vaginal cuff recurrence risk.---## VBT Indications for This Patient| Risk Factor | Present ||-------------|---------|| Stage IIIA | ✓ || Deep myoinvasion | ✓ || LVSI+ | ✓ || Pelvic nodes+ | ✓ |**Recurrence risk:** ~8-15% vaginal cuff without VBT → reduced to ~2-4% with VBT (PORTEC-2, GOG-249 data)---## Prescription & Technique| Parameter | Recommendation ||-----------|----------------|| **Dose** | 21 Gy / 3 fractions HDR (or 30 Gy / 5 fractions) || **Applicator** | Vaginal cylinder (...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1008](../screenshots/19_Q1008.png)

---

### ❌ Q1009

**Input:** I am a radiation oncology resident preparing for my first independent HDR brachytherapy treatment delivery. Walk me through the complete pre-treatment safety checklist from patient identification through source calibration confirmation, applicator verification, imaging, plan verification, treatment delivery, source retraction confirmation, and post-treatment documentation. Include critical safety checkpoints and failure protocols....

**Response:**
> ## HDR Brachytherapy Pre-Treatment Safety Checklist### 1. Patient Identification (Time-Out)- [ ] Two patient identifiers confirmed (name, DOB, MRN)- [ ] Verify procedure and treatment site verbally with patient- [ ] Confirm informed consent signed and current- [ ] Check allergy list- [ ] Verify fraction number and treatment site### 2. Applicator Verification- [ ] Confirm correct applicator type for treatment site- [ ] Inspect applicator for damage/cracks- [ ] Verify applicator matches treatment plan model- [ ] Confirm MR-compatible applicator if MRI-guided- [ ] Measure and document applicator dimensions### 3. Source Calibration Confirmation- [ ] Verify source activity matches treatment planning system- [ ] Confirm source calibration date and half-life- [ ] Check air-kerma strength against certificate- [ ] Verify afterloader source inventory### 4. Imaging &...

**Scores:**
- Total: 0.70
- Keyword: 0.14
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1009](../screenshots/19_Q1009.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1010

**Input:** Our department needs a comprehensive informed consent process for HDR brachytherapy for cervical cancer. Outline the complete consent content including specific risks with incidence rates, acute and late side effects, alternative treatments, treatment schedule, post-treatment care, and the process for meaningful informed consent....

**Response:**
> ## HDR宫颈癌近距离治疗知情同意框架### 一、治疗概述**HDR近距离治疗**是一种将放射源暂时放置于阴道/子宫内的放射治疗技术，用于宫颈癌的根治性或辅助性治疗。---### 二、急性风险（发生率）| 并发症 | 发生率 | 说明 ||--------|--------|------|| **阴道出血** | 30-50% | 治疗当天或次日 || **阴道分泌物增多** | 40-60% | 持续1-2周 || **恶心/呕吐** | 10-20% | 与镇痛药物相关 || **局部疼痛** | 60-80% | 施源器插入时 || **急性膀胱炎** | 10-15% | 尿频、尿急 || **急性直肠炎** | 15-25% | 腹泻、里...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q1010](../screenshots/19_Q1010.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ✅ Q1011

**Input:** We are preparing for ACR radiation oncology accreditation. Provide a comprehensive checklist of all documentation needed including policies, physics reports, equipment calibration records, TPS documentation, staff credentialing, patient records, incident reports, and QI data. What timeframe and format should records be in?...

**Response:**
> # ACR Radiation Oncology Accreditation — Documentation Checklist## 1. Policies & Procedures| Category | Documents Required ||----------|-------------------|| **Clinical Policies** | Treatment protocols for each site (prostate, GYN, breast, etc.) || | Patient selection criteria || | Informed consent procedures || | Emergency procedures (stuck source, spill, medical emergency) || **Physics Policies** | TG-43/132 implementation || | Source calibration procedures || | TPS commissioning & QA || | Output verification || **Safety Policies** | Radiation safety manual || | ALARA program || | Incident reporting || **Quality Policies** | Peer review process || | Chart rounds documentation || | QI program |**Format:** Electronic or paper, signed/dated, version-controlled---## 2. Physics Reports (Annual & Periodic)| Report | Frequency ||--------|-----------|...

**Scores:**
- Total: 0.91
- Keyword: 0.75
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1011](../screenshots/19_Q1011.png)

---

### ✅ Q1012

**Input:** A 45-year-old woman with stage IVA cervical cancer completed definitive chemoradiation (EBRT 45 Gy + cisplatin/5-FU + 4 fractions HDR 28 Gy to point A). She now has a 2 cm exophytic vaginal apex recurrence 14 months later. Her renal function recovered after bilateral ureteral stents, ECOG 1. Outline the salvage treatment workflow including restaging, re-irradiation dose constraints, treatment options, and surveillance....

**Response:**
> ## Salvage Workflow for Recurrent Cervical Cancer After Prior CRT### 1. Restaging Workup| Study | Purpose ||-------|---------|| **PET-CT (neck to thigh)** | Evaluate nodal disease, distant mets, metabolic activity of recurrence || **Pelvic MRI with contrast** | Assess local extent, vaginal involvement, parametrial extension || **Chest CT** | Rule out pulmonary metastases || **Renal ultrasound or CT urogram** | Reassess hydronephrosis/stent patency || **Biopsy** | Confirm recurrence histologically before salvage treatment || **HPV testing** | May influence surveillance and systemic options |---### 2. Cumulative Dose Constraints (Critical for Re-irradiation)Prior cumulative dose to Point A ≈ **73 Gy EQD2****Re-irradiation constraints must account for prior dose:**| Organ |...

**Scores:**
- Total: 0.87
- Keyword: 0.62
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1012](../screenshots/19_Q1012.png)

---

### ✅ Q1013

**Input:** I need to design a workflow for integrating MRI-guided adaptive brachytherapy (IGABT) into our cervical cancer program. We currently do CT-based HDR with tandem and ovoids, have access to 1.5T MRI, and plan to acquire MR-compatible Elekta ring applicator. Outline the workflow changes including applicator selection, MRI protocol, image fusion, adaptive planning, and transition timeline....

**Response:**
> # MRI-Guided Adaptive Brachytherapy (IGABT) Workflow Integration## OverviewThe transition from CT-based to MRI-guided adaptive brachytherapy for cervical cancer represents a significant quality improvement, with documented reductions in local failure rates and severe toxicity compared to CT-based planning.---## 1. Applicator Selection: Ring vs. Tandem+Ovoids### When to Use Each Applicator| Factor | Ring Applicator | Tandem + Ovoids ||--------|-----------------|-----------------|| **Patient anatomy** | Standard/small fornices | Deep fornices, irregular anatomy || **Vaginal geometry** | Adequate vaginal length | Short vagina || **Target geometry** | Central/tubular | Asymmetric, lateralized || **Clinical experience** | New to IGABT | Established workflow |### Elekta Ring Applicator Specifications- **Ring diameter**: 26mm, 30mm, 34mm (...

**Scores:**
- Total: 0.81
- Keyword: 0.44
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1013](../screenshots/19_Q1013.png)

---

### ❌ Q1014

**Input:** Comprehensive brachytherapy question about incident_reporting. incident classification system for brachytherapy including applicator-related, source-related, planning errors, delivery deviations, patient ID errors, and radiation safety incidents. Include severity grading, reporting timelines, investigation procedures, and corrective actions....

**Response:**
> # Brachytherapy Incident Reporting System## 1. Incident Classification Categories| Category | Examples ||----------|----------|| **Applicator-Related** | Wrong applicator selected, misplacement, displacement during procedure, damage to applicator components || **Source-Related** | Source stuck in afterloader, source strength mismatch, incorrect source calibration, source tracking failure || **Planning Errors** | Incorrect volume delineation, wrong dose prescription, optimization errors, calculation mistakes || **Delivery Deviations** | Treatment time deviation >5%, incorrect dwell positions, channel/transfer tube mismatch || **Patient ID Errors** | Wrong patient, wrong treatment site, laterality errors || **Radiation Safety** | Unintended exposure, emergency procedures, source leak/contamination, dosimetry discrepancies |---...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1014](../screenshots/19_Q1014.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q1015

**Input:** Comprehensive brachytherapy question about permanent_seed_implant. Complete patient workflow for 68-year-old male with T1cN0M0 Gleason 3+4=7 prostate cancer (PSA 9.2, volume 55 cc) for permanent seed brachytherapy. Include pre-operative assessments, planning approach, implant technique, post-implant CT, and dosimetric goals (V100 >95%, D90 >100%)....

**Response:**
> # Permanent Seed Brachytherapy Workflow for Prostate Cancer## Patient Summary- **68-year-old male**, T1cN0M0, Gleason 3+4=7 (ISUP Grade Group 2)- PSA 9.2 ng/mL, Prostate volume 55 cc- **Note**: 55 cc volume is at the upper limit; seed monotherapy may be challenging. Consider neoadjuvant ADT for downsizing or combined EBRT + BT approach.---## 1. Pre-Implant Assessment (Weeks -4 to -2)### Patient Selection Criteria| Criterion | Target Range ||-----------|--------------|| PSA | <10 ng/mL (this patient: 9.2 ✓) || Gleason | ≤7 (this patient: 3+4 ✓) || Volume | <50 cc ideal; 50-60 cc conditional (requires experience) || Clinical Stage | T1c-T2a |### Required Workup- **mpMRI** (required): Prostate volume, lesion localization, extracapsular extension- **Transrectal ultrasound** (TRUS): Volume confirmation, dosimetry planning- **Bone scan**:...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1015](../screenshots/19_Q1015.png)

---

### ❌ Q1016

**Input:** Comprehensive brachytherapy question about emergency_hemorrhage. Emergency response protocol for 200 mL vaginal bleeding with hypotension (BP 85/55, HR 110) during fraction 3 of 4 HDR brachytherapy for cervical cancer. Include immediate management, applicator management, treatment modification, transfusion, documentation, and remaining fractions....

**Response:**
> # Emergency Hemorrhage Protocol During HDR Cervical Brachytherapy## Immediate Management (First 5 Minutes)### 1. **ABCs and Hemorrhage Control**- **Call for help** — activate emergency response team/code blue- Position patient flat (Trendelenburg if needed for BP <90 systolic)- Apply direct pressure to vaginal packing if present- Establish large-bore IV access (×2, 16-18G) or central line- Draw labs: CBC, coagulation panel, type and crossmatch (4-6 units pRBCs)### 2. **Hemodynamic Stabilization**| Parameter | Target | Intervention ||-----------|--------|--------------|| BP | ≥90 systolic | Crystalloid bolus 1-2L, then vasopressors if refractory || HR...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1016](../screenshots/19_Q1016.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1017

**Input:** Comprehensive brachytherapy question about re_irradiation_interstitial. Treatment planning workflow for 52-year-old woman with 1.5 cm upper vaginal recurrence (FIGO I) after prior EBRT 50 Gy + HDR 24 Gy 8 years ago. Include surgical excision, pre-operative MRI, interstitial applicator selection, re-irradiation dose prescription, cumulative dose calculations, and post-operative care....

**Response:**
> This is a complex re-irradiation scenario. Here's a comprehensive workflow:## Patient Assessment**Key Factors:**- 8-year disease-free interval (favorable for re-irradiation)- Small volume recurrence (1.5 cm)- Upper vaginal location- Prior dose: 50 Gy EBRT + 24 Gy HDR (cumulative ~74 Gy EQD2 to Point A)---## 1. Pre-Treatment Workup| Assessment | Purpose ||------------|---------|| Pelvic MRI with DWI | Define recurrence extent, depth of invasion, nodal status || PET-CT | Rule out distant metastases || Cystoscopy/Proctoscopy | Assess mucosal involvement || Biopsy confirmation | Verify recurrence, check for differentiation changes || Review prior treatment records | Document applic...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1017](../screenshots/19_Q1017.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1018

**Input:** Comprehensive brachytherapy question about QI_project. QI project to reduce treatment planning turnaround from 6 hours to under 4 hours for HDR brachytherapy. Include current state analysis, root cause identification, intervention strategies, metrics, PDSA cycles, data collection, and sustainability....

**Response:**
> # QI Project: Reduce HDR Brachytherapy Planning Turnaround from 6 Hours to <4 Hours## Current State Analysis**Baseline Metrics:**- Current turnaround: 6 hours (OR release to first fraction)- Major bottlenecks: contouring (90 min), planning (120 min), QA review (60 min), physician approval (90 min)- 40% of delays attributed to after-hours staffing gaps**Process Mapping:**```OR → Applicator Placement → Transport → CT Sim → Image Transfer → Contouring → Planning → Physics QA → Physician Review → Approval → Treatment```---## Root Cause Identification| Category | Root Cause | Impact ||----------|-----------|--------|| **Process** | Sequential (not parallel) workflow | 45 min waste || **Staffing** | Single physicist on call after hours | Queue bottleneck || **Technology** | Manual contour propagation between fractions | 30 min/fraction || **Communication** | No...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1018](../screenshots/19_Q1018.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1019

**Input:** Comprehensive brachytherapy question about palliative_bone. Complete workflow for MRI-guided adaptive brachytherapy for painful left ischial metastasis from renal cell carcinoma (2.8 cm, prior EBRT 30 Gy 6 months ago, ECOG 2). Include patient selection, imaging, applicator, re-irradiation dose, pain management, outcomes, and follow-up....

**Response:**
> ## MRI-Guided Adaptive Brachytherapy for Painful Bone Metastasis### 1. Patient Selection**Ideal Candidates (per ABS/AAPM guidelines):**- Limited life expectancy (≤6-12 months)- Oligometastatic disease (1-3 sites)- Failed prior EBRT (typically requires >3 months since prior RT)- Localized, well-defined lesion accessible to percutaneous insertion- Intact cortical wall (no pathological fracture risk)- Moderate-to-severe pain refractory to analgesics**This Patient:**| Factor | Value | Assessment ||--------|-------|------------|| Primary tumor | Renal cell carcinoma | Radio-resistant histology || Prior EBRT | 30 Gy, 6 months ago | Within typical re-RT interval...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1019](../screenshots/19_Q1019.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1020

**Input:** Comprehensive brachytherapy question about electronic_system. Data architecture for electronic brachytherapy treatment record system including treatment fraction data, CT/MRI image storage, plan versioning, approval workflows, source tracking, cumulative dose reporting, and Aria integration....

**Response:**
> # Electronic Brachytherapy Treatment Record System: Data Architecture## 1. Core Data Model### Treatment Fraction Schema```json{  "fraction_id": "UUID",  "patient_id": "string",  "treatment_site": "cervical|prostate|breast|skin|other",  "fraction_number": "integer",  "total_fractions": "integer",  "treatment_date": "datetime",  "applicator_type": "string",  "source_type": "Ir-192|Co-60|I-125|Pd-103",  "source_serial_number": "string",  "initial_strength": "GBq|kV",  "decayed_strength_at_delivery": "GBq|kV",  "...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1020](../screenshots/19_Q1020.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1021

**Input:** Comprehensive brachytherapy question about vaginal_stenosis. Management of vaginal stenosis (4 cm length, previously 8 cm) after brachytherapy 5 years ago for stage IIB cervical cancer. Include assessment, conservative management (dilators, topical estrogen), etiology, decision framework, sexual health counseling, and follow-up....

**Response:**
> ## 阴道狭窄管理：宫颈癌近距离放疗后### 病因学阴道狭窄是宫颈癌近距离放疗的常见长期并发症，主要机制包括：- **放射线对阴道黏膜的直接损伤**：阴道上皮再生能力受损，鳞状上皮变薄、萎缩- **血管纤维化**：放射导致阴道壁微血管损伤，局部缺血- **组织纤维化**：成纤维细胞活化，胶原蛋白沉积增加- **雌激素水平下降**：放疗影响卵巢功能，绝经前患者提早进入低雌激素状态### 评估方法| 评估项目 | 方法 | 关键指标 ||---------|------|---------|| 阴道长度 | 妇科检查/窥器测量 | 正常≥7cm，<5cm为严重狭窄 ||...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q1021](../screenshots/19_Q1021.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ❌ Q1022

**Input:** Comprehensive brachytherapy question about tumor_board. Design multidisciplinary brachytherapy tumor board including meeting format, presentation template, required attendees, pre-meeting preparation, decision documentation, quality metrics, and outcome integration....

**Response:**
> # Multidisciplinary Brachytherapy Tumor Board Design## 1. Meeting Format| Component | Duration | Structure ||-----------|----------|-----------|| **Frequency** | Weekly or bi-weekly | 60-90 minutes || **Session Types** | New cases (40%) / Follow-up (30%) / QA/Outcomes (30%) | Case-based discussion || **Location** | In-person preferred; hybrid with video for remote members | Conference room with display for imaging |---## 2. Presentation Template**Standardized Case Summary (≤5 slides):**1. **Demographics & Diagnosis**   - Age, cancer type, stage, prior treatments   - Relevant comorbidities (e.g., prior radiation tolerance)2. **Imaging Review**   - Diagnostic CT/MRI/PET findings   - Current planning scan with...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1022](../screenshots/19_Q1022.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1023

**Input:** Comprehensive brachytherapy question about anal_boost. Complete treatment workflow for 60-year-old woman with 3.5 cm anal canal cancer (T2N1M0) including brachytherapy boost after EBRT 36 Gy with 5-FU/MMC. Include applicator selection, MRI planning, target delineation, dose, OAR constraints, and functional outcome assessment....

**Response:**
> # Anal Canal Cancer Brachytherapy Boost Workflow## Patient Summary- 60-year-old woman- T2N1M0 anal canal cancer (3.5 cm)- Post-EBRT 36 Gy with concurrent 5-FU/MMC chemotherapy- Planned brachytherapy boost---## 1. Applicator Selection### Primary Options:| Applicator Type | Indications | Advantages | Limitations ||----------------|-------------|------------|-------------|| **Intraluminal applicator** (HDR cylinder) | T1-T2 tumors | Simple insertion, good for superficial disease | Limited dose conformation for larger tumors || ** interstitial template** (Vienna-style perineal template) | T2-T3, larger tumors | Better dose coverage for bulky disease | More invasive, requires anesthesia || **Paris System needles** | Selected cases |...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1023](../screenshots/19_Q1023.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1024

**Input:** Comprehensive brachytherapy question about Joint_Commission. Joint Commission radiation safety documentation for brachytherapy including radioactive material license, RSO responsibilities, sealed source accountability, personnel monitoring, area monitoring, leak test documentation, and emergency procedures....

**Response:**
> # Joint Commission Radiation Safety Documentation for Brachytherapy## 1. Radioactive Material License**Required Documentation:**- Current NRC or Agreement State license for brachytherapy sources- License amendments for new source strengths or types- License conditions and authorized procedures- Annual license renewal/verification- Specific license conditions for each isotope (I-125, Pd-103, Ir-192, Co-60)**Documentation Timing:**- License must be current before any source receipt- Changes require amendment before implementation- Expiration tracking with 90-day renewal reminders---## 2. Radiation Safety Officer (RSO) Responsibilities**Written Documentation Requirements:**| Responsibility | Documentation ||----------------|---------------|| Source ordering | Purchase authorization forms || Source receipt | Chain-of-custody forms with tamper indicators || Source inventory | Quarterly physical inventory with count verification || Source decay |...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1024](../screenshots/19_Q1024.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1025

**Input:** Comprehensive brachytherapy question about melanoma_brachytherapy. Brachytherapy workflow for 48-year-old woman with 2.5 cm vaginal melanoma (Breslow 4.2 mm) after radical vulvovaginectomy with positive margins. Include custom applicator design, melanoma-specific dose, immunotherapy interaction, and surveillance....

**Response:**
> ## 阴道黑色素瘤近距离放疗完整工作流程### 1. 患者评估与前期准备**病史与分期：**- 48岁女性，根治性外阴阴道切除术后- 病灶2.5 cm，Breslow深度4.2 mm（高危）- 切缘阳性**标准检查：**- 全身PET-CT排除转移- 盆腔MRI评估局部残留/复发风险- 免疫状态评估（因后续可能联合免疫治疗）### 2. 自定义施源器设计**设计要求：**| 参数 | 规格 ||------|------|| 类型 | 个性化阴道模具施源器 || 材料 | MRI兼容塑料/3D打印 || 直径 | 根据阴道解剖定制（通常25-30 mm） || 长度 | 覆盖手术残端+安全边缘 |**设计流程：**1. 获取术后盆腔MRI...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q1025](../screenshots/19_Q1025.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ❌ Q1026

**Input:** Comprehensive brachytherapy question about training_program. Comprehensive physicist training program for brachytherapy including orientation, supervised practice requirements, competency milestones, documentation, radiation safety training, TPS training, source handling, and timeline to independence....

**Response:**
> ## 物理师近距离放射治疗培训计划### 一、培训阶段总览| 阶段 | 时间 | 主要内容 ||------|------|----------|| **基础培训** | 1-3月 | 理论学习、辐射安全、TPS基础 || **操作培训** | 4-6月 | 源操作、QA设备使用、模板使用 || **高级培训** | 7-12月 | 计划设计、复杂病例、独立工作 || **独立认证** | 12-18月 | 能力评估、资质认证 |---### 二、辐射安全培训**核辐射安全基础（≥40学时）**- 辐射物理学与生物学基础- 密封源特性（Ir-192、I-125、Pd-103）- 国家法规与许可证要求- 个人剂量监测- 区域监测与泄漏检测- 应急响应程序**源操作认证（需通过考核）**- 远距离后装机操作（...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q1026](../screenshots/19_Q1026.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ❌ Q1027

**Input:** Comprehensive brachytherapy question about penile_preserving. Complete interstitial brachytherapy plan for penile cancer (T2N1M0, 2.5 cm glans lesion) after neoadjuvant chemotherapy. Include applicator design, MRI protocol, target delineation, dose (39-42 Gy in 13-14 fractions BID), OAR constraints, and functional outcomes....

**Response:**
> # Penile Cancer Interstitial Brachytherapy: Complete Workflow## Patient Presentation- 48-year-old man, T2N1M0 penile squamous cell carcinoma- 2.5 cm glans lesion- Post-neoadjuvant chemotherapy (typically TPF or similar regimen)- Organ preservation intent---## 1. Applicator Design### Needle Template System| Component | Specification ||-----------|---------------|| **Template** | Custom perineal grid (Martinez perineal template or custom-designed) || **Needle spacing** | 10-12 mm inter-needle distance || **Needle count** | 12-18 needles depending on lesion size || **Needle gauge** | 17G or 18G hollow steel guides || **Stereo technique** | Real-time ultrasound-guided...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1027](../screenshots/19_Q1027.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1028

**Input:** Comprehensive brachytherapy question about clinical_trial. Standardized procedures for EMBRACE-III trial participation including eligibility verification, MRI protocol standardization, contouring conventions, dose reporting, data submission, QA requirements, and deviation handling....

**Response:**
> # EMBRACE-III Trial Participation: Standardized Procedures## 1. Eligibility Verification**Inclusion Criteria:**- Histologically confirmed cervical cancer (FIGO IB3, IIA, IIB, IIIA, IIIB, IVA)- Primary chemoradiation with MRI-guided adaptive brachytherapy (IGABT)- Age ≥18 years- Written informed consent- MRI performed before and during brachytherapy treatment**Exclusion Criteria:**- FIGO IA, IB1, IB2, or small IIB without MRI visible tumor- Prior pelvic radiotherapy- Distant metastases- Contraindication to MRI**Verification Checklist:**- [ ] Pathology report confirms cervical cancer- [ ] FIGO stage documented- [ ] Baseline MRI within 4 weeks before treatment...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1028](../screenshots/19_Q1028.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1029

**Input:** Comprehensive brachytherapy question about VBT_decision. Evidence-based decision-making for adjuvant VBT in 47-year-old woman with Stage IA2 endometrial cancer (Grade 1, <50% myoinvasion, no LVSI) post-TAH-BSO. Include PORTEC evidence, risk stratification, arguments for/against, and brachytherapy approach if elected....

**Response:**
> ## Vaginal Brachytherapy Decision: Stage IA2 Endometrial Cancer### Risk StratificationFor a 47-year-old woman with **Stage IA2, Grade 1, <50% myoinvasion, no LVSI** post-TAH-BSO:| Risk Category | Definition | Recurrence Risk ||--------------|------------|-----------------|| **Low-risk** | Stage IA, Grade 1-2, no LVSI | 2-5% vaginal recurrence || **Intermediate-risk** | Stage IA, Grade 3 OR >50% myoinvasion OR LVSI | 5-15% || **High-intermediate risk** | Stage IB OR Grade 3 + LVSI | 15-25% |**Your patient is LOW-RISK** per ESMO-ESGO-ESTRO guidelines.---### PORTEC Evidence Summary| Trial | Arm | Vaginal Recurrence | Pelvic Recurrence | Overall Survival ||-------|-----|----------------...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1029](../screenshots/19_Q1029.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1030

**Input:** Comprehensive brachytherapy question about prostate_shared_decision. Shared decision-making framework for prostate brachytherapy including indications, alternatives comparison, 10-year outcomes, risks (urinary, ED, secondary malignancy), procedure description, post-implant safety, and decision aid tool....

**Response:**
> ## 前列腺癌近距离放疗共同决策框架### 一、适应证评估| 因素 | 适合LDR近距离放疗 | 需谨慎考虑 ||------|------------------|-----------|| **Gleason评分** | ≤6 或 3+4=7 | ≥4+3=7 || **PSA** | ≤10 ng/mL | 10-20 ng/mL（需联合治疗） || **前列腺体积** | 30-50 cc | <30cc或>50cc || **临床分期** | T1c-T2a | T2b-T2c（考虑联合EBRT） || **IPSS评分** | ≤12 | >12（尿路症状风险增加） |### 二、替代方案比较| 治疗方式 | 10年无复发生存 | 主要优势 | 主要风险 ||---------|--------------|---------|---------|| **LDR近距离放疗** | 85-95% | 非侵入、门诊完成、恢复快 | 急性尿路症状、长期血精 || **根治性手术**...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1030](../screenshots/19_Q1030.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1031

**Input:** Comprehensive brachytherapy question about oropharyngeal_salvage. Role of brachytherapy in salvage for 59-year-old man with 2.0 cm retropharyngeal lymph node recurrence after definitive IMRT 70 Gy for HPV+ oropharyngeal cancer. Include re-irradiation considerations, applicator selection, surgical coordination, dose, and cumulative tolerance....

**Response:**
> ## 复发性口咽癌近距离放疗挽救治疗### 患者概况- 59岁男性- HPV+ 口咽鳞状细胞癌- 原发灶已根治性IMRT 70 Gy- 现发现2.0 cm复发性咽后淋巴结---### 1. 再程放疗评估**复发性咽后淋巴结的处理原则：**| 因素 | 考量 ||------|------|| **既往剂量** | 70 Gy EQD2 已接近所有正常组织耐受上限 || **复发位置** | 咽后淋巴结紧邻颈动脉、颅底、脊髓 || **肿瘤体积** | 2.0 cm - 可考虑多种治疗方式 || **间隔时间** | 需 >18-24个月才考虑再程放疗 |**再程放疗绝对禁忌证：**- 复发距原放疗 <12个月- 既往剂量 >80 Gy EQD2- 颈动脉包裹/即将破裂- 皮肤/皮下组织严重纤维化---###...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q1031](../screenshots/19_Q1031.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ❌ Q1032

**Input:** Comprehensive brachytherapy question about RCA_near_miss. Root cause analysis for 3 brachytherapy near-misses (wrong applicator size, CT without applicator, dwell position discrepancy). Include RCA methodology, common root causes, corrective actions, system improvements, and monitoring plan....

**Response:**
> # Root Cause Analysis for Brachytherapy Near-Misses## Incident Summary| Incident | Description | Potential Severity ||----------|-------------|-------------------|| **#1** | Wrong applicator size selected (small ovoids used instead of medium) | Moderate-High || **#2** | CT scan performed without applicator in place | High || **#3** | 4 mm dwell position discrepancy in TPS reconstruction | Moderate |---## 1. RCA Methodology### Framework: **ISHIKAWA + 5 Whys Hybrid**```                    ┌─────────────────────────────┐                    │     Near-Miss Event         │                    └──────────────┬──────────────┘                                   │              ┌────────────────────┼────────────────────┐              ▼                    ▼                    ▼        ┌──────────┐         ┌──────────┐         ┌──────────┐        │ People   │         │ Process  │         │ Equipment│        └────┬─────┘         └────┬─────┘         └────┬─────┘             │                    │    ...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1032](../screenshots/19_Q1032.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1033

**Input:** Comprehensive brachytherapy question about ovarian_vaginal. Brachytherapy workflow for 72-year-old woman with 4 cm ovarian cancer vaginal metastasis (platinum-sensitive, partial response to carbo/gem). Include rationale, applicator selection, dose, fractionation, IP chemotherapy integration, and evidence....

**Response:**
> ## Brachytherapy Workflow for Ovarian Cancer Vaginal Metastasis### 1. Rationale for BrachytherapyVaginal metastases from ovarian cancer are rare (2-5% of vaginal cancers) but present unique treatment challenges. Brachytherapy is appropriate here because:- **Anatomic location**: Vaginal apex lesions are ideal for intracavitary brachytherapy- **Dose falloff**: Spares surrounding rectum/bladder while delivering high dose to target- **Platinum-sensitive disease**: Supports aggressive local treatment- **Palliative + potential cure**: Provides both symptom control and chance for local control### 2. Applicator Selection| Patient Factor | Recommended Applicator ||----------------|----------------------|| Lesion at apex, 4 cm | **Ovoids or ring applicator** (30-35 mm diameter) || Mid-vaginal involvement | Cylinder + interstitial...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1033](../screenshots/19_Q1033.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1034

**Input:** Comprehensive brachytherapy question about patient_satisfaction. Design brachytherapy-specific patient satisfaction survey covering pre-treatment experience, treatment experience, recovery, follow-up, and overall satisfaction. Include validated PROMs (EORTC QLQ-CX24, EPIC), Likert scales, and QI integration....

**Response:**
> # Brachytherapy Patient Satisfaction Survey Design## Survey Architecture### Domain Structure| Domain | Items | Purpose ||--------|-------|---------|| Pre-Treatment Experience | 8 | Information, scheduling, anxiety || Treatment Experience | 12 | Comfort, staff interactions, environment || Recovery | 6 | Symptoms, support, instructions || Follow-Up Care | 5 | Access, communication, continuity || Overall Satisfaction | 4 | Recommendation, willingness to return |---## Validated PROMs Integration### EORTC QLQ-CX24 (Cervical Cancer Module)```Symptom Experience Scale (9 items):- Lymphedema- Peripheral neuropathy...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1034](../screenshots/19_Q1034.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1035

**Input:** Comprehensive brachytherapy question about ovarian_VBT_repeat. Treatment plan for 43-year-old woman with ovarian cancer vaginal apex recurrence (high-grade serous, R0 resection) after prior hysterectomy and EBRT 45 Gy 3 years ago. Include VBT evidence, applicator, dose, niraparib timing, and surveillance....

**Response:**
> ## VBT for Ovarian Cancer Vaginal Recurrence with Prior EBRT### 1. Clinical Rationale**Evidence for VBT in ovarian vaginal recurrence:**- Vaginal recurrence after R0 resection has ~15-30% local failure rate without adjuvant therapy- VBT provides high conformal dose to vaginal apex with steep dose falloff- Prior EBRT complicates re-treatment but VBT's localized dose may be acceptable### 2. Applicator Selection| Option | Considerations ||--------|----------------|| **Cylindrical vaginal applicator** | Most common; 2-3 cm diameter, length covering apex + 1-2 cm margin || **Ovoids with tandem** | If anatomy permits; better OAR sparing posteriorly || **Custom...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1035](../screenshots/19_Q1035.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q0956

**Input:** A 52-year-old woman named Maria presents with Stage IIB squamous cell carcinoma of the cervix. She has completed 45 Gy in 25 fractions of pelvic EBRT with weekly cisplatin. MRI shows a 4 cm residual tumor extending into the left parametrium. She has a tandem and ring applicator in place. Her BMI is 32, she has type 2 diabetes, and she is very anxious about the brachytherapy procedure. Provide a comprehensive treatment plan recommendation and explain it to the patient in accessible language....

**Response:**
> # Treatment Plan Recommendation for Maria## Clinical Summary| Parameter | Value ||-----------|-------|| **Stage** | IIB (parametrial involvement) || **Prior Treatment** | EBRT 45 Gy + cisplatin × 5 || **Residual Disease** | 4 cm (left parametrium) || **Applicator** | Tandem + Ring (in place) || **Comorbidities** | Obesity, Type 2 DM |---## Treatment Plan Recommendation### Brachytherapy PrescriptionBased on ABS/GEC-ESTRO guidelines for cervical cancer with residual parametrial disease:| Component | Dose ||-----------|------|| **Brachytherapy** | 28 Gy in 4 fractions (7 Gy × 4) || **EBRT + BT Total EQD2** | ~79 Gy to HR-CTV || **Fraction...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0956](../screenshots/19_Q0956.png)

---

### ✅ Q0957

**Input:** A 68-year-old retired teacher named Robert has been diagnosed with favorable intermediate-risk prostate cancer (Gleason 3+4=7, PSA 9.5, clinical stage T1c, prostate volume 38 cc). He is very active and concerned about maintaining his quality of life, particularly sexual function and urinary control. He is considering between HDR brachytherapy monotherapy and LDR permanent seed implantation. Walk through the decision-making process with him....

**Response:**
> # Shared Decision-Making: HDR vs LDR Brachytherapy for Robert## Your Clinical Profile Summary- **Age**: 68 years old- **Cancer**: Favorable intermediate-risk (Gleason 3+4=7, PSA 9.5)- **Prostate volume**: 38 cc (suitable for either approach)- **Priority concerns**: Sexual function and urinary continence---## Treatment Option Comparison| Factor | HDR Brachytherapy | LDR Seed Implantation ||--------|-------------------|----------------------|| **Procedure** | Catheter placement → multiple fractions → catheters removed | Seeds permanently implanted || **Fractions** | Usually 2 fractions (1 week apart) | Single procedure || **Hospital stay** | 1-2 days (overnight) | Same-day discharge || **Radiation exposure to others** | None after treatment | Low dose (precautions for ~2 months) || **Dose uniformity** | Highly conformal, computer-optimized | Based...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0957](../screenshots/19_Q0957.png)

---

### ✅ Q0958

**Input:** A 78-year-old woman named Dorothy is being treated for recurrent endometrial cancer at the vaginal cuff. She had a total hysterectomy 3 years ago and now has a 1.5 cm biopsy-proven recurrence at the vaginal apex. She has a history of congestive heart failure (EF 35%), chronic kidney disease stage 3, and is on warfarin for atrial fibrillation. Design a comprehensive treatment plan accounting for all her comorbidities....

**Response:**
> # Comprehensive Treatment Plan for Dorothy: Recurrent Endometrial Cancer at Vaginal Cuff## Patient Summary| Factor | Details ||--------|---------|| Age | 78 years || Diagnosis | Recurrent endometrial cancer at vaginal cuff (1.5 cm) || Prior Treatment | Total hysterectomy 3 years ago || **Comorbidities** | || - Cardiac | CHF (EF 35%) || - Renal | CKD Stage 3 || - Hematologic | Warfarin anticoagulation for A-fib |---## 1. Comorbidity Management### 1.1 Warfarin Management**Recommendation**: Continue warfarin throughout treatment.| Strategy | Details ||---------|---------|| **Approach** | Bridging NOT required for brachytherapy || INR Target | Maintain 2.0-3.0 (standard therapeutic range) || Pre-procedure | Check INR day before/...

**Scores:**
- Total: 0.95
- Keyword: 0.86
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0958](../screenshots/19_Q0958.png)

---

### ✅ Q0959

**Input:** A 35-year-old woman named Aisha is 20 weeks pregnant and has been diagnosed with Stage IB2 cervical cancer. She and her husband desperately want to continue the pregnancy while receiving cancer treatment. The multidisciplinary team must balance fetal safety with maternal cancer treatment. Design a treatment approach that considers all aspects of this complex situation....

**Response:**
> # Cervical Cancer in Pregnancy: Comprehensive Treatment Approach## Case Summary**Patient**: Aisha, 35-year-old woman, 20 weeks pregnant**Diagnosis**: Stage IB2 cervical cancer (2-4 cm tumor, confined to cervix)**Goals**: Continue pregnancy while receiving definitive cancer treatment---## 1. Initial Assessment and Staging### Imaging Modifications for Pregnancy| Investigation | Standard | Pregnancy-Modified ||---------------|----------|-------------------|| MRI (pelvis) | Full protocol | ✓ Safe - no contrast, no ionizing radiation || Chest X-ray | Standard | ✓ Safe with abdominal shielding || PET-CT | Standard | ✗ Contraindicated - excessive fetal dose || Cystoscopy | Standard | ✓ Safe under anesthesia || Examination under anesthesia | Standard | ✓ Essential for accurate staging |### Key Staging Information Needed- Tumor dimensions and vaginal extension- Parametrial involvement (MRI)- Pelvic lymph node status...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0959](../screenshots/19_Q0959.png)

---

### ❌ Q0960

**Input:** A 65-year-old man named James has a T3N0M0 anal canal squamous cell carcinoma. He has completed 54 Gy of concurrent chemoradiation with mitomycin C and 5-FU. The post-treatment MRI shows a good partial response with a 1.5 cm residual abnormality. The tumor board is discussing whether to recommend observation, completion surgery, or brachytherapy boost. Analyze the options and provide a recommendation....

**Response:**
> ## James的肛管癌治疗后方案分析### 病例摘要- **诊断**：肛管鳞状细胞癌，T3N0M0- **已完成治疗**：54 Gy 同步放化疗（丝裂霉素C + 5-FU）- **当前状态**：MRI显示部分缓解，残留1.5 cm异常---### 三个选项的分析#### 1. 观察等待**优点**：- 避免进一步治疗毒性- 约70-80%患者在标准CRT后可获得完全缓解**缺点**：- T3肿瘤局部失败率较高（约20-30%）- 残留病灶若不处理，可能进展为侵袭性复发- 挽救性手术在复发后更复杂、预后更差---#### 2. 挽救性手术（APR）**优点**：- 根治性切除- 明确病理分期**缺点**：- 永久性结肠造口- 显著影响生活质量...

**Scores:**
- Total: 0.66
- Keyword: 0.17
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q0960](../screenshots/19_Q0960.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ✅ Q0961

**Input:** A 45-year-old woman named Priya has a Stage IIIA endometrial cancer (serous histology) and has undergone total hysterectomy with bilateral salpingo-oophorectomy. The pathology shows deep myometrial invasion and lymphovascular space invasion. She needs adjuvant therapy and the team is considering EBRT alone versus EBRT with vaginal cuff brachytherapy boost. Analyze the treatment options for this patient....

**Response:**
> ## Treatment Options Analysis: Stage IIIA Endometrial Cancer (Serous)### Patient Risk Profile| Risk Factor | Status | Clinical Significance ||-------------|--------|------------------------|| Stage | IIIA (FIGO 2009) | Uterine serosa/adnexal involvement || Histology | Serous | High-risk, aggressive subtype || Myometrial invasion | Deep (>50%) | Increased local recurrence risk || LVSI | Positive | Strong predictor of vaginal/pelvic recurrence |### Evidence Base**PORTEC-3 Trial Results** (high-risk endometrial cancer):- Stage III patients showed significant benefit from **EBRT + chemotherapy** vs EBRT alone- 5-year overall survival: 79% vs 70% (HR 0.70, p=0.014)- Progression-free survival improved from 58% to 79%**Role of Vaginal Cuff Brachytherapy Boost:**| Factor | EBRT Alone...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0961](../screenshots/19_Q0961.png)

---

### ✅ Q0962

**Input:** A 72-year-old man named William has been diagnosed with a 5 mm Stage IA1 squamous cell carcinoma of the cervix with no lymphovascular invasion. He is asking whether he needs brachytherapy or whether surgery alone is sufficient. The gynecologic oncologist has recommended radical hysterectomy but is open to discussing brachytherapy as an alternative. How should this low-risk case be discussed with the patient?...

**Response:**
> # Stage IA1 Cervical Cancer: Treatment Discussion for William## Important ClarificationFirst, I should note: **cervical cancer occurs in individuals with a cervix (females)**. Cervical cancer in a 72-year-old *male* is not possible. Please verify whether this patient is female. I will proceed with clinical guidance assuming a 72-year-old *woman* with Stage IA1 cervical cancer.---## Stage IA1 Cervical Cancer OverviewStage IA1 is **microinvasive carcinoma** defined as:- Stromal invasion ≤3 mm depth- No lymphovascular space invasion (LVSI)- **Excellent prognosis**: >98% cure rate with appropriate treatment---## Treatment Options### Option 1: Simple Hysterectomy (Standard)| Aspect | Detail ||--------|--------|| **Rationale** | Definitive treatment...

**Scores:**
- Total: 0.80
- Keyword: 0.43
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0962](../screenshots/19_Q0962.png)

---

### ✅ Q0963

**Input:** A 58-year-old woman named Linda has a 3 cm rectal cancer located 5 cm from the anal verge. She has completed neoadjuvant chemoradiation with 50.4 Gy and capecitabine. The restaging MRI shows a good response with the tumor downsized to 1.5 cm. The surgeon believes she may be a candidate for watch-and-wait management, but the radiation oncologist is recommending a brachytherapy boost. Analyze this clinical scenario and the decision-making process....

**Response:**
> # Clinical Analysis: Rectal Cancer Response Management## Patient Summary- **58-year-old woman** with 3 cm rectal cancer (5 cm from anal verge)- Completed **neoadjuvant chemoradiation**: 50.4 Gy + capecitabine- **MRI response**: Good partial response, tumor downsized to **1.5 cm**- **Dilemma**: Surgeon recommends watch-and-wait; radiation oncologist recommends brachytherapy boost---## 1. Assessment of Treatment Response### Clinical Response Evaluation| Parameter | Finding | Interpretation ||-----------|---------|-----------------|| **Tumor size** | 3 cm → 1.5 cm (50% reduction) | Good response || **cCR assessment** | Size reduction alone insufficient | Requires comprehensive evaluation || **MRI features** | T2/DWI signal changes | Need to distinguish fibrosis from residual tumor || **Clinical exam** | Not...

**Scores:**
- Total: 0.94
- Keyword: 0.83
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0963](../screenshots/19_Q0963.png)

---

### ❌ Q0964

**Input:** A 82-year-old woman named Helen has a small vaginal cancer (1.5 cm, Stage I) and is being considered for brachytherapy. She lives alone, has mild cognitive impairment, and relies on her daughter who lives 45 minutes away for transportation. She also has osteoporosis and is on a bisphosphonate. Design a treatment approach that accounts for all of her practical and medical considerations....

**Response:**
> ## 阴道癌近距离放疗方案设计### 患者：Helen，82岁，1.5 cm I期阴道癌---### 一、疾病特点与治疗选择**分期评估**- I期阴道癌：肿瘤局限于阴道壁，<2 cm- 1.5 cm肿瘤属于小病灶，可选择：  - 单纯近距离放疗  - 联合EBRT（通常用于更大或位置更深的病变）**老年患者特殊考量**| 因素 | 临床意义 ||------|---------|| 年龄82岁 | 预期寿命有限，需权衡治疗强度 || 轻度认知障碍 | 影响知情同意能力，需评估决策能力 || 独居 | 治疗期间安全支持需求 || 骨质疏松 | 需避免体位相关骨折风险 |---### 二、推荐治疗方案**方案：单纯HDR近距离放疗（门诊治疗）****剂量方案选项：**| 方案 | 剂量/分割 | 治疗次数 | 优势 ||------|----------|--------...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q0964](../screenshots/19_Q0964.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ✅ Q0965

**Input:** A 40-year-old man named Carlos has a penile cancer involving the glans penis (Stage T2). He is very concerned about sexual function and body image. The options discussed at tumor board include partial penectomy, brachytherapy, or Mohs surgery. He wants to understand the pros and cons of each option specifically in terms of sexual function outcomes. Provide a detailed comparison tailored to his concerns....

**Response:**
> ## Penile Cancer Treatment Options: Sexual Function & Body Image Comparison### Patient Summary- 40-year-old male- T2 glans penis lesion (invading submucosa/spongiosum)- Primary concerns: sexual function, body image---## Treatment Options Comparison### 1. Brachytherapy (Preferred for glans lesions ≤2-3 cm)| Aspect | Details ||--------|---------|| **Sexual function** | **Best preserved** — penis remains anatomically intact || **Erectile function** | 70-85% preservation rate in published series || **Orgasm/ejaculation** | Generally preserved || **Urination** | Normal in >90% || **Body image** | **Excellent** — natural appearance maintained || **Cosmetic outcome** | Penis appears completely normal in most...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0965](../screenshots/19_Q0965.png)

---

### ❌ Q0966

**Input:** A 60-year-old woman named Fatima has a recurrent cervical cancer after hysterectomy. The PET-CT shows a 3 cm pelvic sidewall recurrence adjacent to the left ureter. She has had prior EBRT of 50 Gy. The team is discussing re-irradiation with brachytherapy versus systemic chemotherapy. She is asking about the chances of cure versus palliation and what the treatment will be like. Address both the medical decision-making and the patient communication aspects....

**Response:**
> # 复发宫颈癌的治疗决策与患者沟通## 医学决策分析### 病例评估| 因素 | 详情 | 临床意义 ||------|------|----------|| **复发位置** | 盆腔侧壁，毗邻左侧输尿管 | 紧邻关键正常组织，增加治疗难度 || **肿瘤大小** | 3 cm | 局部晚期复发，符合再程放疗指征 || **既往放疗** | EBRT 50 Gy | 累积剂量限制，限制再程放疗空间 || **既往手术** | 全子宫切除术后 | 解剖结构改变，需评估瘢痕组织 |### 治疗选项对比#### 选项一：近距离放射治疗（再程放疗）**证据基础：**- EMBRACE研究显示局部复发宫颈癌再程近距离放疗的5年局部控制率约为50-60%- MD...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q0966](../screenshots/19_Q0966.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ✅ Q0967

**Input:** A 55-year-old man named Thomas has a large (80 cc) prostate with low-risk prostate cancer (Gleason 3+3=6, PSA 5.5, Stage T1c). He is interested in brachytherapy but has significant lower urinary tract symptoms with an IPSS of 16. He wants to know whether brachytherapy will worsen his urinary symptoms and whether he is a good candidate. Evaluate his candidacy and explain the expected urinary outcomes....

**Response:**
> ## Clinical Evaluation: Thomas - Prostate Brachytherapy Candidacy### Summary of Risk StratificationThomas has **low-risk prostate cancer** by all three parameters (Gleason 6, PSA 5.5, T1c). His cancer has an excellent prognosis regardless of treatment chosen.### Prostate Volume Assessment| Parameter | Thomas | Brachytherapy Threshold ||----------|--------|------------------------|| Prostate Volume | 80 cc | Typically <50-60 cc preferred || IPSS | 16 (moderate-severe) | Higher IPSS associated with worse outcomes |### Candidacy Evaluation**Generally NOT recommended for brachytherapy monotherapy:**- Large prostate (80 cc) exceeds the typical upper limit of 50-60 cc- Moderate-to-severe LUTS (IPSS ≥15) is a relative contraindication- Higher risk of urinary retention, acute urinary retention rate 5-15%- Increased risk of seed...

**Scores:**
- Total: 0.95
- Keyword: 0.86
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0967](../screenshots/19_Q0967.png)

---

### ✅ Q0968

**Input:** A 48-year-old woman named Mei has been diagnosed with a rare clear cell adenocarcinoma of the vagina. The tumor is 4 cm and involves the upper two-thirds of the vagina. She has no prior history of pelvic radiation. The multidisciplinary team is unfamiliar with this rare histology and is unsure about the optimal treatment approach. Research the evidence for this rare tumor type and recommend a treatment plan....

**Response:**
> Clear cell adenocarcinoma of the vagina is an extremely rare malignancy, historically associated with in utero diethylstilbestrol (DES) exposure, though DES-related cases have declined significantly. In patients without DES history, as with Mei, the prognosis is generally less favorable.## Disease Characteristics- **Epidemiology**: Peak incidence in women aged 15-30 (DES-related) or 50-70 (non-DES-related)- **Association**: 60-70% of classic DES-related cases arise from upper 1/3 vagina; non-DES cases often more diffuse- **Staging**: FIGO staging for vaginal cancer## Treatment Recommendations for Mei (4 cm, upper...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0968](../screenshots/19_Q0968.png)

---

### ❌ Q0969

**Input:** A 70-year-old man named Richard has been treated with HDR brachytherapy for prostate cancer and is 2 years post-treatment. He presents with new-onset rectal bleeding. He is worried about cancer recurrence. Evaluate the likely causes of his rectal bleeding, the workup needed, and how to counsel him while managing his anxiety about recurrence....

**Response:**
> ## Clinical Evaluation: Rectal Bleeding Post-Prostate HDR Brachytherapy### Differential Diagnosis**Most Likely Causes:**| Diagnosis | Likelihood | Timeline ||-----------|------------|----------|| **Radiation proctitis** | High | Typically 6 months - 3 years post-treatment || **Rectal telangiectasia** | Moderate | Develops gradually, visible on endoscopy || **Hemorrhoids** | Common | Incidental finding, not related to treatment || **Angiodysplasia** | Possible | Age-related, especially with anticoagulation |**Must Rule Out:**- Local tumor recurrence (PSA monitoring critical)- Second primary rectal malignancy- Colorectal cancer...

**Scores:**
- Total: 0.71
- Keyword: 0.17
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0969](../screenshots/19_Q0969.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q0970

**Input:** A 38-year-old woman named Amara has a Stage IVA cervical cancer with bladder wall involvement. She has completed 45 Gy of EBRT with cisplatin. The MRI shows good response with tumor shrinkage, but there is still residual disease extending into the bladder wall. The team is debating whether brachytherapy boost is feasible given the bladder involvement, or whether the patient should be offered pelvic exenteration. Analyze this complex clinical scenario....

**Response:**
> ## Clinical Analysis: Stage IVA Cervical Cancer with Bladder Involvement### Staging and Prognostic Context**Stage IVA** (FIGO 2018) defines cervical cancer with **invasion of bladder or rectal mucosa**, which distinguishes this from Stage IIIB (parametrial extension to pelvic sidewall). The presence of bladder invasion carries significant implications:| Factor | Consideration ||--------|---------------|| **5-year survival** | ~40-55% with chemoradiation + brachytherapy || **Bladder involvement** | Increases local failure risk by 15-20% || **Response to CRT** | Pathologic complete response rate ~50-60% || **Bladder-sparing** | Feasible in selected responders |---### Option 1: Brachytherapy Boost (Preserving Bladder)#### Feasibility AssessmentBrachytherapy **remains feasible** but requires careful technical planning...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0970](../screenshots/19_Q0970.png)

---

### ✅ Q0971

**Input:** A 62-year-old man named George has been treated with interstitial brachytherapy for a recurrent squamous cell carcinoma of the oral tongue. He had prior surgery (partial glossectomy) and chemoradiation. The interstitial implant used 6 needles and the treatment was completed uneventfully. He now presents 2 weeks post-treatment with pain, swelling, and purulent discharge from the implant sites. Evaluate his symptoms and design a management plan....

**Response:**
> ## Clinical Assessment: Post-Brachytherapy Infection### Symptom AnalysisThe presentation of **pain, swelling, and purulent discharge at 2 weeks post-treatment** is highly concerning for **interstitial brachytherapy site infection**, which is a recognized complication of head and neck brachytherapy.**Key clinical considerations:**| Symptom | Significance ||---------|-------------|| Pain | Expected acutely (days 1-5), but worsening at 2 weeks suggests infection or tissue necrosis || Swelling | Could indicate cellulitis, abscess, or edema from treatment || Purulent discharge | Strong indicator of bacterial infection requiring intervention |### Differential Diagnosis1. **Bacterial infection** (most likely) - wound infection, cellulitis, or deep space abscess2. **Radiation necrosis** - can mimic infection...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0971](../screenshots/19_Q0971.png)

---

### ✅ Q0972

**Input:** A 75-year-old woman named Dorothy2 has a Stage IIA cervical cancer. She is a Jehovah's Witness and has stated that she will not accept blood transfusions under any circumstances. She needs brachytherapy with interstitial needle placement. Given the bleeding risk associated with interstitial procedures, discuss how to manage this patient safely while respecting her religious beliefs....

**Response:**
> # Managing Interstitial Brachytherapy in a Jehovah's Witness Patient## Key Principles**Patient autonomy** is paramount. A competent adult's informed refusal of blood products must be respected, regardless of medical consequences. This is both ethically required and legally protected in most jurisdictions.---## Pre-Procedure Risk Mitigation### 1. Preoperative Optimization| Factor | Target ||--------|--------|| Hemoglobin | ≥12 g/dL (consider erythropoietin if needed) || Iron studies | Correct iron deficiency || Blood pressure | Optimize control || Medications | Hold anticoagulants if medically safe |### 2. Anemia Management- **Erythropoiesis-stimulating agents (ESA)**: Start 4-6 weeks pre-procedure- **Iron supplementation**: IV iron preferred for rapid repletion- **Folate...

**Scores:**
- Total: 0.80
- Keyword: 0.43
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0972](../screenshots/19_Q0972.png)

---

### ✅ Q0973

**Input:** A 50-year-old man named Ahmed has prostate cancer with a very large prostate (140 cc), Gleason score 4+3=7, PSA 15, and Stage T2c. He is interested in HDR brachytherapy as monotherapy but the large prostate size raises concerns about catheter placement and dose coverage. Evaluate his candidacy for HDR brachytherapy and discuss any modifications needed for his large prostate....

**Response:**
> ## HDR Brachytherapy for Large Prostate (140 cc): Candidacy Evaluation### Patient Summary| Parameter | Value | Interpretation ||-----------|-------|----------------|| Prostate Volume | 140 cc | **Significantly enlarged** (>3× normal ~30 cc) || Gleason Score | 4+3=7 | Intermediate-unfavorable risk || PSA | 15 ng/mL | Intermediate risk (>10-20) || Clinical Stage | T2c | Palpable on both lobes |### Candidacy Assessment**Generally NOT an ideal candidate for HDR monotherapy** due to:1. **Technical challenges**:   - Catheter placement difficulty through large gland   - Increased risk of pubic arch interference   - Longer treatment time with more catheters needed   - Steeper dose gradients required to cover large volume2. **Dose coverage concerns**:   - Peripheral seeds...

**Scores:**
- Total: 0.95
- Keyword: 0.86
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0973](../screenshots/19_Q0973.png)

---

### ❌ Q0974

**Input:** A 42-year-old woman named Sarah has a Stage II vaginal clear cell carcinoma. She had a prior history of diethylstilbestrol (DES) exposure in utero. The tumor is located in the upper third of the vagina and is 3 cm. She is being treated at a center where the radiation oncologist has limited experience with vaginal brachytherapy. How should this rare case be managed, and what resources should be sought to ensure optimal treatment?...

**Response:**
> 这是一个需要综合考虑临床专业知识、指南和罕见肿瘤管理原则的复杂病例。让我为您提供详细解答：## 1. DES暴露与阴道透明细胞癌的关系**流行病学背景：**- 母亲孕期使用己烯雌酚（DES）的女性，阴道透明细胞腺癌风险增加40倍- 发病年龄通常在15-30岁，但该患者42岁，需考虑其他危险因素- 透明细胞癌占原发性阴道癌的5-10%，是DES暴露后代最常见的恶性肿瘤**临床意义：**- DES相关透明细胞癌常呈息肉样或内生性生长- 可能与阴道发育异常（腺病、结构畸形）相关- 需要全面评估阴道解剖结构## 2. Stage...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q0974](../screenshots/19_Q0974.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ❌ Q0975

**Input:** A 67-year-old woman named Patricia has completed brachytherapy for cervical cancer and is 6 months post-treatment. She reports difficulty with vaginal dilator use due to pain and is concerned about vaginal stenosis. She is also experiencing depression related to her cancer treatment. Address both the physical (vaginal stenosis prevention) and psychological (depression, treatment anxiety) aspects of her post-treatment care....

**Response:**
> # Post-Brachytherapy Care for Patricia: Comprehensive Management## Physical Management of Vaginal Stenosis### Assessment FirstBefore treatment, perform a vaginal examination to grade the stenosis:- **Grade 1**: Vaginal length 5-7 cm, minimal narrowing- **Grade 2**: Vaginal length 3-5 cm, moderate narrowing  - **Grade 3**: Vaginal length <3 cm, severe narrowing/oblitertion### Vaginal Dilator Protocol**Timing**: Begin 2-4 weeks after acute inflammation subsides, typically 4-6 weeks post-treatment**Technique**:1. Use smallest dilator (fingertip size) first2. Apply water-based lubricant liberally3. Insert gently with slow rotation, hold for 1-2 minutes4. Progress to next size when insertion is comfortable...

**Scores:**
- Total: 0.75
- Keyword: 0.29
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0975](../screenshots/19_Q0975.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q0976

**Input:** A 55-year-old man named Michael has a recurrence of squamous cell carcinoma in the base of tongue after prior transoral robotic surgery (TORS) and adjuvant chemoradiation. The recurrence is 2 cm and confined to the tongue base. The ENT surgeon is recommending salvage surgery (total glossectomy), but the radiation oncologist believes salvage brachytherapy may be feasible. Analyze the options considering his functional outcome expectations (speech and swallowing)....

**Response:**
> # Salvage Treatment Analysis: Base of Tongue Recurrence## Clinical Scenario Summary- 55-year-old male with 2 cm base of tongue SCC recurrence- Prior treatment: TORS + adjuvant chemoradiation- Key considerations: functional preservation (speech/swallowing), salvage potential, cumulative radiation dose---## Option 1: Salvage Surgery (Total Glossectomy)### Procedure Details- Total glossectomy removes the entire tongue base- Often requires flap reconstruction (free flap or pedicled flap)- May require laryngectomy if aspiration risk is high### Functional Outcomes| Function | Expected Outcome ||----------|------------------|| **Speech** | Significantly impaired; requires extensive speech therapy; may need speech prosthetic device || **Swallowing** | High aspiration risk; many patients require PEG tube long-term; aspiration pneumonia risk || **Quality of Life** | Major functional impact; adapted eating (may be NPO or thickened liquids only) |### Advantages- Provides definitive pathological as...

**Scores:**
- Total: 0.90
- Keyword: 0.71
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0976](../screenshots/19_Q0976.png)

---

### ✅ Q0977

**Input:** A 80-year-old woman named Eleanor has a recurrent endometrial cancer at the vaginal vault. She has a history of aortic valve replacement (mechanical valve) requiring lifelong warfarin. She needs brachytherapy but the anticoagulation complicates the procedure. The cardiology team is concerned about bridging anticoagulation. Design a comprehensive management plan that balances cancer treatment, bleeding risk, and thromboembolic risk....

**Response:**
> # Comprehensive Management Plan: Brachytherapy in Anticoagulated Patient with Mechanical Heart Valve## Patient Summary- **Age**: 80 years old- **Diagnosis**: Recurrent endometrial cancer at vaginal vault- **Comorbidity**: Mechanical aortic valve replacement- **Anticoagulation**: Lifelong warfarin- **Key Risk**: High thromboembolic risk + bleeding risk during brachytherapy---## 1. Risk Assessment### Thromboembolic Risk (机械瓣膜血栓风险)| Risk Factor | Assessment ||------------|------------|| Mechanical aortic valve | **High risk** (4-5% annual stroke risk without anticoagulation) || Age >75 | Additional risk factor || Prior stroke/TIA | Must assess || Atrial fibrillation | Must assess |**Annual thromboembolism risk without anticoagulation**: 4-22%### Bleeding Risk (出血风险)| Procedure | Risk Level ||--------...

**Scores:**
- Total: 0.95
- Keyword: 0.86
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0977](../screenshots/19_Q0977.png)

---

### ✅ Q0978

**Input:** A 29-year-old woman named Zara has a Stage IA1 cervical adenocarcinoma with lymphovascular invasion. She is nulliparous and desires future fertility. The options discussed are cold knife conization, radical trachelectomy with lymph node dissection, or definitive chemoradiation with brachytherapy. Analyze the evidence for each option in terms of oncological safety and fertility preservation for this young patient....

**Response:**
> # Treatment Analysis for Stage IA1 Cervical Adenocarcinoma with LVI in a Fertility-Desiring Patient## Case Summary- **Patient**: 29-year-old woman, nulliparous, desires fertility preservation- **Diagnosis**: Stage IA1 cervical adenocarcinoma with lymphovascular invasion (LVI)- **Treatment Options**: Cold knife conization, radical trachelectomy with lymph node dissection, or definitive chemoradiation with brachytherapy---## Impact of Lymphovascular InvasionLVI significantly upgrades the risk profile for Stage IA1 cervical cancer:| Risk Factor | IA1 without LVI | IA1 with LVI ||-------------|-----------------|--------------|| Lymph node metastasis risk | 0-2% | 5-10% || Recurrence risk | 1-3% | 5-15% || Parametrial involvement | Rare | Possible || Recommended management | Conservative | More aggressive |This distinction is **critical** for treatment decision-making.---## Option 1: Cold Knife Conization### Procedure- Removes cone-shaped portion of cervix- Preserves entire uterus and ferti...

**Scores:**
- Total: 0.95
- Keyword: 0.86
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0978](../screenshots/19_Q0978.png)

---

### ✅ Q0979

**Input:** A 73-year-old man named Joseph has had a total hip replacement on the right side and requires HDR brachytherapy for a left-sided prostate cancer. The right hip prosthesis limits his positioning on the treatment table and may cause metal artifacts on CT. He also has a right inguinal hernia. Describe the complete treatment planning and delivery approach for this patient with multiple anatomical challenges....

**Response:**
> # HDR Brachytherapy Planning for Prostate Cancer with Hip Prosthesis and Inguinal Hernia## Patient Assessment Summary- **73-year-old male** with left-sided prostate cancer- **Right total hip replacement** — positioning limitation and metal artifact- **Right inguinal hernia** — potential discomfort with positioning/applicator placement- **Challenge**: Multiple anatomical factors complicating standard HDR approach---## 1. Imaging Strategy### CT Simulation| Issue | Solution ||-------|----------|| Metal artifact from hip prosthesis | Use iterative metal artifact reduction (MAR) algorithms; increase kVp to 140; consider gap-filling techniques || Artifact in vicinity of prostate | Metal artifact typically spares left prostate; verify artifact extent on planning...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0979](../screenshots/19_Q0979.png)

---

### ✅ Q0980

**Input:** A 60-year-old woman named Grace has a Stage IIB cervical cancer. She has completed 45 Gy of EBRT and is scheduled for brachytherapy. However, she develops a pulmonary embolism 2 days before the planned brachytherapy procedure. She is started on therapeutic anticoagulation with enoxaparin. The team must decide whether to proceed with brachytherapy or delay treatment. Analyze the risks and benefits of proceeding versus delaying....

**Response:**
> ## Analysis: Brachytherapy Decision in Patient with Active PE and Anticoagulation### Clinical Summary- **Patient**: 60-year-old woman, Stage IIB cervical cancer- **Current Status**: Completed 45 Gy EBRT, PE diagnosed 2 days ago- **Anticoagulation**: Therapeutic enoxaparin (LMWH)- **Decision**: Proceed vs. delay brachytherapy---### Risk-Benefit Analysis#### **Arguments for PROCEEDING with Brachytherapy**| Factor | Consideration ||--------|---------------|| **Treatment time** | Prolonged overall treatment time (>56 days) negatively impacts local control in cervical cancer || **Tumor biology** | Cervical cancer cells repopulate; delay may reduce efficacy || **PE stability** | If PE is being appropriately managed, procedural risk may be acceptable || **Bleeding risk** | Vaginal/uterine...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0980](../screenshots/19_Q0980.png)

---

### ❌ Q0981

**Input:** A 45-year-old woman named Kim has a Stage II vaginal cancer treated with combined EBRT and brachytherapy. Five years after treatment, she develops a new primary breast cancer. She asks whether her prior pelvic radiation has any impact on her breast cancer treatment options, particularly regarding radiation therapy for the breast. Provide evidence-based counseling about the interaction between prior pelvic radiation and breast cancer management....

**Response:**
> ## Impact of Prior Pelvic Radiation on Breast Cancer Treatment### SummaryPrior pelvic radiation for vaginal cancer **does not preclude breast radiation therapy** for her new breast cancer. The anatomic separation between the pelvis and breast means the previously irradiated tissues are not in the radiation field. However, several considerations apply.---### 1. Can She Receive Breast Radiation?**Yes, generally.** Key points:| Consideration | Explanation ||--------------|------------|| **Anatomic separation** | Pelvic and breast radiation fields do not overlap; there is no cumulative dose to thoracic structures || **Tissue independence** | Pelvic organs (uterus, vagina, rectum) have separate radiation tolerance considerations from breast tissue || **No direct contraindication** | Prior pelvic brachytherapy does not affect breast tissue tolerance |---### 2. Technical Considerations for Breast Radiation Planning**Modern techniques provide additional...

**Scores:**
- Total: 0.70
- Keyword: 0.14
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0981](../screenshots/19_Q0981.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1000

**Input:** A 55-year-old woman named Eleanor presents with Stage IIB cervical cancer. She has completed 45 Gy of pelvic EBRT with concurrent cisplatin. She has a tandem and ring applicator in place for brachytherapy. However, she also has a history of lupus nephritis and is on chronic immunosuppressive therapy with mycophenolate. Her creatinine clearance is 45 mL/min. Design a comprehensive treatment plan that addresses her cancer treatment needs while accounting for her autoimmune disease, renal impairmen...

**Response:**
> # 综合治疗方案：55岁IIB期宫颈癌伴狼疮性肾炎## 患者概况总结| 因素 | 状态 | 治疗影响 ||------|------|----------|| **肿瘤分期** | IIB期宫颈鳞癌 | 标准治疗：EBRT 45Gy + brachytherapy boost || **EBRT完成** | 已完成45Gy/25f | 继续brachytherapy || **肾功能** | CrCl 45 mL/min | 需调整 cisplatin 剂量 || **免疫抑制** | Mycophenolate | 感染风险增加 || **自身免疫病** | 狼疮性肾炎 | 多器官受累风险 |---## 一、化疗调整### 顺铂剂量调整**问题**：标准剂量 cisplatin 40 mg/m² 每周方案在 CrCl 45 mL/min 时需调整。| CrCl (mL/min) | 顺铂建议 ||---------------|----------|| >60 | 40 mg/m²（标准） || 30-59 | 30-35 mg/m²，需水化 || <30 | 考虑不含顺铂方案...

**Scores:**
- Total: 0.70
- Keyword: 0.14
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1000](../screenshots/19_Q1000.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1441

**Input:** 52yo F, 4.5cm IIB cervical SCC, HPV16+, left parametrial to pelvic sidewall, 2cm left external iliac LN. Post-EBRT 45Gy/cisplatin with LN response. Tandem/ovoid in place. Hgb 10.2, Cr 1.1, ECOG 1. Comprehensive treatment plan including applicator modifications, dose, optimization, and follow-up....

**Response:**
> ## 综合治疗计划：IIB期宫颈鳞状细胞癌（伴左侧宫旁浸润及髂外淋巴结转移）### 病例摘要| 参数 | 值 ||------|-----|| **年龄** | 52岁 || **分期** | IIB期宫颈 SCC || **HPV状态** | HPV16+ || **肿瘤特征** | 左侧宫旁延伸至盆壁，髂外淋巴结 2 cm || **已完成治疗** | EBRT 45 Gy + 顺铂（淋巴结有反应） || **血红蛋白** | 10.2 g/dL || **肌酐** | 1.1 mg/dL || **功能状态** | ECOG 1 |---### 1. 近距离放疗指征与目标**治疗目标：**- HR-CTV 根治性覆盖（...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q1441](../screenshots/19_Q1441.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ❌ Q1442

**Input:** 68yo M, Gleason 4+5=9, PSA 22.5, T3b, 85cc prostate. Completed EBRT 50Gy/docetaxel. HDR boost planned. Large median lobe, IPSS 22, prior TURP 5y ago (20g). Complete plan addressing anatomy, urinary risk, and dose....

**Response:**
> # HDR Brachytherapy Boost Planning: High-Risk Prostate Cancer with Challenging Anatomy## Patient Summary| Parameter | Value | Clinical Significance ||-----------|-------|----------------------|| Age | 68 years | Standard for HDR || Gleason | 4+5=9 | Highest risk group || PSA | 22.5 ng/mL | High-risk definition || Stage | T3b | Seminal vesicle involvement || Prostate Volume | 85 cc | Large; requires modified approach || IPSS | 22 | Moderate-severe LUTS || Prior TURP | 20g, 5 years ago | Increased incontinence risk |## Clinical Challenges### 1. **Large Prostate (85 cc)**- HDR boost monotherapy typically limited to prostate <50 cc- With EBRT 50 Gy, HDR boost is feasible for larger glands- Increased difficulty with catheter placement in enlarged gland### 2....

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1442](../screenshots/19_Q1442.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1443

**Input:** 35yo F at 24 weeks gestation with 3.5cm IB2 cervical SCC. Wishes to continue pregnancy (delivery at 32 weeks). On neoadjuvant cis/gem. Comprehensive multidisciplinary plan including fetal protection and delivery planning....

**Response:**
> # Treatment Plan: Cervical Cancer in Pregnancy## Patient Summary- **Age:** 35-year-old female- **Gestational age:** 24 weeks- **Diagnosis:** 3.5 cm Stage IB2 cervical SCC- **Fetal goal:** Continue pregnancy to 32 weeks (for lung maturity)- **Neoadjuvant chemotherapy:** Cisplatin-based (note: standard is cisplatin + 5-FU, not gemcitabine in pregnancy)---## Multidisciplinary Team| Specialty | Role ||-----------|------|| Gynecologic oncology | Primary treatment coordination || Radiation oncology | Brachytherapy planning || Maternal-fetal medicine | Fetal monitoring, delivery planning || Neonatology | Preterm delivery preparedness || Anesthesiology | Anesthesia for delivery/C-section || Physics/Radiation safety | Fetal dose protection |---## Treatment Timeline### Phase 1: Neoadjuvant Chemotherapy (24-32 weeks)**Regimen:**- Cisplatin 40 mg/m² weekly (preferred in pregnancy)- Alternative: Cisplatin 75 mg/m² + 5-FU 1000 mg/m² every 3 weeks**Duration...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1443](../screenshots/19_Q1443.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1444

**Input:** 45yo F with 3cm vaginal cuff recurrence (Grade 3 serous) after TAH-BSO + EBRT 45Gy 2y ago. BMI 42, HbA1c 8.2%, OSA on CPAP. Interstitial brachytherapy plan addressing comorbidities and technical challenges....

**Response:**
> # Interstitial Brachytherapy Plan for Vaginal Cuff Recurrence## Patient Summary- **45yo F** with 3cm vaginal cuff recurrence (Grade 3 serous)- **Prior treatment**: TAH-BSO + EBRT 45 Gy (2 years ago)- **Comorbidities**: BMI 42, HbA1c 8.2%, OSA on CPAP---## Clinical Assessment### Disease Considerations| Factor | Implication ||--------|-------------|| **Grade 3 serous** | High-risk histology, aggressive behavior || **Prior EBRT 45 Gy** | Cumulative dose constraint critical || **2-year disease-free interval** | Some tissue recovery, but re-irradiation still challenging || **3 cm recurrence** | Moderate volume, may be amenable to interstitial implant |### Re-Irradiation Dose Considerations- **Prior vaginal cuff dose**: ~...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1444](../screenshots/19_Q1444.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q1445

**Input:** 60yo M, recurrent Gleason 4+4=8 prostate after RP + EBRT 64Gy. PSMA PET: anastomotic + SV bed recurrence. CAD (recent stent, dual antiplatelet), DM, BMI 34. Salvage HDR plan with cardiac and bleeding risk management....

**Response:**
> This is a complex salvage HDR case with multiple significant comorbidities. Let me provide a comprehensive treatment plan.---## Salvage HDR Brachytherapy Plan### Patient: 60-year-old male | Recurrent Prostate Cancer---## Clinical Summary| Parameter | Value ||-----------|-------|| **Diagnosis** | Gleason 4+4=8 prostate cancer recurrence || **Prior Treatment** | RP + EBRT 64 Gy || **Recurrence Site** | Anastomosis + SV bed (PSMA PET positive) || **Prostate Volume** | Not specified (likely small, post-RP) || **Comorbidities** | CAD (stent), DM, BMI 34 || **Antiplatelet** | Dual therapy (aspirin + clopidogrel) |---## Salvage HDR Plan### 1. Pre-Treatment Assessments**Cardiac Evaluation:**- Cardiology consult regarding DAPT management- Risk-benefit analysis: continue D...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1445](../screenshots/19_Q1445.png)

---

### ❌ Q1446

**Input:** 28yo F with 2cm IA2 cervical adenocarcinoma, cold knife conization with negative margins. Desires fertility preservation. Pre-conization MRI no residual. LVSI negative. 3mm DOI. Observation vs adjuvant VBT decision....

**Response:**
> # IA2 Cervical Adenocarcinoma: Observation vs. Adjuvant VBT## Case Summary| Parameter | Value ||-----------|-------|| Age | 28 years || Histology | Adenocarcinoma || Stage | IA2 || Cone margins | Negative || MRI residual | None || LVSI | Negative || DOI | 3 mm |## Clinical Analysis### Risk AssessmentThis patient has **favorable prognostic factors**:- **Negative surgical margins** – most important factor- **No residual disease on MRI** – confirms complete excision- **LVSI negative** – no vascular invasion- **3 mm DOI** – shallow invasion (threshold for IA2 is ≤3 mm with <50% stromal invasion, or >3 mm with ≤50% invasion)### NCCN/ESGO GuidelinesFor **IA2 adenocarcinoma with negative margins after conization**:| Recommendation | Strength ||---------------|----------|| Observation | Preferred || Adjuvant VBT | Only if high-risk features present |**High-risk features warranting adjuvant therapy:**- Positive...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1446](../screenshots/19_Q1446.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1447

**Input:** 70yo F with 5cm cT3N1M0 rectal cancer (3cm from anal verge), post-nCRT with good response. Organ preservation with brachytherapy boost. COPD (FEV1 45%), CKD (GFR 35), PVD. Comorbidity management and plan....

**Response:**
> ## Treatment Plan for 70yo F with Rectal Cancer - Organ Preservation with Brachytherapy Boost### Clinical Summary| Parameter | Value ||-----------|-------|| **Age** | 70 years || **Diagnosis** | cT3N1M0 rectal adenocarcinoma || **Tumor size** | 5 cm || **Distance from anal verge** | 3 cm || **Comorbidities** | COPD (FEV1 45%), CKD (GFR 35), PVD || **Treatment goal** | Organ preservation |---### 1. Pre-Treatment Assessment**Restaging workup post-nCRT:**- MRI pelvis with diffusion-weighted imaging (DWI) to assess response- Digital rectal exam (DRE) under anesthesia if needed- Consider endorectal ultrasound for wall layer assessment- PET-CT if MRI equivocal for nodes**Comorbidity management:**...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1447](../screenshots/19_Q1447.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1448

**Input:** 42yo M with 2cm T1N0M0 anal canal SCC, complete response post-EBRT 45Gy/5-FU/MMC. Brachytherapy boost planned. HIV+ (CD4 650, undetectable on ART). HIV-specific considerations and monitoring....

**Response:**
> ## Comprehensive Brachytherapy Plan: HIV+ Patient with Anal Canal Cancer### Clinical Summary| Parameter | Value ||-----------|-------|| Age/Sex | 42yo Male || Diagnosis | T1N0M0 Anal Canal SCC || Prior Treatment | EBRT 45 Gy + 5-FU/MMC || Response | Complete || HIV Status | CD4 650, VL undetectable, on ART || Planned | Brachytherapy boost |---### 1. Applicator Selection**Recommended: Intraluminal Applicator**- Flexible vaginal/anal cylinder: 2.0-2.5 cm diameter- Length: 4-6 cm coverage- Rationale: T1 lesion (...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1448](../screenshots/19_Q1448.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1449

**Input:** 55yo F with 3cm vaginal melanoma (Breslow 3.5mm) after excision with 0.5mm deep margin. Right nephrectomy 10y ago (solitary left kidney, GFR 55). Adjuvant interstitial plan with renal considerations....

**Response:**
> ## Comprehensive Brachytherapy Plan: Vaginal Melanoma with Solitary Kidney### Patient Summary| Parameter | Value ||-----------|-------|| Age | 55 years || Diagnosis | Vaginal melanoma, 3 cm || Breslow depth | 3.5 mm || Surgical margin | 0.5 mm (deep) || Renal status | Solitary left kidney || GFR | 55 mL/min (Stage 3a CKD) |---### Clinical Analysis**Why adjuvant brachytherapy is indicated:**- Breslow depth 3.5 mm = T3 classification (high-risk melanoma)- Close deep margin (0.5 mm) requires coverage of vaginal wall- Melanoma has lower radiosensitivity compared to SCC; however, brachytherapy remains effective for local control- Studies show adjuvant radiation reduces local recurrence for high-risk vaginal melanoma---### Treatment Planning Approach**Applicator Selection:**- **Multi-catheter interstitial implant** is preferred given:  - Upper vaginal location requiring coverage  - Need...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1449](../screenshots/19_Q1449.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1450

**Input:** 65yo M, intermediate-risk prostate (T2b, 38cc). Permanent I-125 seed implant. Penile prosthesis, left hip replacement, bilateral hand arthritis. Positioning and procedural challenges....

**Response:**
> # Prostate Seed Implant with Anatomical Challenges## Patient Assessment Summary| Factor | Finding | Planning Impact ||--------|---------|-----------------|| **Prostate volume** | 38 cc | Acceptable for seed implant || **Penile prosthesis** | Unknown type | Artifact, positioning concern || **Hip replacement** | Left side | Artifact, positioning limitation || **Hand arthritis** | Bilateral | Reduced manipulation capacity |---## 1. Penile Prosthesis Considerations**Pre-operative:**- Determine prosthesis type (inflatable vs. malleable) and manufacturer- Obtain implant passport/identification card for TG-263 compliance- Discuss positioning requirements with urologist who placed the implant**Planning implications:**- Prosthesis may cause beam hardening artifacts on TRUS- Malleable prostheses may be repositioned; inflatable should...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1450](../screenshots/19_Q1450.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1451

**Input:** 48yo F with IIIC2 cervical cancer post-EBRT. Tandem/ring + interstitial needles. Day 2 post-placement: fever 38.5C, lower abdominal pain, WBC 12,500. Blood cultures pending. Emergency management....

**Response:**
> ## Emergency Management: Post-Brachytherapy Infection### Immediate Assessment (0-30 minutes)**Patient Stabilization:**- Vital signs monitoring (BP, HR, RR, SpO2, temperature)- Establish IV access (2 large-bore IVs)- Fluid resuscitation if hypotensive- Pain control (IV analgesics)**Laboratory Studies:**- CBC with differential (evaluate leukocytosis, left shift)- Comprehensive metabolic panel (renal function, electrolytes)- Lactate level (assess systemic response)- CRP and procalcitonin (infection markers)- Blood cultures × 2 sets (already pending)**Clinical Examination:**- Abdominal exam (localize pain, assess for peritonitis)- Pelvic exam (discharge, vaginal cuff tenderness, foul odor)- Assess applic...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1451](../screenshots/19_Q1451.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1452

**Input:** 72yo F with recurrent IIIB cervical cancer (4cm, right parametrium) after definitive CRT. Pelvic exenteration + IORT considered. EF 35%, DM, mild cognitive impairment. Complex management plan....

**Response:**
> ## Treatment Plan for Recurrent IIIB Cervical Cancer with Multiple Comorbidities### Patient Summary- **72-year-old female** with recurrent cervical cancer (4 cm, right parametrium)- **Prior treatment:** Definitive chemoradiation (CRT)- **Comorbidities:** EF 35% (heart failure), diabetes mellitus, mild cognitive impairment- **Considered options:** Pelvic exenteration + IORT---### 1. Disease Assessment**Recurrence characterization:**- **Biopsy confirmation** required to document recurrence- **PET-CT** to evaluate extent: local recurrence vs. distant metastases- **MRI pelvis** with contrast to assess parametrial involvement and relationship to pelvic sidewall- ** cystoscopy/sigmoidoscopy** to evaluate bladder/rectal invasion**Key questions:**- Is recurrence confined to cervix...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1452](../screenshots/19_Q1452.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1453

**Input:** 14yo F with 3cm pelvic RMS (bladder/prostate, stage III, Group III). Post VAC/VI with partial response. Brachytherapy boost, Tanner I, organ preservation. Pediatric-specific plan....

**Response:**
> # Pediatric Pelvic Rhabdomyosarcoma Brachytherapy Boost Plan## Patient Summary- **Age:** 14 years old, Tanner Stage I- **Diagnosis:** Pelvic rhabdomyosarcoma (bladder/prostate origin)- **Stage:** Stage III, Group III (residual disease after initial chemotherapy)- **Prior Treatment:** VAC/VIP chemotherapy regimen with partial response- **Goal:** Organ preservation with brachytherapy boost## Treatment Considerations### Pediatric-Specific Factors| Factor | Consideration ||--------|---------------|| **Organ Preservation** | Critical - bladder and prostate function will determine quality of life || **Growth Considerations** | Tanner I = pre-pubertal; significant growth potential remaining || **Tissue Tolerance** | Pediatric tissues generally more radiosensitive but also more susceptible to late effects || **Secondary Malignancy Risk** | Higher lifetime risk from radiation in children |### Technical Approach**Brachytherapy Modality:** Inter...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1453](../screenshots/19_Q1453.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1454

**Input:** 59yo M, recurrent HPV+ oropharyngeal cancer (2.5cm retropharyngeal LN) after IMRT 70Gy + TORS 2y ago. ORN of mandible, xerostomia. Salvage plan addressing prior complications....

**Response:**
> ## Salvage Brachytherapy Plan: Recurrent HPV+ Oropharyngeal Cancer### Case Summary- **Patient:** 59-year-old male- **Diagnosis:** Recurrent HPV+ oropharyngeal cancer, 2.5 cm retropharyngeal LN- **Prior Treatment:** IMRT 70 Gy + TORS 2 years ago- **Complications:** Osteoradionecrosis of mandible, xerostomia---### Clinical Challenge Assessment**Prior Cumulative Dose:**- Oropharynx/pharynx: 70 Gy EQD2- Mandible: Already at tolerance (ORN indicates overdose)- Retropharyngeal region: Limited data, likely ≥70 Gy**Re-irradiation Considerations:**- Cumulative tolerance to retropharyngeal region: typically 100-110 Gy EQD2 (EMBRACE data)- Available dose budget...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1454](../screenshots/19_Q1454.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1455

**Input:** 45yo F with 2cm Stage I vaginal SCC. SLE on HCQ + prednisone. Definitive brachytherapy. Autoimmune considerations: flare risk, immunosuppression, infection monitoring....

**Response:**
> ## Treatment Plan: Stage I Vaginal SCC with SLE### Disease Summary- **Stage**: FIGO I (T1N0M0) - 2 cm lesion in upper vagina- **Autoimmune status**: SLE on hydroxychloroquine + prednisone 10 mg/day- **Primary treatment**: Definitive brachytherapy---### Brachytherapy Technique| Parameter | Recommendation ||-----------|----------------|| **Technique** | Interstitial template (Syed template) or tandem + ovoids || **Prescription** | 65-70 Gy EQD2 (T) to tumor volume || **Fractionation** | 3.4-4 Gy × 17-20 fractions (LDR equivalent) or 5.5 Gy ×...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1455](../screenshots/19_Q1455.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1456

**Input:** 58yo M, Gleason 3+4=7, PSA 12, T2c, 72cc. EBRT + HDR boost. Bilateral hip replacements, severe kyphoscoliosis. Positioning challenges and needle placement modifications....

**Response:**
> This is a challenging case with multiple anatomical considerations. Let me provide a comprehensive treatment approach:## Case Analysis: 58yo Male, Gleason 3+4=7, PSA 12, T2c, 72cc Prostate### Treatment Context**EBRT + HDR Boost** is appropriate for intermediate-risk prostate cancer. Standard approach: 45-50 Gy EBRT to prostate + seminal vesicles followed by HDR boost of 15-18 Gy in 2 fractions.---## Anatomical Challenges & Solutions### 1. Bilateral Hip Replacements**Imaging Implications:**| Modality | Challenge | Solution ||----------|-----------|----------|| CT | Metal artifacts obscure prostate, bladder, rectum | Use MRI for primary delineation; apply metal artifact reduction algorithms || MR | Susceptibility artifacts near implants | Use SE sequences; avoid gradient echo near implants || Dosimetry | HU assignment...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1456](../screenshots/19_Q1456.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1457

**Input:** 55yo F with 2.5cm recurrent Grade 2 endometrial at vaginal cuff after TAH-BSO + VBT 21Gy/3fx 5y ago. Hypothyroidism, HTN, osteoporosis (T-score -3.0). Repeat VBT plan....

**Response:**
> ## Treatment Plan: Recurrent Endometrial Cancer - Vaginal Brachytherapy### Patient Summary- **55yo F** with 2.5 cm vaginal cuff recurrence (Grade 2 endometrioid)- **Prior treatment**: TAH-BSO + VBT 21 Gy/3 fractions, 5 years ago- **Comorbidities**: Hypothyroidism, HTN, osteoporosis (T-score -3.0)---### Clinical Assessment**Re-irradiation Considerations:**- Prior cumulative vaginal wall dose: ~21 Gy EQD2- With α/β=10 for tumor: ~21 Gy- With α/β=3 for late effects: ~24 Gy EQD2- Maximum cumulative tolerance (vagina): ~80-90 Gy EQD2 (limited data)**Dose Calculation for Repeat VBT:**| Prior Fraction | Dose per Fraction | EQD2 (α/β=10) | EQD2 (α/β=3) ||----------------|...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1457](../screenshots/19_Q1457.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1458

**Input:** 50yo F with IIB cervical cancer, posterior tumor 2mm from rectum. Tandem/ovoid in place. On warfarin for DVT (bridging to LMWH). Tight posterior margin and anticoagulation management....

**Response:**
> ## Treatment Plan: Cervical Cancer with Posterior Tumor + Anticoagulation### Clinical Summary| Parameter | Value ||-----------|-------|| **Age/Stage** | 50 yo, FIGO IIB cervical SCC || **Tumor location** | Posterior, 2 mm from rectal wall || **Applicator** | Tandem + ovoids in place || **Anticoagulation** | Warfarin for DVT, bridging to LMWH |---### Key Challenges**1. Tight Posterior Margin**- 2 mm gap between tumor and rectum = minimal planning margin- Risk of rectal hot spots with standard dwell patterns- May require modified dwell optimization**2. Anticoagulation**- Warfarin must be bridged to LMWH for invasive procedure- Bleeding risk during applicator manipulation...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1458](../screenshots/19_Q1458.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1459

**Input:** 70yo F with 2.5cm ovarian cancer vaginal cuff recurrence after R0 resection. Prior breast cancer (ER+ PR+ HER2-, on tamoxifen 8y ago). Adjuvant VBT plan with tamoxifen interaction....

**Response:**
> ## Comprehensive Vaginal Brachytherapy Plan### Patient Summary- **70-year-old female** with 2.5 cm vaginal cuff recurrence- **Ovarian cancer** (high-grade serous) - status post R0 resection- **Prior breast cancer** (ER+/PR+/HER2-) - on tamoxifen × 8 years- **Comorbidities**: Age-related considerations, VTE risk elevated by tamoxifen---### Clinical Assessment| Factor | Assessment ||--------|------------|| **Recurrence size** | 2.5 cm - moderate volume || **Margins** | R0 resection achieved || **Risk factors** | Ovarian cancer + tamoxifen use || **Tamoxifen effects** | ↑ VTE risk, vaginal atrophy, altered tissue healing |---### Treatment Recommendation: Adjuvant VBT**Rationale:** Given R0 resection but high-risk features (serous histology, recurrence), adjuvant VBT reduces vaginal vault recurrence risk.#### Vaginal Cylinder Selection- **Applicator**: Cylindrical applicator (2.0-2.5 cm diameter)- **Active length**: 3-4 cm covering vaginal cuff + 1 cm margin- **Due to tam...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1459](../screenshots/19_Q1459.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1460

**Input:** 42yo F with IB1 cervical adenocarcinoma after radical trachelectomy + PLND (nodes negative). Desires fertility (12 oocytes frozen). Bicornuate uterus with functional right horn. Fertility-preserving VBT....

**Response:**
> ##  Fertility-Preserving VBT for Cervical Adenocarcinoma Post-Trachelectomy### Patient Summary- **42yo F**, IB1 cervical adenocarcinoma- **Prior treatment**: Radical trachelectomy + PLND (nodes negative)- **Fertility status**: Desires preservation; 12 oocytes frozen- **Anatomic variant**: Bicornuate uterus with functional right horn---### Clinical Considerations**1. Indication for Adjuvant VBT**- IB1 adenocarcinoma with negative nodes has favorable prognosis- Risk factors warranting adjuvant therapy: lymphovascular invasion (LVSI), deep stromal invasion, close margins, glandular histology- If no high-risk features present, observation may be appropriate- Discuss at multidisciplinary tumor board**2. Bicornuate Uterus Implications**- Two separate uterine cavities create applicator placement challenges- Vaginal cylinder may not achieve adequate contact in both horns- Consider custom applic...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1460](../screenshots/19_Q1460.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1461

**Input:** 60yo M, recurrent Gleason 4+5=9 prostate after RP + EBRT 66Gy. Anastomotic site recurrence. Parkinson's disease (tremor, bradykinesia, carbidopa-levodopa). Salvage HDR with neurological considerations....

**Response:**
> ## Salvage HDR Brachytherapy for Prostate Cancer Recurrence with Parkinson's Disease### Case Summary| Factor | Details ||--------|---------|| **Age** | 60 years || **Diagnosis** | Anastomotic recurrence, Gleason 4+5=9 || **Prior Treatment** | RP + EBRT 66 Gy || **Comorbidity** | Parkinson's disease (tremor, bradykinesia) || **Medications** | Carbidopa-levodopa |---### 1. Disease Assessment**Recurrence Characteristics:**- Anastomotic recurrence after prior RP + EBRT- Gleason 9 indicates aggressive biology with high local progression risk- Limited treatment options due to prior EBRT tolerance...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1461](../screenshots/19_Q1461.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1462

**Input:** 48yo F with 4cm IIIC2 endometrial cancer (Grade 2 endometrioid). Post TAH-BSO + PLND. EBRT 45Gy/carbo. VBT planned. Renal transplant 8y ago (tacrolimus, mycophenolate). Immunocompromised management....

**Response:**
> ## Comprehensive Treatment Plan: Endometrial Cancer IIIC2 with Renal Transplant### Patient Summary- **48-year-old female** with Grade 2 endometrioid endometrial carcinoma- **Stage:** IIIC2 (4 cm primary, para-aortic/pelvic nodal involvement)- **Status:** Post TAH-BSO + pelvic lymph node dissection- **Completed:** EBRT 45 Gy with weekly carboplatin- **Planned:** Vaginal brachytherapy (VBT) boost- **Comorbidity:** Renal transplant 8 years ago on tacrolimus and mycophenolate---### Treatment Rationale**Why VBT after EBRT for IIIC2?**For high-intermediate risk endometrial cancer (grade 2-3, >50% myometrial invasion, LVSI) and Stage IIIC disease, combined EBRT + VBT reduces vaginal vault recurrence from ~12% to ~4%. V...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1462](../screenshots/19_Q1462.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1463

**Input:** 60yo M with 2cm T2N0M0 anal canal SCC, complete response post-nCRT. Liver transplant 5y ago (tacrolimus, mycophenolate). Colostomy from diverticulitis. Definitive brachytherapy with immunosuppression....

**Response:**
> ## Comprehensive Brachytherapy Plan for Immunosuppressed Anal Canal Cancer Patient### Patient Summary- **Age/Sex:** 60-year-old male- **Primary:** T2N0M0 anal canal SCC, complete response to nCRT- **Comorbidities:** Liver transplant (5 years ago), on tacrolimus and mycophenolate, colostomy from prior diverticulitis- **Treatment Intent:** Definitive brachytherapy boost---### Treatment Planning Considerations#### 1. Immunosuppression Management**Pre-Treatment Assessment:**- Consult transplant hepatology regarding immunosuppression optimization- Consider reducing mycophenolate 2-4 weeks pre-procedure if clinically safe- Monitor CMV/EBV viral loads (reactivation risk with radiation)- Ensure prophylaxis: TMP-SMX for PCP, antivirals for HSV**Infection Risk:**- Pre-procedure antibiotic prophylaxis (cefazolin or according to transplant protocol...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1463](../screenshots/19_Q1463.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1464

**Input:** 35yo F with IA2 cervical SCC (no LVSI, negative conization margins). Desires fertility. Bipolar disorder (lithium, controlled), hypothyroidism, BMI 38. Fertility-preserving VBT with psychiatric and metabolic comorbidities....

**Response:**
> # Fertility-Preserving Vaginal Brachytherapy Plan## Patient Summary- **Age:** 35-year-old female- **Diagnosis:** IA2 cervical squamous cell carcinoma- **Pathology:** No LVSI, negative conization margins- **Comorbidities:** Bipolar disorder (controlled), hypothyroidism, BMI 38- **Goal:** Fertility preservation## Clinical Assessment### IA2 Cervical Cancer OverviewIA2 is defined as stromal invasion >3 mm to ≤5 mm with horizontal spread ≤7 mm. With negative margins after conization, this patient has excellent prognostic features.### Fertility Preservation DecisionGiven the favorable pathology (no LVSI, negative margins), **observation may be appropriate** after conization. However, if adjuvant treatment is deemed necessary, VBT preserves uterine function.## Treatment Plan...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1464](../screenshots/19_Q1464.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1465

**Input:** 70yo M, recurrent Gleason 4+5=9 after RP + EBRT 66Gy. Anastomotic + bilateral pelvic LN (3 nodes). Mechanical aortic valve (warfarin), HTN, DM. Salvage HDR + abiraterone with anticoagulation management....

**Response:**
> ## Salvage HDR Brachytherapy Plan — Recurrent Prostate Cancer with Comorbidities### Patient Summary| Parameter | Value ||-----------|-------|| Age | 70 years || Gleason Score | 4+5=9 (Group 5) || PSA | Assumed elevated (recurrent) || Prior Treatment | RP + EBRT 66 Gy || Disease Extent | Anastomosis + bilateral pelvic LNs (3 nodes) || Comorbidities | Mechanical AVR (warfarin), HTN, DM |---### 1. Treatment RationaleThis is a challenging salvage scenario with:- **Prior EBRT** precludes conventional dose escalation- **Lymph node involvement** indicates systemic disease component- **Mechanical valve** requires careful anticoagulation management- **Abiraterone** addresses androgen receptor-positive disease---...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1465](../screenshots/19_Q1465.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1466

**Input:** 55yo F with IIB cervical cancer (6cm tumor). EBRT 45Gy + cisplatin completed. Tandem placed. On imaging, tandem perforated uterine fundus into cul-de-sac. Hemodynamically stable. Emergency management....

**Response:**
> ## Emergency Management: Uterine Perforation During Brachytherapy### Immediate Actions (0-30 minutes)**Patient Safety**- Stop treatment immediately- Retract source to safe position- Keep patient flat with minimal movement- Establish IV access, cardiac monitoring- Complete blood count, type and screen**Imaging Assessment**- STAT CT with contrast to assess:  - Extent of perforation  - Bowel involvement  - Vascular injury  - Free fluid- Consultation with interventional radiology if vascular injury suspected**Surgical Consultation**- Immediate gynecology/obstetrics consult- Assess need for emergent laparoscopy vs. observation### Key Decision Points| Finding | Management ||---------|------------|| Hemodynamically stable, no bowel/vascular injury | Antibiotics, observation, delayed replan || Bowel involvement suspected | Laparoscopic exploration || Vascular...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1466](../screenshots/19_Q1466.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1467

**Input:** 42yo M, T1cN0M0 Gleason 3+3=6, PSA 5.2, 32cc prostate. Focal hemi-gland brachytherapy. Tumor right peripheral zone mid-gland. Family history (father, brother). Anxiety, normal sexual function. Focal treatment plan....

**Response:**
> # Focal Hemi-Gland Brachytherapy Plan## Patient Summary| Parameter | Value ||-----------|-------|| Age | 42 years || Stage | T1cN0M0 || Gleason | 3+3=6 || PSA | 5.2 ng/mL || Prostate Volume | 32 cc || Tumor Focus | Right peripheral zone, mid-gland |## Candidacy Assessment**Appropriate for focal brachytherapy** because:- Low-risk disease (Gleason ≤6, PSA <10)- Unifocal disease on mpMRI and biopsies- Small focus amenable to focal treatment- Young age with quality-of-life concerns**Risk factors to address:**- Family history increases recurrence risk—counsel about possible need for whole-gland salvage- Anxiety—pre-procedure psychological evaluation recommended---## Treatment Plan...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1467](../screenshots/19_Q1467.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1468

**Input:** 55yo F with IB2 cervical SCC. EBRT 45Gy/cisplatin completed. Tandem/ovoid in place. Jehovah's Witness (no blood products). Hgb 8.5, symptomatic anemia. Outpatient treatment. Management without transfusion....

**Response:**
> # Brachytherapy Management for Jehovah's Witness Patient with IB2 Cervical Cancer## Clinical Summary- **Patient:** 55-year-old female, IB2 cervical SCC- **Completed:** EBRT 45 Gy + cisplatin- **Status:** Tandem/ovoid in place for brachytherapy boost- **Complication:** Symptomatic anemia (Hgb 8.5), Jehovah's Witness (refuses blood products)---## 1. Treatment Plan Recommendation### Standard of Care for IB2 Cervical Cancer Post-Chemoradiation| Parameter | Recommendation ||-----------|----------------|| **Brachytherapy Dose** | 7 Gy × 4 fractions HDR (Point A) || **Total EQD2** | ~85 Gy to high-risk CTV || **Applicator** | Tandem + ovoids (in place) || **Setting** | Outpatient acceptable if stable |### Anemia Management (No...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1468](../screenshots/19_Q1468.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1469

**Input:** 68yo M with 3cm Gleason 4+3=7 (T2c, 58cc). Permanent Pd-103 seed implant. Bladder augmentation (ileocystoplasty), suprapubic catheter, colostomy. Complex abdominal anatomy plan....

**Response:**
> ## Comprehensive Pd-103 Permanent Seed Implant Plan**Patient:** 68yo M | **Diagnosis:** Prostate Cancer T2c, Gleason 4+3=7 | **Volume:** 58 cc---### Clinical Considerations for Altered Anatomy| Factor | Challenge | Management ||--------|-----------|------------|| **Ileocystoplasty** | Bladder repositioned, altered anatomy | Modified seed distribution avoiding bowel || **Suprapubic catheter** | Tissue tract vulnerability | Exclude catheter tract from high-dose region || **Colostomy** | Positioning, imaging | Lateral decubitus positioning may improve || **58 cc prostate** | Moderate volume | Acceptable for seed implant (≤60 cc ideal) |---### Pd-103 Implant Plan**Prescription:** 115 Gy (standard LDR monotherapy)| Parameter | Target | Notes ||-----------|--------|-------|| D...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1469](../screenshots/19_Q1469.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1470

**Input:** 32yo F with 1.5cm Stage I vaginal clear cell adenocarcinoma (no DES exposure). Fertility-sparing brachytherapy. Normal ovarian function (AMH 3.2). Comprehensive fertility-preserving plan....

**Response:**
> # Fertility-Preserving Brachytherapy Plan: Vaginal Clear Cell Adenocarcinoma## Patient Summary- **Age**: 32-year-old female- **Diagnosis**: Stage I vaginal clear cell adenocarcinoma, 1.5 cm- **Location**: Upper vagina (assumed)- **Ovarian Reserve**: Normal (AMH 3.2 ng/mL)- **Fertility**: Desires preservation- **Prior History**: No DES exposure---## Treatment Decision Framework### Primary Option: Wide Local ExcisionBefore proceeding with brachytherapy, assess surgical feasibility:- Tumor size (1.5 cm) may be amenable to conservative excision- Negative margins essential- If margins achievable → surgical approach preferred for fertility preservation### If Brachytherapy Required#### 1. Target Volume Definition**GTV**: Visible tumor on MRI + examination findings**CTV (Clinical Target Volume)**:- Primary: GTV + 1-2 cm margin along vaginal wall- Upper vagina involvement...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1470](../screenshots/19_Q1470.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1471

**Input:** 60yo M with 4cm cT3N1M0 rectal cancer (2.5cm from anal verge), post-nCRT with good response. Severe claustrophobia (no MRI), pacemaker (MRI-conditional), chronic constipation. Endorectal brachytherapy with CT-based planning....

**Response:**
> ## Comprehensive Treatment Plan: Rectal Cancer Brachytherapy Boost### Patient Summary- **60-year-old male** with cT3N1M0 rectal cancer- **Tumor**: 4cm, 2.5cm from anal verge- **Response**: Good partial response to neoadjuvant chemoradiation- **Comorbidities**: Severe claustrophobia (no MRI), MRI-conditional pacemaker, chronic constipation---### 1. Treatment Context| Parameter | Value ||-----------|-------|| **Prior EBRT** | ~50.4 Gy in 28 fractions (standard nCRT) || **Planned Boost** | Brachytherapy boost to residual tumor || **Brachytherapy Modality** | Endorectal HDR or contact therapy || **Planning Modality** | CT-based (MRI contraindicated due to claustrophobia) |---### 2. Applicator Selection**Options for rectal cancer brachytherapy:**| Applic...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1471](../screenshots/19_Q1471.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1472

**Input:** 45yo F with 3cm recurrent IIB cervical cancer (left parametrium) after RP + EBRT 50Gy 3y ago. Colostomy (diverticulitis), left nephrostomy (ureteral stricture). Interstitial brachytherapy with altered anatomy....

**Response:**
> ## Interstitial Brachytherapy for Recurrent Cervical Cancer with Altered AnatomyThis is a complex re-irradiation case with significant technical challenges. Here's a comprehensive analysis:### Case Summary| Factor | Details ||--------|---------|| **Age** | 45 years old || **Tumor** | 3 cm recurrent cervical cancer, left parametrial involvement || **Prior Treatment** | Radical hysterectomy + EBRT 50 Gy (3 years ago) || **Comorbidities** | Colostomy (diverticulitis), left nephrostomy (ureteral stricture) |### Key Challenges**1. Altered Anatomy**- Prior hysterectomy eliminates the uterus as applicator pathway- Colostomy limits inferior perineal access and changes bowel anatomy- Left nephrostomy indicates prior ureteral injury; right ureteral involvement...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1472](../screenshots/19_Q1472.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1473

**Input:** 70yo F with 2cm recurrent Grade 1 endometrial at vaginal apex after hysterectomy + EBRT 45Gy 4y ago. Severe kyphosis (Cobb 65), COPD on O2, mild dementia (MMSE 22). Daughter has healthcare POA. Complex management....

**Response:**
> ## Clinical Case: Recurrent Endometrial Cancer with Multiple Comorbidities### Patient Summary- **Age:** 70-year-old woman- **Diagnosis:** 2 cm Grade 1 endometrial recurrence at vaginal apex- **Prior Treatment:** TAH-BSO + EBRT 45 Gy (4 years ago)- **Comorbidities:**  - Severe kyphosis (Cobb angle 65°)  - COPD on supplemental oxygen  - Mild dementia (MMSE 22)  - Healthcare POA held by daughter### Clinical Assessment**Oncology Considerations:**| Factor | Assessment ||--------|------------|| Tumor characteristics | Small (2 cm), low-grade, isolated vaginal recurrence || Prior EBRT dose | 45 Gy — significant constraint on re-irradiation || Location | Vaginal apex — favorable for VBT or interstitial || Disease-free interval | 4 years — suggests more indolent biology |**Re-irradiation Feasibility:**- Prior 45 Gy EQD2 to vaginal apex limits available retreatment dose- Cumulative EQD2 tolerance: ~80-90 Gy to vaginal wall- Remaining re-irradiation budget: ~35-45 Gy EQ...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1473](../screenshots/19_Q1473.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1474

**Input:** 52yo M, T1cN0M0 Gleason 3+4=7, PSA 9.8, 50cc. HDR monotherapy 36Gy/4fx. Spinal cord stimulator, DVT 2y ago (off anticoagulation), severe needle phobia. Device safety and anxiety management....

**Response:**
> ## HDR Monotherapy Plan: 52yo Male, Intermediate-Risk Prostate Cancer### Patient Summary| Parameter | Value ||-----------|-------|| Age | 52 years || Stage | T1cN0M0 || Gleason | 3+4=7 || PSA | 9.8 ng/mL || Prostate Volume | 50 cc || Plan | HDR Monotherapy 36 Gy / 4 fractions |### HDR Fractionation**36 Gy in 4 fractions (9 Gy × 4)** is a standard HDR monotherapy regimen for intermediate-risk prostate cancer.| Fraction | Dose | Schedule ||----------|------|----------|| Fx 1 | 9 Gy | Day 0 || Fx 2 | 9 Gy | Day 1-7 || Fx 3 | 9 Gy | Day 1-7 || Fx 4 | 9 Gy | Day 1-7 |---### Special Considerations#### 1. Spinal Cord Stimulator**Risk...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1474](../screenshots/19_Q1474.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1475

**Input:** 65yo F with 3.5cm IVA vaginal SCC (bladder base involvement). Renal transplant 8y ago (tacrolimus, mycophenolate, prednisone). Immunosuppression, skin fragility. Definitive chemoradiation + brachytherapy....

**Response:**
> # Comprehensive Brachytherapy Plan: Vaginal SCC with Immunosuppression## Patient Summary- **Age:** 65-year-old female- **Diagnosis:** Stage IVA vaginal SCC (3.5 cm) with bladder base involvement- **Comorbidity:** Renal transplant (8 years), immunosuppressed- **Medications:** Tacrolimus, mycophenolate, prednisone- **Special considerations:** Skin fragility## Treatment Approach### 1. Pretreatment Evaluation- **Imaging:** Pelvic MRI for tumor extent, PET-CT for nodal/distant disease- **Renal function:** GFR, tacrolimus levels (maintain therapeutic)- **Infectious disease...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1475](../screenshots/19_Q1475.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1476

**Input:** 48yo M, recurrent HPV- oropharyngeal cancer (2cm surgical bed) after IMRT 70Gy + TORS 2y ago. Severe dysphagia (MDADI 45/100), PEG-dependent, bilateral vocal cord paralysis. Salvage interstitial plan....

**Response:**
> # Salvage Interstitial Brachytherapy Plan: Recurrent Oropharyngeal Cancer## Patient Summary| Parameter | Value ||-----------|-------|| **Age/Sex** | 48-year-old male || **Diagnosis** | Recurrent HPV- oropharyngeal SCC (surgical bed) || **Prior Treatment** | IMRT 70 Gy + TORS 2 years ago || **Comorbidities** | Severe dysphagia, PEG-dependent, bilateral vocal cord paralysis || **Target Size** | 2 cm surgical bed recurrence |## Clinical Challenges1. **Prior cumulative dose**: 70 Gy EBRT to the region2. **HPV- status**: Poorer prognosis, more aggressive biology3. **Functional impairment**: Severe dysphagia, aspiration risk4. **Airway compromise**: Bilateral vocal cord paralysis5. **Limited salvage options**: Surgery often not feasible, re-irradiation high-risk## Treatment Approach### Applicator Selection**Recommended**: Interstitial needle...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1476](../screenshots/19_Q1476.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1477

**Input:** 55yo F, recurrent IIB cervical cancer (1.5cm left parametrium) after CRT. Crohn's disease (infliximab, remission), severe aortic stenosis (valve area 0.8cm), bilateral LE lymphedema. Interstitial plan with multiple comorbidities....

**Response:**
> ## Recurrent Cervical Cancer Brachytherapy Plan — 55yo F with Multiple Comorbidities### Disease Summary- **Diagnosis**: Recurrent squamous cell carcinoma, cervix- **Stage**: IIB (left parametrial involvement, 1.5cm)- **Prior treatment**: Definitive chemoradiation (presumably 45-50 Gy EBRT + cisplatin)- **Current status**: biopsy-proven recurrence, candidate for salvage interstitial brachytherapy---### Comorbidity Assessment & Risk Stratification| Comorbidity | Severity | Impact on Brachytherapy ||-------------|----------|------------------------|| **Crohn's disease** (infliximab) | Active immunotherapy | ↑ Infection risk, impaired wound healing, may need holding infliximab around procedure || **Severe aortic stenosis** | Valve area 0.8 cm² | **Critical**: High procedural risk for any sedation/anesthesia; hemodynamic instability risk || **Bilateral LE lymphedema** | Grade II-III | ↑ Infection risk, impaired lymphatic drainage, positioning challenges |---### Pre...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1477](../screenshots/19_Q1477.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1478

**Input:** 48yo F with IIB cervical cancer (6cm), EBRT 45Gy + cisplatin. Tandem/ring + 4 interstitial needles. Fraction 2 completed. AKI: creatinine 0.9→2.1, oliguria. Emergency management plan....

**Response:**
> This is a clinical emergency requiring immediate action. With applicators in place and oliguria, ureteral obstruction must be assumed until proven otherwise.## Emergency Management Plan### Immediate Actions (0-30 minutes)**1. Stop current treatment activities**- Do not proceed with remaining dwell positions- Keep patient in treatment room until stabilized- Call attending radiation oncologist and gynecologic oncology immediately**2. Urgent imaging**- STAT non-contrast CT of abdomen/pelvis to assess:  - Applicator position (rule out perforation)  - Hydronephrosis (bilateral vs unilateral)  - Free fluid in pelvis  - Kidney size and collecting system dilation**3. Laboratory evaluation**- Basic metabolic panel (repeat creatinine)- Complete blood count- Urinalysis- Consider cystoscopy with ureter...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1478](../screenshots/19_Q1478.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1479

**Input:** 72yo F, recurrent Grade 3 serous endometrial (2cm vaginal cuff) after hysterectomy + EBRT 45Gy 3y ago. Severe neuropathy (taxane, walking aid), bilateral LE edema, recurrent UTIs. Interstitial plan with functional limitations....

**Response:**
> ## Comprehensive Interstitial Brachytherapy Plan for Recurrent Endometrial Cancer with Functional Limitations### Patient Summary| Parameter | Value ||-----------|-------|| Age | 72 years || Diagnosis | Recurrent Grade 3 serous endometrial carcinoma || Location | Vaginal cuff, 2 cm recurrence || Prior Treatment | TAH-BSO + EBRT 45 Gy, 3 years ago || Comorbidities | Severe neuropathy, LE edema, recurrent UTIs |---### 1. Pre-Treatment Assessment**Functional Evaluation:**- **ECOG Performance Status**: 3 (limited ambulation, nursing care)- **Neuropathy Assessment**: Taxane-induced peripheral neuropathy Grade 2-3, affects positioning and needle tolerance- **Mobility**: Wheelchair-bound, requires transfer assistance- **LE Edema**: Likely from lymphatic disruption; positioning during procedure will be challenging**Imaging Requirements:**- Pelvic MRI with T2-weighted sequences for tumor delineation- CT abdomen/pelvis for...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1479](../screenshots/19_Q1479.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ✅ Q1480

**Input:** 60yo M, 3cm T2N0M0 prostate (Gleason 4+3=7, PSA 12, 50cc). Combined EBRT 46Gy + HDR boost 18Gy/2fx. Total colectomy (end ileostomy), neurogenic bladder (CIC 4x daily), peripheral neuropathy. Absent rectum plan....

**Response:**
> This is a legitimate clinical question about a complex prostate cancer case. Let me provide a comprehensive treatment plan analysis.## Case Summary- **60yo M**, T2N0M0, Gleason 4+3=7, PSA 12, 50cc prostate- **Plan**: EBRT 46Gy + HDR boost 18Gy/2fx- **Complexities**: Total colectomy (end ileostomy), neurogenic bladder (CIC 4×/day), peripheral neuropathy## HDR Boost Plan### Dose Prescription| Parameter | Value ||-----------|-------|| HDR boost | 9 Gy × 2 fractions || Total dose (with EBRT) | 55 Gy EQD2 (α/β=1.5 for prostate) || Fractionation | Twice daily or 1-week interval |### Applicator Selection- **17G interstitial needles**: 18-22 needles based on 50cc volume- **Template-guided**: Perineal template for uniform coverage- **Needle spacing**: 10-12 mm to achieve V...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1480](../screenshots/19_Q1480.png)

---

### ❌ Q1481

**Input:** 48yo F, IIB cervical cancer (5cm), EBRT 45Gy/carboplatin (cisplatin intolerance). Tandem/ovoid in place. Residual 2.5cm, left parametrial. CINV history, anxiety (sertraline), GERD (omeprazole). Supportive care challenges....

**Response:**
> ## Comprehensive Brachytherapy Treatment Plan### Patient Summary- **48-year-old female, Stage IIB cervical SCC, 5cm primary**- Completed EBRT 45 Gy with carboplatin (cisplatin intolerance)- Tandem/ovoid applicator in place- **Residual disease**: 2.5cm with left parametrial involvement- **Comorbidities**: CINV history, anxiety, GERD---### Treatment Plan#### Brachytherapy Fractionation| Parameter | Value ||-----------|-------|| **Technique** | HDR tandem/ovoid || **Dose** | 30 Gy / 5 fractions || **EQD2 (TCD 10)** | 40 Gy (with 45 Gy EBRT = 85 Gy total) || **Dose per fraction** | 6 Gy |...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1481](../screenshots/19_Q1481.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ✅ Q1482

**Input:** 70yo M, recurrent Gleason 5+4=9 (T3bN0M0) after RP + salvage EBRT 64Gy 5y ago. Anastomotic mass 2cm extending to bladder neck. Bladder diverticulum 2.5cm, ureteral stricture disease. Salvage HDR plan....

**Response:**
> # Salvage HDR Brachytherapy Plan: Recurrent Prostate Cancer## Patient Summary| Parameter | Value ||-----------|-------|| Age | 70 years || Diagnosis | Recurrent prostate cancer, Gleason 5+4=9 || Stage | rT3bN0M0 || Prior Treatment | RP + salvage EBRT 64 Gy || Current Disease | 2 cm anastomotic mass extending to bladder neck || Comorbidities | Bladder diverticulum (2.5 cm), bilateral ureteral strictures |---## Clinical Challenges### 1. Prior Radiation Dose- Salvage EBRT 64 Gy already delivered- Cumulative EQD2 to adjacent organs is a major concern- Re-irradiation tolerance significantly reduced### 2. Anatomic Considerations- Anastomotic location: complex geometry, proximity to urethral anastomosis- Bladder neck involvement: difficult to spare bladder wall- Bladder diverticulum: evaluate for tumor seeding, consider prophylactic treatment...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1482](../screenshots/19_Q1482.png)

---

### ❌ Q1483

**Input:** 38yo F, IIIC1 cervical cancer (4cm), EBRT 45Gy/cisplatin. Tandem/ovoid in place. Olympic track cyclist. Iron deficiency anemia, left tibial stress fracture (healed 6mo ago), OCP use. Athletic performance concerns....

**Response:**
> ## Treatment Plan: Cervical Cancer Brachytherapy Boost### Patient Summary38-year-old Olympic track cyclist with Stage IIIC1 cervical cancer (4cm primary + nodal involvement), completed EBRT 45 Gy with cisplatin, now presenting for brachytherapy boost.---### Clinical Status Assessment| Parameter | Status ||-----------|--------|| **Primary Tumor** | 4cm cervical mass, partial response to EBRT || **Lymph Nodes** | IIIC1 classification (pelvic/paraaortic nodes involved) || **Applicator** | Tandem and ovoids in place || **Hemoglobin** | Low (iron deficiency anemia) || **Bone Health** | Prior tibial stress fracture, now healed || **Performance Status** | ECOG 0, elite athlete |---### Recommended Brachytherapy Approach**Technique:** MRI-guided adaptive brachytherapy (IGABT) with tandem/ovoid ± interstitial needles**Fractionation:**- **Standard approach:** 5 fractions × 5-6 Gy (...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1483](../screenshots/19_Q1483.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1484

**Input:** 65yo M, 3cm Gleason 4+5=9 prostate (T3a, PSA 25, 75cc). EBRT 50Gy + HDR boost 26Gy/2fx. Prior APR 10y ago (colostomy), right inguinal hernia mesh. Altered pelvic anatomy plan....

**Response:**
> ## Treatment Plan: High-Risk Prostate Cancer with Prior APR and Altered Pelvic Anatomy### Patient Summary| Parameter | Value | Clinical Significance ||-----------|-------|----------------------|| Age | 65 | Standard treatment considerations || Gleason | 4+5=9 | Highest risk group || T stage | T3a | Extracapsular extension || PSA | 25 ng/mL | High-risk category || Prostate volume | 75cc | Large, impacts brachytherapy feasibility || Prior surgery | APR + colostomy | Absent rectum in radiation field || Hernia mesh | Right inguinal | Imaging artifact potential |---### Treatment Rationale**High-risk prostate cancer** (Gleason 9, PSA 25, T3a) requires multimodal therapy. The combination of EBRT (50 Gy) + HDR boost (26 Gy) provides:- 76 Gy total...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1484](../screenshots/19_Q1484.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1485

**Input:** 52yo F, 2.5cm recurrent Grade 3 serous endometrial at vaginal apex after hysterectomy + EBRT 45Gy 3y ago. New breast cancer (ER+ PR+ HER2-, 1.5cm, node-negative). Treatment sequencing for two cancers....

**Response:**
> ## Treatment Sequencing for Synchronous Dual Primary Cancers### Clinical Summary- **Vaginal recurrence**: 2.5cm Grade 3 serous endometrial cancer at vault, 3 years post-EBRT 45 Gy- **Breast cancer**: 1.5cm ER+/PR+/HER2- invasive carcinoma, node-negative### Key Decision Points**1. Priority Assessment**| Factor | Vaginal Recurrence | Breast Cancer ||--------|-------------------|---------------|| Histology | High-grade serous (aggressive) | Low-grade endocrine responsive || Stage | Local recurrence after RT | Early stage || Time sensitivity | Higher (underwent prior RT) | Lower (indolent biology) || Treatment options | Limited by prior EBRT | Multiple options |**2. Recommended Sequencing****Phase 1: Breast Surgery First**- Lum...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1485](../screenshots/19_Q1485.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1486

**Input:** 45yo M, 2cm T1N0M0 penile cancer (glans) after Fournier gangrene (3y ago, scarring). Type 1 DM (insulin pump, HbA1c 7.2%), smoking history. Penile-preserving brachytherapy with wound healing concerns....

**Response:**
> ## Penile-Preserving Brachytherapy Plan for T1N0M0 Glans Cancer with Wound Healing Risk Factors### Clinical Assessment**Tumor Characteristics:**- 2 cm glans lesion, T1N0M0- Suitable for penile-preserving approach- Well-suited for surface mold or interstitial brachytherapy**Risk Factors for Wound Healing:**| Factor | Impact | Management ||--------|--------|------------|| Prior Fournier gangrene | Fibrosis, compromised tissue | Careful technique, minimal trauma || Type 1 DM (HbA1c 7.2%) | Impaired healing | Optimize glycemic control pre-treatment || Smoking | Vasoconstriction, hypoxia | **Strong recommendation for cessation** |### Treatment Recommendation**Brachytherapy Modality:** HDR surface mold or interstitial implant**Dose Fractionation:**- HDR: 48-56 Gy in 8-10 fractions BID (standard for penile preservation)- LDR:...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1486](../screenshots/19_Q1486.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1487

**Input:** 60yo F, 3.5cm IIIC1 endometrial cancer (Grade 2 endometrioid). Post TAH-BSO + EBRT 45Gy/carbo. VBT planned. Post-gastric bypass (BMI 35, from 48), IDDM (HbA1c 8.5%), OSA (BiPAP). VBT with altered anatomy....

**Response:**
> ## VBT Treatment Plan: Endometrial Cancer with Altered Anatomy### Patient Summary- **Age:** 60-year-old female- **Diagnosis:** Grade 2 endometrioid endometrial cancer, Stage IIIC1- **History:** TAH-BSO + PLND completed, completed EBRT 45 Gy with concurrent carboplatin- **Significant comorbidities:**  - Post-gastric bypass (BMI reduced from 48 to 35)  - Insulin-dependent diabetes (HbA1c 8.5%)  - Obstructive sleep apnea (on BiPAP)### Clinical Considerations**Gastric Bypass Anatomy Impact on VBT:**- Altered bowel distribution may affect dosimetry- Increased risk of bowel adherence in pelvis- May need longer vaginal cylinder for adequate coverage- PET-CT or planning CT in treatment position essential**Diabetic Considerations:**- HbA1c 8.5...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1487](../screenshots/19_Q1487.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q1488

**Input:** 75yo M, recurrent Gleason 3+4=7 (PSA 6.5) after RP + salvage EBRT 66Gy 6y ago. Solitary anastomotic recurrence. ESRD (dialysis 3x/wk), CAD (2 MIs, EF 30%), bilateral BKA. Wheelchair user. Salvage HDR with severe functional limitations....

**Response:**
> This is a complex salvage HDR case with significant competing risks. Let me provide a comprehensive analysis:## Salvage HDR Brachytherapy Plan### 75-year-old male with Anastomotic Recurrence---## Clinical Assessment**Tumor Factors:**- Gleason 3+4=7 (favorable intermediate-risk pattern)- PSA 6.5 ng/mL (low-level recurrence)- Solitary anastomotic lesion (limited disease)- Prior full-dose EBRT (66 Gy) = high re-irradiation risk**Life-Limiting Comorbidities:**| Comorbidity | Impact on Treatment ||--------------|---------------------|| ESRD on dialysis | Bleeding risk, wound healing, medication clearance || CAD, EF 30% | Anesthesia risk, cardiac events...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1488](../screenshots/19_Q1488.png)

---

### ❌ Q1489

**Input:** 32yo F, IA2 cervical adenocarcinoma with LVSI (conization specimen), negative margins. Desires fertility preservation. Observation vs adjuvant VBT decision framework with competing risks....

**Response:**
> ## Clinical Decision Framework: IA2 Cervical Adenocarcinoma with LVSI, Fertility Preservation### Patient Summary- **Age:** 32 years old- **Stage:** IA2 cervical adenocarcinoma- **Pathology:** LVSI positive, margins negative on conization- **Goal:** Fertility preservation---### Understanding the Risk Profile**IA2 cervical cancer characteristics:**- Stromal invasion 3-5 mm depth, horizontal spread ≤7 mm- With LVSI: increased risk of:  - Parametrial involvement (2-8%)  - Lymph node metastasis (5-15%)  - Vaginal cuff recurrence**Favorable factors in this case:**- Negative margins ✓- No lymph node assessment yet (sentinel lymph node mapping possible)- Young patient with fertility goals---### Decision Framework: Observation vs. Adjuvant VBT| Factor | Observation | Adjuvant VBT ||--------|-------------|--------------|| **Fertility** | Preserved | Preserved || **Recurrence risk** | Slightly higher | Reduced || **Evidence quality** | Limited RCT data | Expert opinion based || **Guideline suppor...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1489](../screenshots/19_Q1489.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1490

**Input:** 58yo M, T1cN0M0 Gleason 3+4=7, PSA 10.5, 42cc. Permanent seed implant. Bilateral hip replacements, severe lumbar stenosis (epidural q3mo), bilateral carpal tunnel (post-decompression L). Positioning challenges....

**Response:**
> ## Treatment Plan: Permanent Seed Implant for Prostate Cancer with Complex Comorbidities### Patient Summary- **Age:** 58 years, male- **Diagnosis:** T1cN0M0, Gleason 3+4=7 (ISUP Grade Group 2), PSA 10.5 ng/mL- **Prostate Volume:** 42 cc (intermediate)- **Risk Category:** Favorable intermediate-risk### Comorbidities & Challenges| Challenge | Impact on Brachytherapy | Mitigation Strategy ||-----------|------------------------|---------------------|| **Bilateral Hip Replacements** | Metal artifact on CT/MRI; may affect seed visualization; positioning limitations | Use MRI for contouring; adjust CT for artifact; TRUS guidance for implantation || **Severe Lumbar Stenosis** | Pain with lithotomy; may not tolerate extended procedure;...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1490](../screenshots/19_Q1490.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1491

**Input:** 45yo F, IIB cervical cancer (4cm). EBRT 45Gy/cisplatin. Tandem/ovoid + 4 needles. Fraction 1 delivered. TPS software error: dwell times based on incorrect source strength (actual 10% weaker). Immediate response....

**Response:**
> 这是一个需要立即处理的近距离治疗实时错误场景。以下是综合分析：---## 紧急响应：TPS源强错误（实际源强比计算值强10%）### 1. 立即评估**剂量影响分析：**| 参数 | 影响 ||------|------|| 处方剂量（如5.5 Gy/fx） | 实际接受约 **6.05 Gy**（+10%）|| OAR剂量 | 所有危及器官接受剂量同步增加10% || 累积效应（若继续） | 5次后累积EQD2约 **超标15%** |**紧急计算：**```python# 处方5.5 Gy × 5 fractions# 实际：5.5 ×...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q1491](../screenshots/19_Q1491.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ❌ Q1492

**Input:** 58yo F, recurrent high-grade serous ovarian cancer (platinum-sensitive, 20mo relapse). 3.5cm vaginal + 1.5cm peritoneal deposit. Post-6x carbo/gem with response. Debulking + IP chemo + VBT boost. Prior bowel obstruction....

**Response:**
> ## Treatment Plan: Recurrent Ovarian Cancer with Vaginal Metastasis### Case Summary| Parameter | Value ||----------|-------|| Age | 58-year-old female || Diagnosis | High-grade serous ovarian cancer, recurrence || Platinum status | Sensitive (20-month relapse interval) || Disease sites | Vaginal apex (3.5 cm), peritoneal deposit (1.5 cm) || Prior treatment | 6x carboplatin/gemcitabine (response achieved) || Comorbidity | Prior bowel obstruction || Planned therapy | Debulking + IP chemo + VBT boost |---### Treatment Sequencing**Phase 1: Surgical Debulking**- Goal: R0 resection (no gross residual)- Vaginal metastasis requires en-bloc resection with vaginal cuff- Peritoneal deposit location needs assessment (...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1492](../screenshots/19_Q1492.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1493

**Input:** 42yo M, 2cm T1N0M0 oral tongue SCC after partial glossectomy, 1mm positive margin. Adjuvant interstitial brachytherapy. Alcohol use disorder (sober 5y, naltrexone), HCV (SVR), nicotine dependence. Anxiety about speech/swallowing....

**Response:**
> ## Adjuvant Interstitial Brachytherapy for Oral Tongue SCC### Clinical IndicationA 1mm positive margin after partial glossectomy is an indication for adjuvant radiation therapy. The combination of close/positive margins and the high-risk location makes interstitial brachytherapy an excellent option for boost delivery.### Target Volume Definition**GTV**: Post-surgical tumor bed with consideration of the 1mm positive margin location**CTV High-Risk (HR-CTV)**:- Surgical bed + 5mm margin- Include the floor of mouth and ventral tongue- Typically extends from anterior tonsillar pillar to circumvallate papillae**CTV Intermediate-Risk**: HR-CTV...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1493](../screenshots/19_Q1493.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1494

**Input:** 70yo F, recurrent IIIB cervical cancer (2.5cm central) after CRT. Pelvic exenteration + IORT. Severe aortic stenosis (valve area 0.6cm, NYHA III), severe osteoporosis (T-score -4.0, 3 vertebral fractures), rivaroxaban. Complex pre-operative plan....

**Response:**
> ## Comprehensive Treatment Plan: Recurrent Cervical Cancer with Pelvic Exenteration + IORT### Patient Summary- **70-year-old female** with recurrent IIIB cervical cancer (2.5 cm central recurrence) after prior chemoradiation- **Severe comorbidities**: Aortic stenosis (valve area 0.6 cm², NYHA III), severe osteoporosis (T-score -4.0), rivaroxaban anticoagulation---### 1. Preoperative Assessment#### Cardiac Evaluation| Parameter | Value | Significance ||-----------|-------|--------------|| Aortic valve area | 0.6 cm² | Critical AS (severe: <1.0 cm²) || NYHA class | III | Marked limitation, HF symptoms || Surgical risk | Very high | STS/MAGIC mortality ~8-15% |**Recommendations:**- **Cardiology consultation** for TAVR evaluation before exenteration- If TAVR not feasible, consider ** transcatheter aortic balloon valvuloplasty** as...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1494](../screenshots/19_Q1494.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1495

**Input:** 55yo M, 2.5cm Gleason 3+4=7 (T2b, 42cc). Permanent seed implant. Crohn's (ileocolonic, adalimumab, remission), prior small bowel resection (20cm ileum), reversed loop ileostomy, bile acid malabsorption. Plan with IBD....

**Response:**
> ## Treatment Plan: Permanent Seed Implant for Prostate Cancer in Patient with Crohn's Disease### Patient Summary- **55yo male** with intermediate-risk prostate cancer (Gleason 3+4=7, T2b, PSA not specified)- **Prostate volume**: 42cc (suitable for seed implant)- **Crohn's disease**: Ileocolonic, on adalimumab, in remission- **Surgical history**: Small bowel resection (20cm ileum), reversed loop ileostomy- **Complication**: Bile acid malabsorption---### Disease Assessment**Prostate Cancer Staging:**- Gleason 3+4=7 is favorable intermediate-risk- T2b indicates palpable tumor involving >50% of one lobe- 42cc prostate is within acceptable range for permanent seed implant (typically <50cc)**Crohn's Disease Considerations:**- Ileocolonic disease may involve terminal ileum (important for vitamin B12 and bile acid absorption)...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1495](../screenshots/19_Q1495.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1496

**Input:** 48yo F, 2.5cm Stage I vaginal SCC. Definitive interstitial brachytherapy. BMI 45, IDDM (insulin pump, HbA1c 9.0%), severe OSA (AHI 45, CPAP), bilateral LE lymphedema, chronic pain (gabapentin, duloxetine). Multiple comorbidities plan....

**Response:**
> ## Comprehensive Brachytherapy Treatment Plan### Patient Summary| Parameter | Value | Clinical Significance ||-----------|-------|----------------------|| Age | 48 | Younger patient, fertility considerations || Tumor | 2.5 cm Stage I vaginal SCC | Centrally located, suitable for brachytherapy || BMI | 45 (Class III obesity) | Technical challenges, infection risk || HbA1c | 9.0% | Poor glycemic control → healing risk || OSA | AHI 45 (severe) | Anesthesia risk || LE lymphedema | Bilateral | Positioning difficulty, DVT risk || Chronic pain | Gabapentin + duloxetine | Requires multimodal analgesia |---### Treatment Approach**Recommended Technique:** Interstitial brachytherapy with Syed-N...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1496](../screenshots/19_Q1496.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1497

**Input:** 65yo M, 3cm T2N0M0 Gleason 4+3=7 (PSA 12, 50cc). EBRT 46Gy + HDR boost 18Gy/2fx. Total colectomy for UC (end ileostomy), neurogenic bladder (CIC 4x daily), peripheral neuropathy. HDR with absent rectum....

**Response:**
> ## HDR Boost Plan for Patient with Absent Rectum and Neurogenic Bladder### Clinical Summary| Parameter | Value | Considerations ||-----------|-------|----------------|| Prostate Volume | 50 cc | Moderate enlargement; may require more needles || Fractionation | 18 Gy / 2 fx | Standard boost after 46 Gy EBRT || Rectal Status | Absent | Major planning advantage || Bladder Function | Neurogenic, CIC | Increased infection risk |### Key Planning Considerations**1. Absent Rectum — OAR Implications**- No rectum to constrain posteriorly- sigmoid colon becomes the critical posterior OAR- Small bowel may occupy the empty pelvic space- Dose redistribution toward bladder and sigmoid**2. Neurogenic Bladder Management**- Pre-procedure: Clean CIC immediately before planning CT- Consider ureth...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1497](../screenshots/19_Q1497.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1498

**Input:** 45yo F, IIB cervical cancer (5cm). EBRT 45Gy/cisplatin. Tandem/ovoid placed. Latex allergy (anaphylaxis). Standard applicator has latex components. Alternative approach and emergency preparedness....

**Response:**
> ## Cervical Brachytherapy with Latex Allergy: Clinical Management### Patient Summary- 45-year-old female- Stage IIB cervical cancer- Completed EBRT 45 Gy + cisplatin- Tandem/ovoid applicator in place- **Latex allergy (anaphylaxis history)**---### 1. Risk Assessment**Severity of concern:** Anaphylaxis history = high riskStandard tandem/ovoid applicators contain latex components in:- O-ring seals on applicator channels- Stopcock mechanisms- Some packaging materials---### 2. Alternative Approaches#### Option A: Latex-Free Applicator Set- Many manufacturers now offer **latex-free silicone/polyurethane** applicator sets- Verify specific model specifications before...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1498](../screenshots/19_Q1498.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1499

**Input:** 70yo M, 3cm Gleason 4+3=7 (T3a, PSA 15, 65cc). EBRT 50Gy + HDR boost 26Gy/2fx. Metastatic colon cancer (liver resected 8y ago, disease-free), T1DM (insulin pump, HbA1c 7.5%), cardiac stent (aspirin + clopidogrel). Multiple cancer and comorbidity management....

**Response:**
> ## Clinical Analysis: HDR Brachytherapy Boost for High-Risk Prostate Cancer with Multiple Comorbidities### Case Summary- **Risk stratification**: High-risk (Gleason 7, PSA 15, T3a)- **Prostate volume**: 65cc — larger volume affects HDR planning- **Prior EBRT**: 50 Gy (standard dose)- **Planned HDR**: 26 Gy in 2 fractions boost### Key Planning Considerations**1. HDR Boost Dose Distribution**| Parameter | Target ||-----------|--------|| CTV | Prostate + 3-5mm margin (accounting for EPE) || D90 | ≥26 Gy (100% of boost prescription) || PTV |...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1499](../screenshots/19_Q1499.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1500

**Input:** 52yo F, 2.5cm Stage I vaginal SCC (posterior wall). Definitive interstitial brachytherapy. Severe claustrophobia (no MRI), latex allergy (anaphylaxis), mechanical mitral valve (warfarin INR 2.5), CKD (GFR 42). Multiple medical constraints plan....

**Response:**
> # Comprehensive Brachytherapy Plan: Vaginal SCC Stage I with Multiple Medical Constraints## Patient Summary- **52yo F, 2.5cm Stage I vaginal SCC (posterior wall)**- **Comorbidities:** Severe claustrophobia, latex allergy (anaphylaxis), mechanical mitral valve (warfarin INR 2.5), CKD GFR 42---## 1. Treatment Approach### Standard of Care for Stage I Vaginal SCCFor localized vaginal cancer, definitive brachytherapy alone or combined EBRT + brachytherapy is standard. For a 2.5cm posterior wall lesion without pelvic sidewall involvement or nodal disease, **interstitial brachytherapy alone** is appropriate.### Recommended Technique**Interstitial template-guided brachytherapy** using the Syed-N...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1500](../screenshots/19_Q1500.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ✅ Q1951

**Input:** I have a 52-year-old female with a Stage IIIB cervical cancer (FIGO 2018). MRI shows a 7 cm cervical tumor with bilateral parametrial extension reaching the pelvic sidewall on the left. She has bilateral hydronephrosis with ureteral stents in place. She has a 20-year history of type 2 diabetes (HbA1c 8.5%), hypertension requiring 3 medications (BP 150/92), and chronic kidney disease stage 3b (GFR 42). She has never been pregnant. She completed 45 Gy pelvic EBRT with weekly cisplatin (dose-reduce...

**Response:**
> ## Comprehensive Brachytherapy Plan for Stage IIIB Cervical Cancer with Multiple Comorbidities### Clinical Summary| Parameter | Value ||-----------|-------|| **Stage** | IIIB (bilateral parametrial extension, pelvic sidewall left) || **Pre-EBRT tumor** | 7 cm || **Post-EBRT residual** | 4 cm central || **Hydronephrosis** | Bilateral (stents in place) || **GFR** | 42 mL/min (CKD 3b) || **HbA1c** | 8.5% || **BP** | 150/92 mmHg |---### 1. Applicator Selection**Recommended: Tandem & Ring + Interstitial Needles**For this Stage IIIB case with:- Parametrial extension to pelvic sidewall- 4 cm residual tumor- Nulligravida (potential for narrower vagina)**Rationale:**| Applicator | Indications | Limitations ||------------|-------------|--------------|| T&O...

**Scores:**
- Total: 0.94
- Keyword: 0.83
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1951](../screenshots/19_Q1951.png)

---

### ❌ Q1952

**Input:** I am treating a 68-year-old male with prostate cancer (Gleason 4+5, Stage T3b, PSA 35, node-positive on PET-CT). He has a history of Crohn disease with an end colostomy, moderate COPD (FEV1 52%), and a mechanical aortic valve requiring lifelong warfarin (INR target 2.5-3.5). Current INR is 2.8. He had a DVT 2 years ago on a previous anticoagulation regimen. He wants definitive treatment. Given his extensive comorbidities, what treatment approach would you recommend? How do I manage his warfarin ...

**Response:**
> This is a complex case requiring careful risk-benefit analysis. Here's a comprehensive approach:## Disease Assessment**High-risk features:**- Gleason 4+5=9 (Grade Group 5)- T3b (seminal vesicle invasion)- PSA 35 ng/mL- **Node-positive** on PSMA PETNode-positive disease significantly changes the treatment paradigm—this requires **systemic therapy**, not local treatment alone.## Recommended Treatment Approach### 1. Androgen Deprivation Therapy (ADT)- **Standard of care** for node-positive disease- LHRH agonist/antagonist started immediately- Duration: 18-36 months minimum- Consider addition of abiraterone or enzalutamide (triplet therapy based on PEACE-1 trial)### 2. External Beam Radiation (Primary Local Treatment)**Preferred...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1952](../screenshots/19_Q1952.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ✅ Q1953

**Input:** I have a 35-year-old female at 22 weeks gestation with a 4 cm Stage IB1 cervical cancer (squamous cell carcinoma). She strongly desires to continue the pregnancy. Her obstetric team at a tertiary center supports continuing the pregnancy. MRI shows the tumor confined to the cervix with no parametrial extension. She has no prior treatment, no comorbidities, and normal labs. What is the recommended treatment approach? What chemotherapy agents are safe during pregnancy? What brachytherapy modificati...

**Response:**
> This is a complex case requiring multidisciplinary management. Here is the evidence-based approach:## Treatment Approach for Cervical Cancer in Pregnancy### General Principles- **Stage IB1 (4 cm, confined to cervix)** is amendable to fertility-sparing approaches when pregnancy desire exists- Goal: Balance oncologic outcomes with fetal preservation- Requires **close collaboration** between radiation oncology, gynecologic oncology, maternal-fetal medicine, neonatology, and anesthesia---### Recommended Treatment Protocol#### Option 1: Neoadjuvant Chemotherapy (NACT) + Delayed Definitive Treatment**This is the preferred approach for IB1 ≥2 cm at 22 weeks:****Chemotherapy Regimen (every 3 weeks):**| Agent | Safety Profile | Notes ||-------|---------------|-------|| **Cisplatin** | Crosses placenta, but used safely...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1953](../screenshots/19_Q1953.png)

---

### ✅ Q1954

**Input:** I am managing a 75-year-old male with prostate cancer (Gleason 3+3, Stage T1c, PSA 6.5) who has advanced Alzheimer dementia (MMSE 10) and lives in a nursing home. His family insists on active treatment despite a life expectancy estimate of 3-4 years from dementia. He has a well-functioning cardiac pacemaker. He has no other significant comorbidities. Given his cognitive impairment and limited life expectancy, should I recommend LDR brachytherapy as a single outpatient procedure, EBRT course, or ...

**Response:**
> ## Clinical and Ethical Analysis### Clinical Assessment**Prostate Cancer Prognosis:**- Gleason 3+3=6, T1c, PSA 6.5 = **low-risk disease**- 10-year cancer-specific survival with observation: ~95%- Prostate cancer unlikely to be his life-limiting condition**Dementia Impact:**- MMSE 10 = advanced dementia- Life expectancy from dementia: 3-4 years- Risk of procedural confusion, post-operative delirium- May not tolerate immobilization for brachytherapy### Treatment Options Analysis| Option | Considerations ||--------|----------------|| **LDR Brachytherapy** | Single procedure, outpatient, but requires anesthesia, immobilization, possible urinary retention || **EBRT** | Daily visits x 20-40 sessions =...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1954](../screenshots/19_Q1954.png)

---

### ✅ Q1955

**Input:** I have a 45-year-old female with a 3 cm endometrial cancer (Grade 1, Stage IA) who has a bicornuate uterus. She strongly desires fertility preservation and has been trying to conceive for 2 years. She has no prior treatment, no comorbidities. Her reproductive endocrinologist has assessed her fertility potential as moderate. MRI shows the tumor is limited to the endometrium with no myometrial invasion. She has failed 6 months of high-dose progestin therapy with persistent disease on biopsy. Given...

**Response:**
> This is a challenging fertility-sparing scenario with several complicating factors. Here's my assessment:## Clinical Assessment**Red flags in this case:**- Age 45 (diminished ovarian reserve at this age)- Failed 6 months of progestin therapy- 2 years of infertility prior to diagnosis- Bicornuate uterus (technical challenge for applicator fit)- 3 cm tumor size (larger than typical fertility-sparing candidates)## Treatment Options**Standard fertility-sparing approach** for Grade 1 Stage IA endometrial cancer is high-dose progestin therapy (medroxyprogesterone acetate 600 mg/day or megestrol acetate 160-320 mg/day) with repeat...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1955](../screenshots/19_Q1955.png)

---

### ✅ Q1956

**Input:** I am treating a 60-year-old male with a 4 cm anal canal squamous cell carcinoma (Stage III, T3N1M0). He has well-controlled HIV with CD4 count of 420 and undetectable viral load on antiretroviral therapy. He has a history of IV drug use (clean for 5 years) and hepatitis C (SVR achieved). He has moderate depression requiring sertraline. He has no prior radiation. Standard treatment is concurrent chemoradiation (Nigro protocol). Should I modify the standard radiation dose or fractionation given hi...

**Response:**
> ## Anal Canal Cancer Treatment in HIV-Positive Patient### HIV Considerations**Standard approach is recommended** for patients with well-controlled HIV:- CD4 count >200 cells/μL and undetectable viral load = treat with standard protocol- Your patient meets these criteria (CD4 420, undetectable VL)Evidence supports comparable outcomes and toxicity profiles in HIV-positive patients receiving standard chemoradiation when HIV is well-controlled.### Standard Nigro Protocol (for reference)| Component | Dose/Regimen ||-----------|--------------|| **EBRT** | 50.4-54 Gy in 28-30 fractions || **5-FU** | 1000 mg/m²/day CIV × 4 days (cycles 1 & 5) || **Mitomycin C** | 10 mg/m² IV bolus (cycles 1 & 5) |### Brachytherapy Boost Consideration**Yes...

**Scores:**
- Total: 0.90
- Keyword: 0.71
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1956](../screenshots/19_Q1956.png)

---

### ❌ Q1957

**Input:** I have a 72-year-old female with a 3 cm vaginal cancer (squamous cell, Stage II) who has severe rheumatoid arthritis requiring chronic prednisone 15 mg daily and methotrexate. She has bilateral total knee replacements and is confined to a wheelchair. She has osteoporosis with a T-score of -3.5 and has had 2 vertebral compression fractures. She has never had prior treatment. Given her severe arthritis, she cannot tolerate the lithotomy position for standard applicator placement. How should I modi...

**Response:**
> This is a complex case requiring careful multidisciplinary planning. Here's my assessment:## Positioning Modifications**Alternative positioning strategies:**- **Supine with hip flexion** - May be feasible if knee replacements allow some flexion- **Lateral decubitus position** - Can accommodate wheelchair-to-table transfer- **Modified dorsal lithotomy** - Using a wheelchair-compatible positioning frame- **Stirrups with adjustable height** - Custom positioning to minimize joint stress**Practical approach:** Simulate the patient in various positions during CT/MRI planning to determine tolerance. Consider procedural sedation if needed for applicator placement.## Applicator Selection| Situation | Recommended Applicator ||----------|----------------------|| Limited mobility | **Vaginal cylinder** (simplest insertion) || Cylinder not suitable | **Perineal template with interstitial...

**Scores:**
- Total: 0.75
- Keyword: 0.29
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1957](../screenshots/19_Q1957.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q1958

**Input:** I am managing a 55-year-old male with recurrent rectal cancer after anterior resection and adjuvant chemoradiation (50.4 Gy EBRT + capecitabine completed 18 months ago). The recurrence is a 5 cm anastomotic recurrence involving the bladder dome and seminal vesicles. He has bilateral hydronephrosis requiring nephrostomy tubes. He has a well-functioning colostomy from the prior surgery. Given the prior radiation, what are the remaining tissue tolerance doses for re-irradiation? Should I recommend ...

**Response:**
> # Recurrent Rectal Cancer with Prior Radiation: Clinical Management## Patient Summary- 55-year-old male, recurrent rectal cancer at anastomosis- Prior treatment: LAR + adjuvant chemoradiation (50.4 Gy + capecitabine) 18 months ago- Recurrence characteristics: 5 cm, involves bladder dome and seminal vesicles- Complications: Bilateral hydronephrosis requiring nephrostomy tubes- Well-functioning colostomy- MSI-H status---## 1. Remaining Tissue Tolerance for Re-irradiation**Key Principle:** Prior EBRT 50.4 Gy limits residual tolerance for additional radiation.| Organ | Cumulative EQD2 Tolerance | Prior Dose (EQD2) | Remaining Tolerance ||-------|------------------------...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1958](../screenshots/19_Q1958.png)

---

### ✅ Q1959

**Input:** I have a 40-year-old female with a 5 cm vulvar melanoma (Stage II, Breslow 4.5 mm, ulcerated, LVSI positive) who had a radical vulvectomy with bilateral inguinal lymphadenectomy (2 of 14 nodes positive on right with extracapsular extension). She has a BRCA2 mutation and a personal history of breast cancer treated with bilateral mastectomy 5 years ago. She has no other comorbidities. She needs adjuvant therapy for her vulvar melanoma. Should I recommend adjuvant radiation? What is the role of imm...

**Response:**
> ## Adjuvant Therapy for Vulvar Melanoma: Clinical Analysis### Patient Summary- 40-year-old female- 5 cm vulvar melanoma, Breslow 4.5 mm, ulcerated, LVSI+- Radical vulvectomy + bilateral inguinal lymphadenectomy- 2/14 nodes positive right inguinal with extracapsular extension (ECE)- BRCA2 mutation, history of breast cancer (bilateral mastectomy)---### 1. Staging and PrognosisThis patient has **Stage IIIC vulvar melanoma** (based on T4 [>4mm or ulcerated] with nodal involvement).**Prognostic factors:**| Factor | This Patient | Implication ||--------|-------------|-------------|| Breslow depth | 4.5 mm | High risk (>4mm) || Ulceration | Present | Worse prognosis || LVSI | Positive | Increased...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1959](../screenshots/19_Q1959.png)

---

### ✅ Q1960

**Input:** I am treating a 65-year-old male with a 2 cm prostate cancer (Gleason 3+4, Stage T2a, PSA 8.2) who has a left total hip arthroplasty and a right total knee arthroplasty. The hip replacement causes significant streak artifacts on CT simulation. He also has a spinal cord stimulator for chronic back pain with the battery implanted in the right buttock and leads in the spinal canal at L3-L4. He wants LDR brachytherapy. How do the hip implant and spinal cord stimulator affect brachytherapy planning? ...

**Response:**
> ## LDR Brachytherapy Planning with Metallic Implants and Spinal Cord Stimulator### CT Artifacts from Hip and Knee Implants**Impact on planning:**- Hip arthroplasty causes significant streak artifacts obscuring the prostate, bladder base, and rectum- Metal artifacts can span 2-4 cm beyond the implant, affecting structures in the field- Seed visualization on CT may be compromised if implants are in the pelvis**Mitigation strategies:**- **Extended CT reconstruction kernels** (sharp...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1960](../screenshots/19_Q1960.png)

---

### ✅ Q1961

**Input:** I have a 48-year-old female with Stage IIIA endometrial cancer (Grade 3, deep myometrial invasion, 3 of 20 pelvic nodes positive with extracapsular extension). She had a total hysterectomy with bilateral salpingo-oophorectomy and pelvic lymphadenectomy. She has a history of breast cancer treated 10 years ago with lumpectomy and adjuvant tamoxifen for 5 years. She has well-controlled hypertension. She needs adjuvant therapy. Should I recommend EBRT alone, vaginal cuff brachytherapy alone, or comb...

**Response:**
> # Adjuvant Therapy for High-Risk Endometrial Cancer with Breast Cancer History## Clinical AssessmentThis patient has **high-risk Stage IIIA endometrial cancer** with multiple adverse features:| Risk Factor | Finding ||-------------|---------|| Stage | IIIA (positive pelvic nodes) || Grade | 3 (high-grade) || Myometrial invasion | Deep || Nodal status | 3/20 positive with ECE || Prior breast cancer | Yes, + tamoxifen |## Recommended Treatment Approach### **Combined Modality Therapy**For Stage III disease with nodal involvement and extracapsular extension, **combined EBRT + chemotherapy** is the standard of care.**Recommended Regimen:**- **EBRT**: 45-50.4 Gy to pelvis ± para-aortic nodes- **Sequential chemotherapy**: 4-6 cycles (carboplatin/paclitaxel)...

**Scores:**
- Total: 0.90
- Keyword: 0.71
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1961](../screenshots/19_Q1961.png)

---

### ✅ Q1962

**Input:** I am managing a 30-year-old male with a recurrent yolk sac tumor of the testis. He had a radical inguinal orchiectomy 2 years ago and completed 4 cycles of BEP chemotherapy. He now has a 5 cm retroperitoneal lymph node recurrence. He has not banked sperm and strongly desires fertility preservation. He has a history of depression treated with fluoxetine. His renal function is borderline (GFR 58) possibly from prior cisplatin. Given the retroperitoneal location, could brachytherapy be used? How sh...

**Response:**
> This is a complex case requiring multidisciplinary management. Let me address each issue:## 1. Brachytherapy for Retroperitoneal Recurrence**Short answer: Brachytherapy is not standard for this indication.**Retroperitoneal lymph node recurrences from testicular cancer are typically managed with:- **Surgical resection** (retroperitoneal lymph node dissection - RPLND) - often first-line for isolated recurrence- **Chemotherapy** (second-line regimens)- **EBRT** in select casesBrachytherapy is not typically used for retroperitoneal tumors because:- Critical structures (kidneys, spinal cord, bowel) are interspersed- No natural body cavity for applicator placement- Interstitial approaches would require extensive needles through critical structures**Exception:** In select cases with very small recurrences (<2 cm), stereotactic body radiation therapy (SBRT) may be considered...

**Scores:**
- Total: 0.80
- Keyword: 0.43
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1962](../screenshots/19_Q1962.png)

---

### ❌ Q1963

**Input:** I have a 55-year-old female with a 3 cm vaginal cancer (squamous cell, Stage II) who has systemic lupus erythematosus requiring chronic hydroxychloroquine, mycophenolate, and low-dose prednisone. Her immunosuppression has resulted in 2 opportunistic infections in the past year (pneumocystis pneumonia and CMV colitis). She has had no prior radiation. Given her severely compromised immune system, should I recommend brachytherapy or systemic therapy alone? How does her immunosuppression affect radi...

**Response:**
> This is a complex case requiring careful multidisciplinary planning. Here's a comprehensive analysis:## Clinical Assessment**Staging Context:**- Stage II vaginal cancer (2-4 cm, invading paravaginal tissues, no pelvic wall extension)- No prior radiation — critical for treatment planning- No evidence of nodal or metastatic disease assumed**Immunosuppression Risk Stratification:**Her risk is **high**: 2 opportunistic infections in the past year indicates functional immune deficiency. Prednisone ≥10 mg...

**Scores:**
- Total: 0.71
- Keyword: 0.17
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1963](../screenshots/19_Q1963.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1964

**Input:** I am treating a 70-year-old male with a 4 cm prostate cancer (Gleason 4+3, Stage T3a, PSA 16) who has severe obstructive sleep apnea requiring CPAP, a BMI of 42, type 2 diabetes on insulin (HbA1c 9.1%), and coronary artery disease with a recent stent placement 4 months ago (on dual antiplatelet therapy with aspirin and clopidogrel). He wants definitive treatment. Given his cardiac risk, obesity, and diabetes, should I recommend LDR brachytherapy, EBRT, or watchful waiting? How do I manage his an...

**Response:**
> # High-Risk Prostate Cancer with Multiple Comorbidities: Treatment Approach## Patient Summary- **High-risk disease**: T3a, Gleason 4+3=7, PSA 16- **Cardiac**: Recent DES stent (4 months), on DAPT (aspirin + clopidogrel)- **Metabolic**: T2DM (HbA1c 9.1%), BMI 42- **Respiratory**: Severe OSA on CPAP---## Treatment Recommendation### Watchful Waiting?**No.** High-risk cancer with 4 cm tumor requires active treatment. Life expectancy from prostate cancer exceeds his cardiac-limited estimate, but comorbidities complicate aggressive therapy.### EBRT vs. LDR Brachytherapy Monotherapy vs...

**Scores:**
- Total: 0.75
- Keyword: 0.29
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1964](../screenshots/19_Q1964.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q1965

**Input:** I have a 42-year-old female with a 6 cm cervical cancer (Stage IIB) who is a Jehovah Witness and refuses blood transfusions. She has no prior treatment and no significant comorbidities. She wants definitive treatment. Should I recommend radical hysterectomy or definitive chemoradiation with brachytherapy? What are the bleeding risks for each approach? How should I manage her treatment to minimize blood loss? What blood conservation strategies can be employed? What are the ethical considerations ...

**Response:**
> ## Treatment Recommendation for Jehovah's Witness Patient with Stage IIB Cervical Cancer### Treatment Options Overview**For Stage IIB cervical cancer, both definitive chemoradiation (including brachytherapy) and radical surgery are considered standard options.** For a 6 cm tumor in a Jehovah's Witness patient, **definitive chemoradiation with brachytherapy boost is generally preferred** due to significantly lower bleeding risk compared to radical hysterectomy.### Bleeding Risk Comparison| Treatment | Estimated Blood Loss | Transfusion Probability ||-----------|---------------------|------------------------|| **Radical hysterectomy (6 cm tumor)** | 800-1500 mL typically | 30-50% without cell salvage || **Definitive chemoradiation + brachytherapy** | Minimal (<100 mL) |...

**Scores:**
- Total: 0.80
- Keyword: 0.43
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1965](../screenshots/19_Q1965.png)

---

### ✅ Q1966

**Input:** I am managing a 62-year-old male with a 3 cm rectal cancer (Stage II, T3N0M0) 3 cm from the anal verge who also has a 2 cm renal cell carcinoma in his left kidney. Both cancers were diagnosed simultaneously. He wants to preserve sphincter function and renal function. He has well-controlled hypertension and no other comorbidities. Should I treat both cancers simultaneously or sequentially? What is the optimal treatment approach for each cancer? Could brachytherapy boost improve the chance of comp...

**Response:**
> # Management of Synchronous Rectal and Renal Cell Carcinoma## Treatment Sequencing StrategyFor a patient with synchronous cancers, I recommend **sequential treatment** with rectal cancer treated first, followed by renal cancer intervention. Rationale:1. **Rectal cancer is more urgent** — T3 disease with higher progression/mets risk requires definitive treatment within 6-8 weeks2. **Renal cancer can be monitored** — Small (2 cm) RCC has slow growth; 2-3 month delay for rectal treatment completion is acceptable3. **Avoids competing treatment toxicities** — Simultaneous pelvic radiation + nephrectomy recovery would delay both...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1966](../screenshots/19_Q1966.png)

---

### ✅ Q1967

**Input:** I have a 50-year-old female with a 2 cm breast cancer (Stage I, ER+/PR+, HER2-) who had a lumpectomy with close margins (1 mm). She is BRCA1 positive and has a strong family history of ovarian and breast cancer. She wants breast-conserving therapy and refuses mastectomy. She is very anxious about cancer recurrence and has been researching treatment options extensively online. She asks about combining brachytherapy boost with PARP inhibitor therapy. Given her BRCA status and anxiety, how should I...

**Response:**
> # Breast Conservation in BRCA1-Positive Patient: Clinical Guidance## Key Clinical Issues| Factor | Assessment ||--------|------------|| BRCA1 status | Germline mutation carrier — impacts recurrence risk and treatment choice || Close margins (1mm) | Insufficient for standard BCS; requires re-excision or boost || Age 50 | Early-onset breast cancer in BRCA1 carrier || Patient preference | Refuses mastectomy, desires breast conservation |---## 1. Margin Status and Re-excision**ABS/ASTRO guidelines** recommend ≥2mm margin for DCIS and infiltrating carcinoma with whole-breast irradiation. A 1mm margin is inadequate and associated with higher local recurrence.**Options:**- **Re-excision lumpectomy** — standard recommendation- **Partial breast irradiation (PBI)...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1967](../screenshots/19_Q1967.png)

---

### ✅ Q1968

**Input:** I am treating a 38-year-old female with a recurrent endometrial stromal sarcoma (low-grade) after hysterectomy and BSO. She had adjuvant megestrol acetate for 2 years. The recurrence is a 5 cm presacral mass. She has a history of deep vein thrombosis and is on lifelong anticoagulation with apixaban. She has a well-functioning IVC filter. Given the hormone-sensitive nature of the tumor, the anticoagulation requirement, and the presacral location, what treatment approach should I recommend? Should...

**Response:**
> ## Treatment Planning for Recurrent Low-Grade Endometrial Stromal SarcomaThis is a complex case requiring multidisciplinary management. Here's a comprehensive approach:### 1. Tumor Biology & Treatment Context**Low-grade endometrial stromal sarcoma (LG-ESS)** is a hormone-sensitive, indolent tumor. Key considerations:- Estrogen and progesterone receptor positive in >90% of cases- Slow growth pattern with high recurrence risk- Prior megestrol failure suggests possible hormone resistance- Presacral location poses technical challenge for local therapy### 2. Recommended Treatment Approach**Primary Recommendation: Combined Modality Therapy**| Component | Rationale ||-----------|-----------|| **Brachytherapy (primary)** | Definitive local control for unresectable recurrence || **Continued hormonal therapy** | Adjuvant systemic...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1968](../screenshots/19_Q1968.png)

---

### ❌ Q1969

**Input:** I have a 65-year-old male with a 5 cm rectal cancer (Stage III, T3N1M0) 5 cm from the anal verge. He has a history of Parkinson disease (Hoehn-Yahr stage 3) requiring carbidopa-levodopa and pramipexole. He has moderate cognitive impairment from his Parkinson disease (MoCA 20). He has frequent falls. He wants to avoid a permanent colostomy. Given his neurological condition, cognitive impairment, and desire for sphincter preservation, what treatment approach should I recommend? How does Parkinson ...

**Response:**
> ## Rectal Cancer Treatment in Parkinson's Disease: Clinical AnalysisThis is a complex case requiring careful multidisciplinary coordination. Here's my assessment:### Treatment Approach Recommendation**Standard chemoradiation remains the foundation**, but modifications are needed:**Recommended approach: Short-course radiotherapy (25 Gy/5 fractions) + delayed surgery**- Aligns with his goal of reducing treatment visits- Reduces daily appointments compared to conventional 45-50 Gy/25 fractions- Allows more time for Parkinson's medication optimization- Consider capecitabine (oral) rather than infusional 5-FU given his tremor and swallowing concerns**Contraindication considerations for brachytherapy boost:**- Per...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1969](../screenshots/19_Q1969.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ✅ Q1970

**Input:** I am managing a 28-year-old female with a 4 cm Ewing sarcoma of the pelvis (Stage III). She completed neoadjuvant VAC/IE chemotherapy with good response. The residual tumor is 3 cm and abuts the left sacroiliac joint. She has severe chemotherapy-induced peripheral neuropathy (CTCAE grade 3) requiring gabapentin. She has a history of anxiety and is on sertraline. She wants to preserve fertility and has not yet had children. Given the pelvic location, young age, fertility desires, and chemotherapy...

**Response:**
> This is a complex case with several competing considerations. Here's my analysis:## Brachytherapy Role in Pelvic Ewing Sarcoma**Brachytherapy is appropriate for this patient** given:- Conservative surgery (if planned) with positive margins- Pelvic location where surgical control is difficult- Young age makes EBRT less ideal (larger treatment volume)**HDR vs LDR:**- **HDR preferred** for sarcoma due to steeper dose gradients, better control of spatial dose distribution, and shorter treatment time- LDR may cause excessive dose to remaining ovarian tissue if ovaries cannot be surgically moved## Fertility Considerations**Critical dose constraints for reproductive organs:**| Organ | Tolerance | Notes ||-------|-----------|...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1970](../screenshots/19_Q1970.png)

---

### ✅ Q1971

**Input:** I have a 55-year-old male with prostate cancer (Gleason 4+4, Stage T2c, PSA 14) who has a history of liver cirrhosis (Child-Pugh class B) from alcohol abuse. He has been sober for 5 years. He has thrombocytopenia (platelets 75,000) and elevated INR (1.6) from his cirrhosis. He has portal hypertension with moderate ascites. He wants definitive treatment. Given his liver disease and coagulopathy, should I recommend LDR brachytherapy, EBRT, or active surveillance? How does his coagulopathy affect t...

**Response:**
> ## Treatment Considerations for Prostate Cancer with Child-Pugh B Cirrhosis### Clinical Assessment**High-risk prostate cancer** (Gleason 8, PSA 14, T2c) requires definitive treatment, but this patient's liver disease creates significant complexity.### Key Coagulation Issues for Brachytherapy| Parameter | Patient Value | Safety Threshold ||-----------|-------------|------------------|| Platelets | 75,000/μL | >50,000 for needle procedures || INR | 1.6 | <1.5 preferred; <1.8 acceptable || Ascites | Moderate | Increases infection/bleeding risk |### Treatment Recommendations**1. LDR Brachytherapy:**- Perineal needle placement carries **elevated bleeding risk** with thrombocytopenia- Ascites may alter perineal anatomy and infection risk- May proceed with platelet...

**Scores:**
- Total: 0.90
- Keyword: 0.71
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1971](../screenshots/19_Q1971.png)

---

### ✅ Q1972

**Input:** I am treating a 45-year-old female with a 3 cm cervical cancer (Stage IB1) who has a bicornuate uterus with a rudimentary left horn. She also has a history of stage 3B chronic kidney disease (GFR 35) from lupus nephritis. She is on mycophenolate and losartan. She has no prior treatment. She wants fertility preservation. Given her uterine anomaly, renal impairment, and desire for fertility, what treatment approach should I recommend? Can brachytherapy be performed with a bicornuate uterus? What a...

**Response:**
> This is a complex case requiring careful balancing of oncologic treatment, fertility preservation, and management of comorbidities. Here's my analysis:## Treatment Approach Recommendation### Primary Option: Fertility-Sparing Radical TrachelectomyFor a 3 cm Stage IB1 cervical cancer in a patient desiring fertility, **radical trachelectomy with pelvic lymphadenectomy** is the preferred approach. This preserves the uterus while removing the cervix and parametrium.**Why not brachytherapy as primary treatment?**- A bicornuate uterus has two separate uterine cavities with a malformed fundus- Standard...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1972](../screenshots/19_Q1972.png)

---

### ✅ Q1973

**Input:** I have a 72-year-old male with a 2 cm prostate cancer (Gleason 3+3, Stage T1c, PSA 6.0) who has end-stage renal disease on hemodialysis (3 times weekly). He has a well-functioning arteriovenous fistula in his left arm. He has a history of renal cell carcinoma treated with right nephrectomy 10 years ago. He is on warfarin for atrial fibrillation (target INR 2.0-3.0, current INR 2.4). He wants definitive treatment. Given his ESRD, warfarin use, and solitary kidney history, should I recommend LDR b...

**Response:**
> ## LDR Brachytherapy for Prostate Cancer in a Complex Patient### Patient Assessment**Favorable factors for LDR brachytherapy:**- Low-risk disease (Gleason 3+3, PSA 6.0, T1c)- Small prostate volume (2 cm ≈ approximately 30-35 cc estimate)- No evidence of extracapsular extension**High-risk factors requiring careful management:**- End-stage renal disease on hemodialysis- Anticoagulation with warfarin- Solitary kidney (left kidney only)- Age 72---### Warfarin Management**Periprocedural bridging strategy:**| Timing | INR Target | Action ||--------|------------|--------|| Pre-procedure (5-7 days) | Hold warfarin | Target INR <1.5 || Day...

**Scores:**
- Total: 0.90
- Keyword: 0.71
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1973](../screenshots/19_Q1973.png)

---

### ✅ Q1974

**Input:** I am managing a 35-year-old male with a 3 cm penile cancer (squamous cell, Stage T2N1M0) who had a partial penectomy with 6 mm margins. He has a positive right inguinal lymph node (1 cm, without extracapsular extension). He completed adjuvant inguinal radiation to 50 Gy. He now has a local recurrence on the penile stump 1.5 cm from the meatus. He refuses radical penectomy and wants organ preservation. He has a history of severe phimosis that was treated with circumcision 5 years ago. He is HIV n...

**Response:**
> # Penile Brachytherapy for Recurrent Penile Cancer After Partial Penectomy## Can Brachytherapy Be Used?**Yes, brachytherapy is technically feasible** for this patient, but several factors require careful consideration:### Challenges for This Specific Case| Factor | Consideration ||--------|---------------|| **Prior partial penectomy** | Limited residual tissue for interstitial implant; may require custom applicator || **Prior 50 Gy inguinal EBRT** | Re-irradiation tolerance of surrounding tissues is a concern || **1.5 cm from meatus** | Urethral involvement risk; urethral dose constraint critical || **Recurrence size 3 cm** | May exceed typical brachytherapy volume for monotherapy || **T2N1M0 with positive node** | Higher risk of additional occult nodal disease |---## Applicator Options...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1974](../screenshots/19_Q1974.png)

---

### ✅ Q1975

**Input:** I have a 60-year-old female with a 4 cm endometrial cancer (Grade 3, Stage IB) who is a professional opera singer. She had a total hysterectomy with BSO and pelvic lymphadenectomy (negative nodes). She needs adjuvant therapy. She is very concerned about vaginal stenosis and its impact on her singing career (she uses her pelvic floor extensively for singing technique). She wants to minimize treatment-related side effects. Should I recommend vaginal cuff brachytherapy alone or combined EBRT and br...

**Response:**
> ## Adjuvant Therapy for Stage IB Grade 3 Endometrial Cancer in an Opera Singer### Risk StratificationStage IB Grade 3 endometrial cancer falls into the **high-intermediate risk (HIR)** category per PORTEC-2 criteria and represents **high-risk** disease per ESMO/ESGO guidelines. Grade 3 histology carries significant recurrence risk (~15-20% vaginal, ~10-15% pelvic) regardless of myometrial invasion depth.### Recommendation: Vaginal Brachytherapy AloneFor this patient, **VBT alone is the appropriate recommendation**, and here's why:| Factor | VBT Alone | EBRT + VBT ||--------|-----------|------------|| Vaginal control | 96-98% | 97-99% || Pelvic recurrence | Low in node-negative | Lower || Vaginal stenosis...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1975](../screenshots/19_Q1975.png)

---

### ❌ Q1976

**Input:** I am treating a 55-year-old female with a 5 cm vaginal cancer (squamous cell, Stage III) who has a history of granulomatosis with polyangiitis (Wegener disease) treated with rituximab. She has chronic kidney disease stage 4 (GFR 22) from renal involvement of her vasculitis. She has bilateral sensorineural hearing loss from prior ototoxic medications. She has a tracheostomy from subglottic stenosis. She has never had prior radiation. Given her complex multisystem disease, should I recommend defin...

**Response:**
> 这是一个复杂的临床病例，需要综合考虑多系统疾病。以下是我的分析：## 疾病评估**阴道癌分期（Stage III）**：肿瘤累及阴道下1/3，累及骨盆壁，需要根治性治疗。**主要合并症挑战**：- GPA活动性血管炎（免疫抑制状态）- CKD 4期（GFR 22）- 双侧感音神经性耳聋（耳毒性药物史）- 气管切开状态---## 治疗方案推荐### 1. 总体治疗策略**推荐：调强放疗（IMRT）+ HDR近距离治疗**根治性放疗是首选，因为：- 患者手术风险极高（合并症限制）- 阴道癌对放化疗敏感- 器官保留目标**不建议同步...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q1976](../screenshots/19_Q1976.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ✅ Q1977

**Input:** I have a 48-year-old male with a 4 cm prostate cancer (Gleason 4+3, Stage T2c, PSA 12) who has a ventriculoperitoneal shunt for normal pressure hydrocephalus. The VP shunt tubing runs through the lower pelvis near the prostate on imaging. He has well-controlled epilepsy on levetiracetam. He has no other significant comorbidities. He wants LDR brachytherapy. Could the VP shunt tubing affect seed placement or dose distribution? Are there concerns about radiation damage to the shunt? Should I consi...

**Response:**
> This is a complex case requiring careful consideration of several factors. Let me address each concern:## VP Shunt Considerations**Radiation Effects on VP Shunt:**- VP shunts contain a pressure valve and subcutaneous reservoir that contain electronic components- Standard brachytherapy doses (145 Gy for I-125, 125 Gy for Pd-103) are unlikely to damage the electronic components- The shunt tubing itself (silicone) is not radiosensitive- **However**, verify the specific valve model for any manufacturer radiation restrictions**Seed Placement:**- The shunt tubing in the lower pelvis may occupy space that would otherwise be used for peripheral seed placement- Pre-planning should include the shunt tubing in OAR delineation- Seeds should...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1977](../screenshots/19_Q1977.png)

---

### ✅ Q1978

**Input:** I am managing a 42-year-old female with a Stage II vaginal clear cell adenocarcinoma (3 cm, upper vagina) with a history of in utero DES exposure. She has a history of bilateral nephrectomy for renal cell carcinoma 8 years ago and is on hemodialysis 3 times weekly. She has a well-functioning AV fistula. She wants definitive treatment. Given her dialysis status and DES-related cancer, what treatment approach should I recommend? How do I manage her dialysis schedule around brachytherapy? What dose...

**Response:**
> # Treatment Plan: Vaginal Clear Cell Adenocarcinoma with ESRD on Dialysis## Patient Summary- **42-year-old female**, Stage II vaginal clear cell adenocarcinoma- 3 cm upper vaginal tumor- DES exposure in utero- **Bilateral nephrectomy** for RCC 8 years ago → **ESRD on hemodialysis** (3x/week)- Well-functioning AV fistula (critical vascular access)- No prior pelvic radiation---## 1. Treatment Approach Recommendation### Primary Modality: Definitive Radiation ± ChemotherapyGiven her DES-associated clear cell adenocarcinoma and absence of prior radiation, **definitive chemoradiation** is the standard approach. Surgery is limited by tumor location and prior bilateral nephrectomy.**Treatment Schema:**| Component | Dose/Fractionation ||----------|-------------------|| EBRT (Pelvis) | 45 Gy in 25 fractions || Brachytherapy Boost | 21-25...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1978](../screenshots/19_Q1978.png)

---

### ✅ Q1979

**Input:** I have a 65-year-old male with a 3 cm prostate cancer (Gleason 3+4, Stage T2a, PSA 9.0) who has a history of pelvic radiation for rectal cancer 15 years ago (54 Gy in 30 fractions). He now has a well-healed colostomy from his rectal cancer surgery. Given his prior pelvic radiation, what are his remaining tissue tolerance limits? Should I recommend LDR brachytherapy, EBRT boost, or radical prostatectomy? What dose constraints apply for the previously irradiated rectum and bladder? Can brachythera...

**Response:**
> This is a complex re-irradiation case. Let me address each component:## Prior Radiation Dose Analysis**15 years ago:** 54 Gy in 30 fractions (EBRT for rectal cancer)- Assuming α/β = 3 for late-responding tissues (rectum, bladder): EQD2 ≈ 50.4 Gy- Assuming α/β = 10 for early-responding tissues: EQD2 ≈ 51.3 Gy- The long interval (15 years) allows partial recovery of late-responding tissues## Remaining Tissue Tolerance (Re-irradiation Principles)Based on QUANTEC, AAPM TG-43, and GEC-ESTRO re-irradiation guidelines:| Organ | Original Tolerance | Estimated Remaining Tolerance | Rationale ||-------|-------------------|------------------------------|-----------|| Rectum | D2cc < 70-75 Gy EQD2 | **...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1979](../screenshots/19_Q1979.png)

---

### ❌ Q1980

**Input:** I am treating a 50-year-old female with a 4 cm vulvar cancer (squamous cell, Stage II, depth of invasion 5 mm, 2 mm margins after radical vulvectomy). She has a positive left inguinal sentinel lymph node (0.3 mm deposit). She has a history of morbid obesity (BMI 48, lost 30 kg with bariatric surgery 2 years ago, current BMI 35). She has residual redundant skin in the inguinal region. She has well-controlled type 2 diabetes (HbA1c 7.0%). She needs adjuvant therapy. Should I recommend adjuvant rad...

**Response:**
> This is a clinically complex case. Let me provide a comprehensive treatment recommendation.## Clinical Assessment### Risk Stratification| Factor | Finding | Risk Level ||--------|---------|------------|| Primary tumor | 4 cm, DOI 5mm | Intermediate-high || Margins | 2 mm (close) | High || LN status | 0.3 mm ITC (single node) | Low-intermediate || LVSI | Not mentioned | Unknown |**NCCN Guidelines indication for adjuvant RT:** Close margins (<5mm) with DOI >...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1980](../screenshots/19_Q1980.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1981

**Input:** I have a 70-year-old female with a 2 cm endometrial cancer (Grade 1, Stage IA) who has severe aortic stenosis (valve area 0.7 cm2, peak gradient 58 mmHg). She is not a surgical candidate due to her cardiac risk. Her cardiologist says she has a 5-year survival of approximately 40% from her cardiac disease. She wants definitive treatment. Should I recommend definitive brachytherapy alone? What fractionation would minimize treatment visits? What anesthesia considerations are important? Should I con...

**Response:**
> This is an excellent clinical scenario that requires balancing oncologic treatment with significant cardiac comorbidity. Let me provide a comprehensive analysis:## Clinical Assessment**Oncologic Considerations:**- Stage IA Grade 1 endometrial cancer has an excellent prognosis (>95% 5-year disease-specific survival)- Brachytherapy alone is guideline-supported for this presentation- She has failed medical management (progestins), so definitive treatment is appropriate**Cardiac Considerations:**- Severe aortic stenosis (valve area <1.0 cm², gradient >40 mmHg) carries significant perioperative risk- 5-year cardiac survival of ~40% means her life expectancy is limited primarily by her cardiac disease, not her endometrial cancer##...

**Scores:**
- Total: 0.71
- Keyword: 0.17
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1981](../screenshots/19_Q1981.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q1982

**Input:** I am managing a 32-year-old female with a recurrent cervical cancer (Stage IIIB) after radical hysterectomy and adjuvant chemoradiation (50.4 Gy EBRT + cisplatin + 30 Gy brachytherapy boost completed 10 months ago). The recurrence is a 4 cm central pelvic mass with bladder invasion causing hematuria. She has bilateral hydronephrosis requiring nephrostomy tubes. Her performance status is ECOG 2. Her creatinine is 2.8 (baseline 0.8). She has lost 15 kg in the past 3 months. Given the extensive pri...

**Response:**
> This is a complex clinical scenario with multiple poor prognostic factors. Let me provide a comprehensive analysis:## Clinical Assessment**Poor Prognostic Factors:**- Disease recurrence within 10 months of completing definitive chemoradiation- Central pelvic mass with bladder invasion (T4 disease)- Prior cumulative dose: 50.4 Gy EBRT + 30 Gy brachytherapy- ECOG 2 performance status- Significant weight loss (15 kg in 3 months)- Renal impairment (Cr 2.8, bilateral hydronephrosis requiring nephrostomy)---## Option Analysis### 1. Re-irradiation**Considerations:**| Factor | Analysis ||--------|----------|| Prior...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1982](../screenshots/19_Q1982.png)

---

### ✅ Q1983

**Input:** I have a 58-year-old male with a 5 cm prostate cancer (Gleason 5+4, Stage T3b, PSA 42) who has bilateral ureteral stents for obstructive uropathy. He has well-controlled type 2 diabetes (HbA1c 7.5%), mild peripheral neuropathy from prior chemotherapy for testicular cancer (cisplatin 15 years ago), and a history of radiation pneumonitis from prior chest radiation for mediastinal seminoma (25 years ago). Given his complex oncologic history, should I recommend combined EBRT and brachytherapy boost?...

**Response:**
> This is a high-risk prostate cancer case with significant complicating factors. Here's my assessment:## Risk StratificationThis patient is **high-risk/very high-risk** based on:- Gleason 9 (ISUP Grade Group 4)- PSA 42 ng/mL- Stage T3b (seminal vesicle invasion)- Large tumor volume (5 cm)## Treatment Recommendation**Combined EBRT + brachytherapy boost is appropriate** per NCCN guidelines for high-risk prostate cancer. However, this case has important caveats:### Prior Radiation Considerations| Organ | Prior Dose | Typical Tolerance | Remaining Capacity ||-------|-----------|-------------------|---------------------|| Chest/lung | For mediastinal seminoma | Variable | Low (pneumonitis history) || Bladder | Likely minimal (different field) | ~65...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1983](../screenshots/19_Q1983.png)

---

### ❌ Q1984

**Input:** I am treating a 45-year-old female with a 3 cm breast cancer (Stage I, triple negative, BRCA1 positive) who had a lumpectomy with close margins (1 mm). She is very physically active and a competitive swimmer. She wants breast-conserving therapy and refuses re-excision. She is concerned about long-term radiation effects on her swimming performance. She asks about the comparison between whole breast radiation, accelerated partial breast irradiation with brachytherapy, and proton therapy. She wants...

**Response:**
> # Breast Cancer Treatment Options for Triple-Negative, BRCA1+ Patient## Clinical AssessmentYour patient's situation involves several competing risk factors that require careful consideration:### Key Risk Factors| Factor | Clinical Implication ||--------|---------------------|| **Triple-negative** | Higher local recurrence risk vs. hormone-positive || **BRCA1+** | Impaired homologous recombination; elevated radiation sensitivity || **Close margins (1mm)** | ~2-3x increased ipsilateral recurrence risk || **Competitive swimmer** | Functional priorities,...

**Scores:**
- Total: 0.70
- Keyword: 0.14
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1984](../screenshots/19_Q1984.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q1985

**Input:** I have a 65-year-old male with a 3 cm rectal cancer (Stage II, T3N0M0) 4 cm from the anal verge who has severe anxiety disorder requiring ongoing benzodiazepine therapy and has had 2 prior psychiatric hospitalizations for panic attacks. He is terrified of surgery and refuses any operation. He wants non-surgical treatment. He has well-controlled hypertension and no other comorbidities. Should I recommend neoadjuvant chemoradiation alone? What role could brachytherapy boost play for organ preserva...

**Response:**
> This is a legitimate clinical question about rectal cancer management. Let me provide a comprehensive response.## Clinical Assessment### Can this patient receive non-surgical treatment?**Yes**, this is a reasonable option given:- Stage II (T3N0), which is a good candidate for non-operative management- 4 cm from anal verge (lower rectum - technically challenging for sphincter preservation but possible)- Severe anxiety about surgery may actually be a relative contraindication to major surgery### Recommended Approach: Total Neoadjuvant Therapy (TNT) with Brachytherapy Boost**Phase 1: Neoadjuvant Chemoradiation**- 45-50.4 Gy pelvic radiation in 25-28 fractions- Concurrent capecitabine (preferred) or 5-FU- Consider adding oxaliplatin if patient can tolerate (improves response rates)**Phase 2: Brachytherapy Boost**For organ preservation, a br...

**Scores:**
- Total: 0.90
- Keyword: 0.71
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1985](../screenshots/19_Q1985.png)

---

### ✅ Q1986

**Input:** I am managing a 40-year-old female with a 4 cm invasive ductal carcinoma of the right breast (Stage IIA, ER+/PR+, HER2 negative, Oncotype DX score 28). She had a lumpectomy with clear margins. She is pregnant at 16 weeks gestation and wants to continue the pregnancy. Her obstetric team is supportive. She has no other comorbidities. Given her pregnancy and intermediate Oncotype score, should she receive chemotherapy during pregnancy? What brachytherapy approach could be used after delivery? What ...

**Response:**
> 这是一个关于妊娠期乳腺癌管理的临床问题。让我从临床知识库中获取相关信息。## Breast Cancer in Pregnancy: Clinical Management### 1. Chemotherapy During Pregnancy**Recommendation: Yes, consider chemotherapy during 2nd/3rd trimester**For a 40-year-old with intermediate Oncotype DX 28, chemotherapy provides meaningful benefit. The general principle is:| Trimester | Chemotherapy Safety ||-----------|-------------------|| 1st (0-12 wks) | **Contraindicated** - organogenesis || 2nd (13-27 wks) | **Generally safe** || 3rd (28+ wks) | **Generally safe**, but avoid near delivery |**Safe regimens during pregnancy:**- **Anthracycline-based**...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1986](../screenshots/19_Q1986.png)

---

### ❌ Q1987

**Input:** I have a 72-year-old male with a 2 cm prostate cancer (Gleason 3+3, Stage T1c, PSA 5.5) who has moderate-to-severe COPD (FEV1 40% predicted, on home oxygen 2 L/min). He has a history of bilateral deep vein thrombosis and is on lifelong rivaroxaban. He has well-controlled atrial fibrillation. He wants definitive treatment. Given his severe COPD, anticoagulation, and atrial fibrillation, should I recommend active surveillance, LDR brachytherapy, or EBRT? What anesthesia considerations are importan...

**Response:**
> 这是一个复杂的临床决策问题，涉及多个合并症的管理。让我从以下几个方面进行分析：## 治疗选择分析### 1. LDR近距离放疗（I-125种子植入）**优势：**- 单次门诊手术，治疗时间短- 放射线集中在前列腺，减少对周围正常组织的影响- 不需要长时间麻醉（通常30-60分钟）- 对于低危前列腺癌（LDR指征明确）：Gleason 3+3=6, PSA 5.5, T1c**适合该患者的原因：**- 低危疾病，单一治疗即可获得良好控制- 年纪较大，手术风险高，但LDR相对微创- COPD患者对短时间麻醉耐受性可能优于长时间EBRT### 2. 主动监测**考虑因素：**- 患者为低危疾病，理论上适合- 但患者有明确治疗...

**Scores:**
- Total: 0.65
- Keyword: 0.14
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q1987](../screenshots/19_Q1987.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ✅ Q1988

**Input:** I am treating a 55-year-old female with a 5 cm locally advanced cervical cancer (Stage IIIB) who has a history of morbid obesity (BMI 50). She has obstructive sleep apnea requiring CPAP, type 2 diabetes on insulin (HbA1c 9.5%), and non-alcoholic steatohepatitis with liver enzymes 3x normal. Standard tandem and ovoid applicators cannot reach the tumor due to her body habitus. MRI shows the tumor extending to the pelvic sidewall. She has never had prior treatment. What applicator alternatives shou...

**Response:**
> ## Management of Locally Advanced Cervical Cancer in Morbid Obesity### Applicator Alternatives**When standard tandem/ovoids cannot reach the tumor:**| Alternative | Description | Considerations ||-------------|-------------|----------------|| **Ring applicator** | Tandem + ring can provide better angle access | May still be limited by body habitus || **Perineal template (Syed-Neblett)** | Interstitial needles via perineum | Allows better coverage of sidewall extension || **Transperineal interstitial implant** | Free-hand or template-guided needle placement | Technical challenge but feasible || **EBRT boost escalation** | If brachytherapy impossible, consider EBRT boost | Lower biological effect but safer...

**Scores:**
- Total: 0.80
- Keyword: 0.43
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1988](../screenshots/19_Q1988.png)

---

### ✅ Q1989

**Input:** I have a 38-year-old female with a Stage IIA cervical cancer (3.5 cm tumor) who desires fertility preservation. She has a history of Crohn disease with an ileorectal anastomosis (subtotal colectomy 5 years ago). She has well-controlled disease on infliximab. Her Crohn disease has not flared in 3 years. She wants to preserve her fertility. Should I recommend neoadjuvant chemotherapy followed by trachelectomy, or should I consider brachytherapy alone? What chemotherapy agents are safe with inflixi...

**Response:**
> This is a complex case requiring careful consideration of multiple factors. Let me provide a comprehensive analysis:## Treatment Options for Fertility Preservation### 1. Radical Trachelectomy with Neoadjuvant Chemotherapy**For tumors >2 cm, neoadjuvant chemotherapy (NACT) followed by trachelectomy is the standard approach:**- **Recommended NACT regimen**: Platinum-based (cisplatin 75-80 mg/m² or carboplatin AUC 5-6) with paclitaxel- **Cycles**: 2-3 cycles before reassessment- **Trachelectomy timing**: 2-3 weeks after final chemotherapy cycle- **Pregnancy rates**: 50-70% after trachelectomy- **Oncologic outcomes**: 5-year survival 90-95% for Stage IB1-IIA after NACT + trachelectomy### 2. Brachytherapy as Primary Treatment**Brachytherapy alone for fertility preservation is less established but technically...

**Scores:**
- Total: 0.80
- Keyword: 0.43
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1989](../screenshots/19_Q1989.png)

---

### ❌ Q1990

**Input:** I am managing a 60-year-old male with a 4 cm rectal cancer (Stage III, T3N1M0) 6 cm from the anal verge who has a history of bilateral lower extremity amputations (below-knee) from peripheral vascular disease. He uses a wheelchair. He has well-controlled diabetes (HbA1c 7.0%) and hypertension. He wants to avoid a permanent colostomy. Given his physical limitations, should I recommend neoadjuvant chemoradiation? How do his amputations affect radiation positioning? What assistive devices might be ...

**Response:**
> ## 直肠癌新辅助放化疗：下肢截肢患者的治疗考量### 1. 治疗建议**新辅助放化疗适应证：**- T3N1M0，肿瘤距肛缘6cm → 符合新辅助放化疗标准- 保肛意愿强烈 → 放化疗可增加保肛机会**推荐方案：长程放化疗（优于短程）**- 理由：截肢患者坐姿耐受性较好，长程方案可提供更充分的肿瘤退缩- 45-50.4 Gy/25-28 fx + 卡培他滨同步---### 2. 定位与摆位挑战| 问题 | 解决方案 ||------|----------|| 双侧膝下截肢 → 无法俯卧 |...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q1990](../screenshots/19_Q1990.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ✅ Q1991

**Input:** I have a 50-year-old female with a 3 cm vaginal cancer (squamous cell, Stage II) who has a history of systemic mastocytosis requiring ongoing treatment with midostaurin. She has recurrent episodes of anaphylaxis requiring epinephrine auto-injectors. She carries an EpiPen at all times. She has osteoporosis with multiple vertebral fractures. She has never had prior radiation. Given her mastocytosis and anaphylaxis risk, how should I manage her during brachytherapy procedures? What anesthesia consi...

**Response:**
> # Brachytherapy Management for Vaginal Cancer in Systemic Mastocytosis## Patient Overview- 50-year-old female, Stage II vaginal SCC (3 cm)- Systemic mastocytosis on midostaurin- Recurrent anaphylaxis, EpiPen dependent- Osteoporosis with vertebral fractures- No prior radiation---## Key Concerns### 1. **Anaphylaxis Risk**Systemic mastocytosis patients have significantly elevated anaphylaxis risk (up to 50% lifetime incidence). Triggers include:- Stress/anxiety (procedure-related)- Certain anesthetic agents- Temperature changes- Direct mucosal manipulation### 2. **Pre-Procedure Planning**| Action | Details ||--------|---------|| **Allergy/Anesthesiology consult** | Required before treatment initiation || **Continue...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1991](../screenshots/19_Q1991.png)

---

### ✅ Q1992

**Input:** I am treating a 65-year-old male with prostate cancer (Gleason 4+3, Stage T3a, PSA 18) who has a history of bilateral adrenal insufficiency requiring lifelong hydrocortisone replacement. He had a pituitary adenoma treated with surgery and radiation 20 years ago. He has hypothyroidism on levothyroxine and growth hormone deficiency on replacement therapy. He has well-controlled hypertension. He wants definitive treatment. Given his multiple endocrine deficiencies, should I modify his treatment app...

**Response:**
> ## Treatment Considerations for Prostate Cancer with Multiple Endocrine Deficiencies### OverviewYour patient has **high-risk prostate cancer** (Gleason 4+3, Stage T3a, PSA 18) with well-controlled endocrine conditions on appropriate replacement therapy. **His endocrine deficiencies do not preclude definitive treatment**, but require specific management.---### Adrenal Insufficiency Management**Pre-procedure:**- Stress-dose steroids are required for any invasive procedure (brachytherapy seed implantation requires spinal/epidural or general anesthesia)- Typical regimen: IV hydrocortisone 100mg at procedure start, then 50mg every 8 hours for 24 hours post-procedure- Patients on chronic...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1992](../screenshots/19_Q1992.png)

---

### ✅ Q1993

**Input:** I have a 42-year-old female with a 4 cm breast cancer (Stage IIA, triple negative, no BRCA mutation) who had a lumpectomy with close margins (1 mm). She is a nursing mother with a 6-month-old infant. She wants to continue breastfeeding if possible. She is very concerned about the impact of radiation on her breast milk and her baby. She wants to understand her treatment options. Should she wean before starting radiation? What is the effect of radiation on breast milk? Could brachytherapy be used ...

**Response:**
> # Breast Cancer Radiation Therapy for a Nursing Mother## Can She Continue Breastfeeding During Radiation?**Weaning is recommended before starting radiation therapy**, but this does not mean she must stop entirely.### Effects of Radiation on Breast Milk- **External beam radiation (EBRT)** to the breast will alter milk composition, reduce production in the treated breast, and may make the milk unsuitable due to inflammatory changes- **The untreated contralateral breast can continue producing milk**, but mixed feeding from one treated and one untreated breast is logistically challenging- Radiation causes DNA damage in glandular tissue - milk from...

**Scores:**
- Total: 0.90
- Keyword: 0.71
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1993](../screenshots/19_Q1993.png)

---

### ✅ Q1994

**Input:** I am managing a 55-year-old male with a 5 cm locally advanced prostate cancer (Gleason 5+4, Stage T3b, PSA 50, node-positive) who has a history of liver transplantation for hepatitis C 8 years ago. He is on lifelong immunosuppression (tacrolimus, mycophenolate, prednisone). His liver function is stable with normal liver enzymes. He has chronic kidney disease stage 3a (GFR 55) from tacrolimus nephrotoxicity. He wants definitive treatment. Given his transplant status, should I recommend brachyther...

**Response:**
> # Treatment Planning for Liver Transplant Patient with Locally Advanced Prostate Cancer## Clinical AssessmentThis patient has **very high-risk prostate cancer** (Gleason 9, T3b, PSA 50, node-positive) with transplant-related comorbidities. Treatment decision requires balancing oncologic efficacy against immunosuppression-related risks.---## Treatment Option Analysis### 1. **Brachytherapy Monotherapy** ⚠️ **NOT RECOMMENDED**- Insufficient for T3b disease with seminal vesicle involvement- Inadequate for node-positive disease- May consider as boost with EBRT (see below)### 2. **EBRT + Brachytherapy Boost** ✓ **PREFERRED OPTION**| Component | Dose | Rationale ||-----------|------|-----------|| Whole pelvis EBRT | 45-50 Gy | Covers pelvic nodes || HDR boost |...

**Scores:**
- Total: 0.94
- Keyword: 0.83
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1994](../screenshots/19_Q1994.png)

---

### ❌ Q1995

**Input:** I have a 70-year-old female with a 2 cm endometrial cancer (Grade 1, Stage IA) who has severe dementia (MMSE 8, bedbound). She is in a nursing home and cannot communicate. Her healthcare proxy (daughter) wants aggressive treatment. Her son (also a healthcare proxy) wants comfort care only. There is a family conflict about treatment. Given the excellent prognosis of Grade 1 Stage IA endometrial cancer and her severe dementia with limited life expectancy, what should I recommend? What are the ethi...

**Response:**
> 这是一个复杂的临床伦理问题，需要综合考虑癌症预后、患者生活质量和家庭决策。## 临床评估**子宫内膜癌 IA期Grade 1的预后**- 5年生存率 >90-95%- 单纯子宫切除术即可治愈- 但该患者因严重痴呆无法手术**严重痴呆的预后影响**- MMSE 8分，属于重度痴呆- 卧床状态：预期寿命通常 2-4年- 主要死因通常是肺炎、感染等并发症，而非癌症## 伦理考量### 1. 治疗目标与患者利益的平衡| 考虑因素 | 积极治疗 | 舒适护理 ||---------|---------|---------|| 癌症控制 | 可能...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q1995](../screenshots/19_Q1995.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ✅ Q1996

**Input:** I am treating a 45-year-old male with a 4 cm anal canal squamous cell carcinoma (Stage II, T2N0M0) who has severe inflammatory bowel disease (Crohn disease with perianal and colonic involvement). He has a diverting colostomy from a recent abscess drainage. He is on infliximab and azathioprine. His CD4 count is 280 from immunosuppression. He has iron deficiency anemia (hemoglobin 8.5 g/dL) requiring IV iron infusions. Standard concurrent chemoradiation (Nigro protocol) with 5-FU and mitomycin-C i...

**Response:**
> # Anal Canal Cancer with Crohn's Disease: Treatment Approach## Case AnalysisThis is a high-risk patient requiring careful multidisciplinary evaluation. Several factors complicate standard treatment:| Risk Factor | Clinical Implication ||-------------|---------------------|| Crohn's disease | Increased radiation sensitivity of bowel; risk of fistulization || Infliximab/azathioprine | Impaired wound healing; infection risk || CD4 count 280 | Opportunistic infection risk during immunosuppression || Anemia (Hgb 8.5) | Reduced oxygen delivery → decreased radiation efficacy || Perianal involvement | High fistulization risk |---## Standard Nigro Protocol Modifications### EBRT Dose Considerations- Standard...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1996](../screenshots/19_Q1996.png)

---

### ✅ Q1997

**Input:** I have a 60-year-old female with a 3 cm vaginal cancer (squamous cell, Stage II) who is a professional opera singer. She had no prior treatment. She is extremely concerned about the impact of treatment on her singing voice and career. She has no significant comorbidities. She wants the treatment with the least impact on her quality of life and career. Should I recommend brachytherapy alone, combined EBRT and brachytherapy, or surgery? How do I minimize treatment side effects that could affect he...

**Response:**
> # Treatment Options for Vaginal Cancer in a Professional Opera Singer## Key Clinical ConsiderationsFor a **3 cm Stage II vaginal cancer** in a professional singer, the treatment decision must balance oncologic efficacy with preservation of her career-critical functions.## Treatment Approach Comparison| Factor | Brachytherapy Alone | EBRT + Brachytherapy | Surgery ||--------|-------------------|---------------------|---------|| **Local Control** | 80-90% | 85-95% | 70-85% || **Vaginal Preservation** | Excellent | Good | Poor || **Vaginal Stenosis Risk** | Moderate (20-30%) | High (40-50%) | Severe (60-80%) || **Treatment Duration** | 4-...

**Scores:**
- Total: 0.80
- Keyword: 0.43
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1997](../screenshots/19_Q1997.png)

---

### ❌ Q1998

**Input:** I am managing a 48-year-old male with a 5 cm prostate cancer (Gleason 4+4, Stage T3a, PSA 22) who has a history of severe opioid use disorder (in sustained remission for 3 years on buprenorphine/naloxone). He has chronic pain from degenerative disc disease requiring ongoing opioid management. He has well-controlled hepatitis C from his prior IV drug use (SVR achieved). He has depression treated with venlafaxine. He wants definitive treatment. Given his substance abuse history and ongoing opioid ...

**Response:**
> 这是一个复杂的临床病例，需要综合考虑多个因素。## 治疗推荐**LDR近距离治疗并非此类患者的最佳选择，原因如下：**### 1. 疾病风险分层- Gleason 4+4=8，PSA 22，肿瘤体积5cm → **高危前列腺癌**- 高危患者通常需要**综合治疗**（EBRT + 近距离治疗boost ± ADT）- 单纯LDR近距离治疗可能不足以控制高危疾病### 2. 阿片类药物管理挑战| 问题 | 临床影响 ||------|----------|| **术前疼痛管理** | 需要与成瘾医学专家协调 || **术后疼痛控制** | 阿片类药物需求可能增加 || **药物相互作用** | 丁丙诺啡与阿片类激动剂存在天花板效应 || **复发风险** | 围手术...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q1998](../screenshots/19_Q1998.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ✅ Q1999

**Input:** I have a 35-year-old female with a 3 cm cervical cancer (Stage IB1) who has a history of Turner syndrome (45,XO) with a hypoplastic uterus. She has never menstruated and has primary amenorrhea. She has coarctation of the aorta (repaired in childhood) with residual bicuspid aortic valve and mild aortic regurgitation. She has type 1 diabetes. She wants fertility preservation despite her complex medical history. Her reproductive endocrinologist has discussed potential gestational surrogacy using do...

**Response:**
> # Fertility-Sparing Treatment for Cervical Cancer in Turner Syndrome## SummaryThis patient presents a complex intersection of cervical cancer requiring treatment, Turner syndrome with anatomical challenges, and fertility preservation goals. The recommended approach is **neoadjuvant chemotherapy followed by radical trachelectomy** rather than primary brachytherapy, due to her hypoplastic uterus anatomy.---## 1. Can Brachytherapy Be Performed in a Hypoplastic Uterus?### Technical Feasibility**Generally not ideal for primary treatment**, but feasibility depends on the degree of hypoplasia:| Uterine Parameter | Normal Adult | Turner Syndrome | Feasibility for Tandem ||-------------------|--------------|-----------------|------------------------|| Uterine length | 6-9 cm | 3-5 cm (often) | May accommodate short...

**Scores:**
- Total: 0.94
- Keyword: 0.83
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1999](../screenshots/19_Q1999.png)

---

### ❌ Q2000

**Input:** I am treating a 50-year-old female with a 4 cm cervical cancer (Stage IIB) who is a healthcare worker (ICU nurse) during a pandemic. She has two young children (ages 4 and 6) and is the primary caregiver. Her husband works overseas and is not currently in the country. She has no significant comorbidities. She wants definitive treatment but is concerned about time away from her children and infection risk during hospital visits. She asks about treatment options that minimize hospital visits. Shou...

**Response:**
> ## 宫颈癌近距离治疗方案优化### 针对该患者的社会情况优化**减少就诊次数的方案选择：**| 方案 | 就诊次数 | 说明 ||------|----------|------|| HDR 4F × 7 Gy | 4次（隔日） | 标准方案，2周完成 || HDR 2F × 8.5 Gy | 2次 | 备选方案，每2周1次 || PDR连续输注 | 1次入院 | 70小时连续住院 |**对于该ICU护士的推荐：**- **HDR 2 fractions方案**（每分数8.5 Gy）是合理选择，可将就诊次数从4次减至2次- 配合EBRT 45 Gy/25fx（可在社区肿瘤中心完成，减少您在主...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q2000](../screenshots/19_Q2000.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

